Fused ring compounds as inhibitors of STAT6
Novel fused ring compounds are developed to inhibit STAT6 signaling, addressing the need for treatments in inflammatory and proliferative disorders by effectively targeting STAT6, thereby treating conditions such as asthma and various cancers.
Patent Information
- Application Number
- PCT/US2026/027170
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-19
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
There is a medical need to develop inhibitors for the STAT6 signaling pathway to treat inflammatory diseases and cellular proliferative disorders characterized by STAT6 overactivity and expression, as STAT6 plays a crucial role in type II immune responses and tumorigenesis.
Development of novel fused ring compounds that inhibit STAT6 signaling, including specific compounds of Formula (I) and their pharmaceutically acceptable salts, stereoisomers, and tautomers, which can be administered to treat diseases and conditions associated with STAT6 signaling.
The compounds effectively inhibit STAT6 signaling, providing therapeutic benefits for inflammatory diseases such as asthma and allergic conditions, as well as cellular proliferative disorders like colon cancer, prostate cancer, and other cancers.
Smart Images

Figure IMGF000002_0001 
Figure IMGF000003_0001 
Figure IMGF000003_0002
Abstract
Description
FUSED RING COMPOUNDS AS INHIBITORS OF STAT6CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U. S. Provisional Patent Application Nos. U. S. S. N. 63 / 801,586 filed May 7, 2025; U. S. S. N. 63 / 887,911 filed September 25, 2025; U. S. S. N. 63 / 926,279 filed November 26, 2025; U. S. S. N. 63 / 986,324 filed February 19, 2026; and U. S. S. N. 64 / 025,138 filed April 1, 2026. The entirety of each of the applications is herein incorporated for all purposes.FIELD
[0002] Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions, for example, in treating diseases, disorders, and conditions, associated with the STAT6 signaling pathway, including, inflammatory diseases, disorders, and conditions and certain cellular proliferative disorders.BACKGROUND
[0003] A type II immune response is an overactivation to an infection or allergen wherein the body mounts a response by creating inflammation. The inflammatory pathway involves the activation of type 2 T helper cells (Th2 cells) and type 2 innate lymphoid cells (ILC2 cells) that secrete interleukin 4 (IL-4) and interleukin 13 (IL- 13). Once released, IL-4 and IL-13 bind to their respective cell surface receptors, leading to STAT6 phosphorylation and activation. Activated STAT6 then translocates to the nucleus to regulate expression of genes involved in the immune response.
[0004] Type II inflammation contributes to a range of allergic diseases and disorders, including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and certain food allergies. Conditions characterized by chronic inflammation, such as inflammatory bowel disease and rheumatoid arthritis are also thought to be caused in part by IL-4 and IL-13. Studies have shown that STAT6 reduces the expression of pro-inflammatory cytokines and chemokines, which can mitigate symptoms of these diseases, disorders, and conditions. Lymphocytes from mice deficient in STAT6 are unable to respond to IL-4 in various in vitro and in vivo assays and exhibit a defect in the generation of Th2 cells (Kaplan, M. H. etal. Immunity, 1996, 4(3), 313-319). In allergen sensitization and asthma models, studies have shown that STAT6-deficienct mice lack features of these disorders (Walford, H. H. and Doherty, T. A. JAKSTAT, 2013, 2(4), e25301). For example STAT6-deficient mice failed to develop airway hyperresponsiveness (AHR), a11107441203\1\AMERICAScharacterization of allergic asthma, after allergen provocation (Kuperman et al. J Exp. Med., 1998, 187(6), 939-948).
[0005] Further, overactive IL-4 / STAT6 signaling has been observed in certain types of cancers (Patel, B. K. Genomics, 1998, 52(2), 192-200; Delgado-Ramirez, Y. et al. Oncol Lett.2020, 20(1), 455-464), especially those related to chronic inflammation. In a murine model of colitis-associated colorectal cancer, 100% of wild-type (WT) mice developed 8 weeks after colitis-associated cancer induction, while 70% of STAT6-deficient mice were tumor-free. The STAT6-deficienct mice also developed fewer and smaller tumors than the WT mice (Leon-Cabrera, S. A. etal. Cancer Immunol Res, 2017, 5(5), 385-396). High expression of STAT6 has also been observed in colon cancer. STAT6-positive expression in a study of colorectal cancer patients from 2002-2004, especially in combination with zeste homologue 2 (EZH2) expression was associated with a worse prognosis and increased metastasis (Wang, C. et al. World J Gastroenterol. 2010, 16(19), 2421-2427).
[0006] Given the importance of STAT6 in inducing a type II immune response and its role in tumorigenesis, there is a medical need to develop STAT6 inhibitors. It is therefore an object of the present disclosure to provide novel compounds and compositions for the treatment of inflammatory diseases, disorders, and conditions and cellular proliferative disorders characterized by STAT6 overactivity and expression.SUMMARY
[0007] In the first aspect, provided herein is a compound of Formula (I),or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof; whereinL is selected from -NR26-, -Ci-salkylene-, -Cs-ecycloalkylene-, -heterocycloalkylene-, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- or -heterocycloalkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25;21107441203\1\AMERICAS-Ci-3alkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -Cs-ecycloalkylene-, -heterocycloalkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -heteroCi-salkylene-, or bond,CR1, X5is N or CRla, and X6is N or CR2provided that only one of X4, X5, and X6is N; or X4is CR1, X5is CRla, and X6is CR2; wherein X7is N or CR6; and whereinthe attachment to the C ring;R26is H, Ci-3alkyl, hydroxyCi-2alkyl, Ci-2alkoxyCi-3alkyl, C3-4cycloalkyl, or heterocycloalkyl optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a phenyl group fused to a heterocycle or 5- to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18; or a phenyl group fused to a heteroaryl or 5- to31107441203\1\AMERICAS6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18;RingY1is CR3borN;Y2is CR3aorN;Y3is CR3b, CR3C, orN;Y4is CR3borN;wherein no more than 3 of Y1, Y2, Y3, or Y4are N;R15is -NR15alC(O)R15a2, -C(O)NR15bR15c, a 5- or 6-membered heterocycloalkyl, a 5-membered heteroaryl, or pyridonyl wherein the 5- or 6-membered heterocycloalkyl, 5-membered heteroaryl, and pyridonyl are optionally substituted with 1, 2, 3, 4, 5, or 6 groups independently selected from R19;R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17c;R15bis H or Ci-ealkyl;R15cis H; Ci-3alkyl optionally substituted with NR28aR28b; Ci-3alkylcarbonyl wherein the Ci-3alkyl is optionally substituted with NR28aR28b; hydroxyCi-salkyl; heterocycloalkyl; heterocycloalkylCi-salkyl; heterocycloalkyloxyCi-salkyl; -CH2-C(O)NR28aR28b; -CH2-phenylene-NHC(O)NR28aR28b; or heteroaryl fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heteroaryl fused to heterocycle is optionally substituted with Ci-4alkyl, Ci-3alkoxyCi-3alkyl, aryl, arylCi-salkyl, halo, heterocycloalkyl, or heterocycloalkylCi-salkyl;or R15band R15care taken together, with the N to which they are attached, to form a 3-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from hydroxy, Ci-3alkyl, halo, C2-3alkylcarbonyl, Ci-3alkoxy, hydroxyCi-3 alkyl, Ci-3alkoxyCi-3alkyl, cyano, Cs-ecycloalkyl, -S(O)2R9, -C(O)NR28aR28b, or -NHC(=O)CH3; or 2 substituents on the same carbon come together to form an oxo group;is a single bond or a double bond;R1is H, halo, Ci-salkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, aryl, heteroaryl, heterocycloalkyl, arylCi-salkyl, heteroarylCi-salkyl, aryloxy, heteroaryloxy, haloCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, deuterium, -OCi-3alkylOCi-3alkyl, -CN, or -SO2R9;41107441203\1\AMERICASRlais H, halo, deuterium, or methyl;R2is H, F, Cl, deuterium, Ci-salkyl, haloCi-4alkyl, hydroxyCi-4alkyl, Ci-2alkoxyCisalkyl, C2-4 alkenyl, Ci-4alkoxy, NR17bR17c, -OCi-salkyl-Cs-ecycloalkyl, or -OCi-salkylOCi-2alkyl;R3aand R3bare independently selected from H; F; Cl; Ci-4alkyl; OH; -CN; hydroxyCi-4alkyl; Ci-4alkoxy wherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is optionally substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl; Ci-2alkoxyCi-5alkyl; -OCi-5alkylOCi-2alkyl; -OC2-salkyl-NR17bR17c; aryl optionally substituted with heterocycloalkyl; heteroaryl; aryloxy; heterocycloalkyl; heteroaryl oxy; -O-Co-Csalkylene-heterocycloalkyl; and C2-ealkynyl optionally substituted with hydroxy, Ci-3alkyloxy, -(Co-3alkylene)NR17bR17c, heterocycloalkyl, or Cs-ecycloalkyl wherein the Cs-ecycloalkyl is optionally substituted with NR17bR17c; wherein the heteroaryl and heterocycloalkyl, alone or part of another group, are optionally substituted with Ci-ealkyl or NR17bR17c;R15alis H or Ci-ealkyl and R3cis hydrogen; or R15aland R3ccome together to form a 5- to 7-membered heterocycle;R5is H; Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; C3-6 alkynyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; -(Ci-Csalkylene)-C(O)NR17bR17c; -(C2-C5alkylene)-NR17b-C(O)R17c; aryl; arylCi-salkyl wherein the aryl of arylCi-salkyl is optionally substituted with heterocycloalkyl; heteroaryl; heteroarylCi-salkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyl; or Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCo-2alkyl and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroarylCi-salkyl, are optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-3alkoxy, heterocycloalkyl, and Cs-ecycloalkyl;R5ais Ci-ealkyl; haloCi-salkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; C3-ecycloalkyl; or, Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 halo which are independently selected;R6is H; F; Cl; Br; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; cyanoCi-salkyl; C2-ealkynyl optionally substituted with Cs-scycloalkyl or NR17bR17c; hydroxyCs-ealkynyl; Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl are independently optionally substituted with 1 or 2 hydroxy groups or 1 Cs-ecycloalkyl group; -(Co-3alkylene)-0- 51107441203\1\AMERICAS(hydroxyCi-ealkyl); Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl;C(O)NR16aR16b; Cs-scycloalkyl; Cs-scycloalkylCi-salkyl wherein the Ci-3alkyl of C3-scycloalkylCi-salkyl is optionally substituted with hydroxy; deuterium; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C0-3alkylene)-SO2R9; -SO2NR17bR17c; cyano; -(C1-C3alkylene)-NR17bR17c; P(O)(CH3)2; heteroaryl; and heteroarylCi-salkyl; wherein the Cs-scycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(O)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl, and cyano; and the heteroaryl, alone or part of heteroarylCi-salkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected; orR5and R6together with the atoms to which they are attached form a heterocycle optionally substituted with 1 or 2 substituents independently selected from Ci-3alkyl, C3-4cycloalkyl, and halo;R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH, Ci-ealkyl or Cs-ecycloalkyl;R13and R13aare independently H; halo; hydroxyCi-2alkyl; heterocycloalkyl optionally substituted with Ci-3alkyl; Cs-scycloalkyl; Ci-3alkoxyCi-3alkyl; -(Co-3alkylene)-NR17bR17c; aryl; heteroaryl; C3-8cycloalkylCi-3alkyl; or alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl;R21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl; orR21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl; orR21and R21acome together to form an oxo group; orR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form cycloalkyl or heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, Cs-scycloalkyl, or alkyl;provided that only one of a) R13and R13a; b) R21and R21a, and c) R13aand R21aform cycloalkyl or heterocycloalkyl;R16aand R16bare independently selected from H; Ci-ealkyl; phenyl; C3-7cycloalkyl; C5-7cycloalkenyl; a 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently61107441203\1\AMERICASselected from nitrogen, oxygen, and S(0)o-2; and a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orR16aand R16bare taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2;each R17is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; methanesulfonylamino; -SO2NR17bR17c; Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; Ci-ealkoxy; Ci-ealkoxy-Ci-ealkyl wherein the Ci-ealkyl of Ci-ealkoxy-Ci-ealkyl are independently optionally substituted with hydroxy; cyano-Ci-ealkyl; Ci-ealkylcarbonyl; dimethylamino-Ci-ealkylcarbonyl; -(Ci-6alkylene)NR17bR17c; N-acetylamino-Ci-ealkyl; Ci-ealkylcarbamoyl; N-methyl-Ci-6alkylcarbamoyl; -C(O)NR17aR17b; -C(O)R17c; -COOH; -NR17bC(O)R17c; -NR17bC(O)NR17cR17cl; -NR17bC(O)C(O)NR17cR17cl; aryl; heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;each R17ais independently selected from H; Ci-ealkyl; OH; Ci-ealkoxy; halo-Ci-ealkoxy; Ci-3alkoxy-Ci-3alkyl; Cs-ecycloalkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyloxy; C3-ecycloalkylCi-salkyloxy; cyano-Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; hydroxy-Ci-ealkyloxy; Ci-ealkoxy-Ci-ealkyloxy; NR17bR17c-Ci-6alkylcarbonyl; -(Ci-Csalkylene)-NR17bR17c; -OC2-4alkylene-NR17bR17c; Ci-2alkoxyCi-3alkyl; -C(O)NHOR24; heterocycloalkyl; heterocycloalkyloxy; heterocycloalkylCi-salkyl; heterocycloalkylCi-salkoxy; aryl; a 5- to 10-membered heteroaryl group; a heteroaryl group fused to heterocycle or cycloalkyl; or heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-3alkyl, the aryl, the heteroaryl, the heteroaryl of heteroarylCi-salkyl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;each R17bis independently selected from hydrogen, Ci-ealkyl, Ci-ealkyloxy, haloCi-ealkyl, and Ci-6alkyloxyCi-3alkyl;each R17Cis independently selected from hydrogen; deuteroCi-ealkyl; Ci-ealkyl; C2-ealkenyl optionally substituted with 1 or 2 halo; Ci-ealkyloxy; hydroxy; haloCi-ealkyl; Ci-6alkyloxyCi-3alkyl; -(Ci-C3alkylene)-NR28aR28b; heterocycloalkyl; a 5- or 6-membered heteroaryl group; heteroaryl group fused to heterocycle or cycloalkyl; and heteroaryl Ci -sal kyl wherein the heterocycloalkyl, alone or part of another group, heteroaryl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;71107441203\1\AMERICASeach R17C1is independently selected from hydrogen; Ci-ealkyl optionally substituted with 1, 2, or 3 groups independently selected from Cs-scycloalkyl, heterocycloalkyl, or methoxy wherein the Cs-scycloalkyl is further optionally substituted with 1 or 2 groups independently selected from -OH and Ci-salkyl; deuteroCi-ealkyl; Cs-scycloalkyl; haloCi-ealkyl; hydroxyCi-ealkyl; Ci-6alkyloxyCi-3alkyl; -CH2-phenylene-NHC(O)NR28aR28b; and heterocycloalkyl; orR17band R17care taken together, with the N to which they are attached, to form a 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or R17Cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R28;each R19is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi -ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxyCi-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heteroaryl group fused to heterocycle are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl; or each R19is as follows:(a) two R19groups on the same carbon come together to form an oxo group;(b) one pair of R19groups on the same carbon come together to form an oxo group and a second pair of R19groups on the same carbon come together to form an oxo group;(c) two R19groups on the same carbon come together to form a Cs-scycloalkyl;(d) two R19groups on the same carbon come together to form a Cs-scycloalkyl and a second pair of R19groups on the same carbon come together to form an oxo group;(e) two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5-to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23; or81107441203\1\AMERICAS(f) two R19groups on the same carbon come together to form an oxo group and two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;and the remaining of the R19groups in (a)-(f) are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(C1-C3alkylene)-SO2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heteroaryl group fused to heterocycle are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;R18, R20, R22, and R23are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-3alkoxy; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxy, and hydroxyCi-ealkyl; C3-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy; haloCi-ealkyl; hydroxyCi-ealkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-Csalkylene)-NR17bR17c; -C(O)R27; -(C0-C3alkylene)-SO2R9; heteroaryl; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl of heterocycloalkylalkyl is optionally substituted with 1 or 2 substituents selected from -NR17bR17c, halo, and -OH; or two R20or R22groups on the same carbon come together form an oxo group;R24is H, Ci-salkyl, C3-6cycloalkylCi-3alkyl, heterocycloalkylCi-salkyl, hydroxyC2-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl;R25is independently selected from halo, Ci-3alkyl, -NR17bR17c, hydroxy, Ci-3alkoxy, and Ci-3alkoxy-Ci-2alkyl;or two R25groups on the same carbon come together to form C3-6cyclopropyl or heterocycloalkyl;R27is selected from Ci-3alkyl optionally substituted with hydroxy; Cs-ecycloalkyl; NR17bR17c; and Ci-3alkoxy;91107441203\1\AMERICASR28is independently selected from Ci-salkyl, halo, haloCi-salkyl, halo-Ci-ealkoxy, cyano, cyanoCi-salkyl, hydroxyl, hydroxyCi-salkyl, -O-(hydroxyCi-3alkyl), -(Co-C3alkylene)NR28aR28b, Ci-3alkoxy, Ci-3alkoxy-Ci-3alkyl, heterocycloalkyl, heterocycloalkylCi-salkyl, and heterocycloalkyloxy; andR28aand R28bare independently H or Ci-ealkyl;wherein whenselected fromCsalkylene)-NR17bR17c; C3-6cycloalkylCi-3alkyl; or Cs-ecycloalkyl.
[0008] The present disclosure provides at least the following embodiments:a) A compound of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g) or a pharmaceutically acceptable salt and / or stereoisomer thereof; b) A compound selected from Compound 1-577 or a pharmaceutically acceptable salt and / or stereoisomer thereof;c) A pharmaceutical composition comprising a compound of (a) or (b) and a pharmaceutically acceptable excipient, diluent, or carrier;d) A method for treating a disease, disorder, or condition associated with the STAT6 signaling pathway comprising administering a compound of (a) or (b) or a pharmaceutically acceptable salt and / or stereoisomer thereof; or a pharmaceutical composition of (c) to a host in need thereof;e) The method of (d) wherein the disease, disorder, or condition is an inflammatory disease, disorder, or condition;101107441203\1\AMERICASf) The method of (e) wherein the disease, disorder, or condition is an allergic inflammatory disease, disorder, or condition;g) The method of (d) wherein the disease, disorder, or condition is selected from asthma, airway hyperresponsiveness (AHR), allergic rhinitis, allergic asthma, emphysema, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, psoriasis, contact dermatitis, and atopic dermatitis;h) The method of (e) wherein the disease, disorder, or condition is a cellular proliferative disorder; andi) The method of (h) wherein the cellular proliferative disorder is cancer, including, but not limited to colon cancer, prostate cancer, breast cancer, gastrointestinal cancer, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and pancreatic cancer.DETAILED DESCRIPTION
[0009] The present disclosure provides for novel STAT6 inhibitor compounds, compositions, and methods of using the compounds and compositions, for example, in treating inflammatory diseases, disorders, and conditions, for example, allergic inflammatory diseases, disorders, and conditions, and proliferative diseases and cancer, including, but not limited to, colon cancer, prostate cancer, breast cancer, gastrointestinal cancer, and pancreatic cancer.Definitions
[0010] When referring to the compounds provided herein, the following terms have the following meanings unless indicated otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise. Unless specified otherwise, where a term is defined as being substituted, the groups in the list of substituents are themselves unsubstituted. For example, a substituted alkyl group can be substituted, for example, with a -OCi-ealkyl group, and the -OCi-ealkyl group is not further substituted unless specified otherwise.
[0011] Reference to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”. As used herein, and unless otherwise specified, the terms “about” and “approximately,” when used in connection with111107441203\1\AMERICAStemperatures, doses, amounts, or weight percent of ingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by those of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. Specifically, the terms “about” and “approximately,” when used in this context, contemplate a dose, amount, or weight percent within 15%, within 10%, within 5%, within 4%, within 3%, within 2%, within 1%, or within 0.5% of the specified dose, amount, or weight percent.
[0012] The terms “a” or “an,” as used in herein means one or more, unless context clearly dictates otherwise. For example, “pharmaceutically acceptable carrier” includes one or more ingredients as provided herein.
[0013] The term “alkyl” as used herein, unless otherwise specified, refers to a saturated straight or branched hydrocarbon. The alkyl group can be a primary, secondary, or tertiary hydrocarbon. In some or any embodiments, the alkyl group includes one to ten carbon atoms, i.e., Ci to Cio alkyl; one to six carbons, i.e., Ci to Ce alkyl; or, one to three carbons, i.e., Ci to C3 alkyl. In some or any embodiments, the alkyl is a Ci-salkyl. In some or any embodiments, the alkyl is a Ci-ealkyl. In some or any embodiments, the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, / -butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3 -methylpentyl, 2,2-dimethylbutyl, and2,3 -dimethylbutyl.
[0014] The term “alkylene” as used herein, unless otherwise specified, refers to a divalent alkyl group as defined herein. In some instances, Co-Csalkylene is used and Co indicates that the group is a bond.
[0015] The term “alkenyl” as used herein, unless otherwise specified, refers to an unsaturated straight or branched hydrocarbon containing one or more double bonds. In some or any embodiments, the alkenyl group includes two to ten carbon atoms, i.e., C2 to Cio alkenyl; two to six carbons, i.e., C2 to Ce alkenyl; three to six carbons, i.e., C3 to Ce alkenyl; or, two to three carbons, i.e., C2 to C3 alkenyl. In some embodiments, alkenyl is C2-4 alkenyl.
[0016] The term “alkynyl” as used herein, unless otherwise specified, refers to an unsaturated straight or branched hydrocarbon containing one or more triple bonds. In some or any embodiments, the alkynyl group includes two to ten carbon atoms, i.e., C2 to Cio alkynyl; two to six carbons, i.e., C2 to Ce alkynyl; three to six carbons, i.e., C3 to Ce alkynyl; or, two to three carbons, i.e., C2 to C3 alkynyl. In some or any embodiments, the alkynyl is C3-6 alkynyl.
[0017] The term “alkoxy” and “alkyloxy” as used herein, and unless otherwise specified, refer to the group -OR' where R' is alkyl as defined herein. In some embodiments, alkoxy 121107441203\1\AMERICASand alkyloxy are Ci-ealkoxy and Ci-ealkyloxy, respectively. In some embodiments, alkoxy and alkyloxy are Ci-4alkoxy and Ci-4alkyloxy, respectively. In some embodiments, alkoxy and alkyloxy are Ci-3alkoxy and Ci-3alkyloxy, respectively. In some embodiments, alkoxy includes, but is not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tertbutoxy, sec-butoxy, n-pentoxy, n-hexyloxy, and 1,2-dimethylbutoxy.
[0018] The term “aryloxy” as used herein, and unless otherwise specified, refers to the group-OR" where R" is aryl as defined herein. In some embodiments, aryloxy is including, but not limited to, phenoxy.
[0019] The term “alkoxyalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with alkoxy as defined herein. In some embodiments, alkoxyalkyl is Ci-2alkoxyCi-4alkyl, Ci-2alkoxyCi-5alkyl, Ci-3alkoxy-Ci-3alkyl, or Ci-2alkoxyC2-salkyl, for example -CH2CH2OCH3 or -CH2OCH3.
[0020] The term “Ci-ealkoxy-Ci-ealkyloxy” as used herein, unless otherwise specified, refers to an -O-Ci-ealkyl group where the Ci-ealkyl is as defined herein and is substituted with Ci-ealkoxy as defined herein. In some embodiments, Ci-ealkoxy-Ci-ealkyloxy is Ci-2alkoxyCi-4alkyloxy or Ci-2alkoxyCi-5alkyloxy, for example -OCH2CH2OCH3.
[0021] The term “Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl” as used herein, unless otherwise specified, refers to a Ci-2alkyl group substituted with Ci-2alkoxyCi-5alkyloxy as defined herein, for example -CH2CH2OCH2CH2OCH3.
[0022] The term “aryl” as used herein, unless otherwise specified, refers to a six- to fourteen-membered aromatic carbocyclic ring system. The aryl group can be monocyclic, bicyclic, or tricyclic wherein at least one ring is aromatic. Aryl groups include, for example, phenyl and naphthyl.
[0023] The term “arylalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with one aryl group as defined herein. In certain embodiments, the arylalkyl is arylCi-salkyl.
[0024] The term “alkylcarbonyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein wherein one -CH2- group is replaced with -C(O)-. In certain embodiments, the alkylcarbonyl group is -C(O)-alkyl. In certain embodiments, the alkylcarbonyl group is selected from the group consisting of a formyl group, an acetyl group, a 2-oxoethyl group, a propionyl group, a 2-oxopropyl group, and a 3-oxopropyl group.
[0025] The term “NR17bR17c-alkylcarbonyl” as used herein, unless otherwise specified, refers to an alkylcarbonyl group as defined herein substituted with -NR17bR17c. In some 131107441203\1\AMERICASembodiments, NR17bR17c-alkylcarbonyl is NR17bR17c-Ci-6alkylcarbonyl. In some embodiments, NR17bR17c-alkylcarbonyl is -C(O)Ci-6alkyl-NR17bR17c.
[0026] The term “alkylcarbamoyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with -C(O)NH2. The term “N-methyl-Ci-ealkylcarbamoyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with -C(O)NH(CH3). In some embodiments, alkylcarbamoyl is Ci-ealkylcarbamoyl.
[0027] The term “cycloalkyl” as used herein, unless otherwise specified, refers to a saturated cyclic hydrocarbon. The cycloalkyl group may be monocyclic (for example, a 3- to 10-membered monocyclic ring) or multi cyclic (for example, a 6- to 15-membered multi cyclic ring) wherein the multicyclic ring is bicyclic or tricyclic. Bicyclic cycloalkyl groups include bridged bicyclic groups, fused bicyclic groups, and spirocyclic bicyclic groups. In certain embodiments, the cycloalkyl group includes three to ten carbon atoms, i.e., C3 to C10 cycloalkyl; three to seven carbons i.e., C3 to C7 cycloalkyl; or three to six carbons i.e., C3 to Ce cycloalkyl. In certain embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0028] The term “cycloalkyloxy” as used herein, unless otherwise specified, refers to an -O-cycloalkyl group as defined herein. In certain embodiments, the cycloalkyloxy is C3-ecycloalkyloxy, including, but not limited to O-cyclopropyl.
[0029] The term “cycloalkylalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with a cycloalkyl group as defined herein. In certain embodiments, the cycloalkylalkyl is C3-6cycloalkylCi-3alkyl.
[0030] The term “cycloalkylalkyloxy” as used herein, unless otherwise specified, refers to an -O-alkyl group where the alkyl is as defined herein and is substituted with a cycloalkyl group as defined herein. In certain embodiments, the cycloalkylalkyloxy is Cs-ecycloalkylCi-salkyloxy.
[0031] The term “Cs-ecycloalkylene” as used herein, unless otherwise specified, refers to a divalent cycloalkyl group as defined herein. In certain embodiments, Cs-ecycloalkylene is cyclopropylene (including cyclopropan-l,l-di-yl and cyclopropan-l,2-di-yl).
[0032] The term “cycloalkenyl” as used herein, unless otherwise specified, refers to a monovalent monocyclic unsaturated cyclic hydrocarbon. In certain embodiments, the cycloalkenyl is Cs-vcycloalkenyl.141107441203\1\AMERICAS
[0033] The term “cyanoalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with a cyano group. In certain embodiments, the cyanoalkyl is cyanoCi-salkyl.
[0034] The term “deuteroCi-ealkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein where one or more (in embodiments, 1, 2, 3, 4, or 5) hydrogen atoms are replaced with deuterium atoms.
[0035] The term “deuteroCi-ealkoxy” as used herein, unless otherwise specified, refers to an alkoxy group as defined herein where one or more (in embodiments, 1, 2, 3, 4, or 5) hydrogen atoms are replaced with deuterium atoms.
[0036] The term “dimethylamino-Ci-ealkylcarbonyl” as used herein, unless otherwise specified, refers to an alkylcarbonyl group as defined herein substituted with -N(CH3)2.
[0037] The term “N-acetylamino-Ci-ealkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with -NHC(O)CH3.
[0038] The term “halo” as used herein, unless otherwise specified, refers to bromo, chloro, fluoro, or iodo.
[0039] The term “haloalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with one or more (in some embodiments 1, 2, 3, 4, or 5) halo groups as defined herein. In certain embodiments, the haloalkyl is haloCi-ealkyl or haloCi-4alkyl.
[0040] The term “haloalkoxy” as used herein, unless otherwise specified, refers to an -OR group where R is haloalkyl as defined herein. In certain embodiments, the haloalkoxy is haloCi-ealkoxy, including, but not limited to, -OCHF2 or -O(CH2)3F.
[0041] The term “heteroaryl” as used herein, unless otherwise specified, refers to a monovalent monocyclic or multicyclic aromatic ring system containing one or more heteroatoms independently selected from oxygen, nitrogen, and sulfur where the remaining ring atoms are carbon. Each ring of a heteroaryl group can contain one or two oxygen atoms, one or two sulfur atoms, and / or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. Unless stated otherwise, the point of attachment to the rest of the molecule is any ring of the heteroaryl group, valency rules permitting. In certain embodiments, the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms. In certain embodiments, the heteroaryl is a 5- or 6-membered ring. In certain embodiments, the heteroaryl is monocyclic or bicyclic. In certain embodiments, the heteroaryl is monocyclic. In certain embodiments, the heteroaryl is bicyclic. In certain embodiments, the heteroaryl is a 5-6 membered heteroaryl having 1-4151107441203\1\AMERICASheteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, the heteroaryl is selected from imidazolyl, thiazolyl, triazolyl, and tetrazolyl. In certain embodiments, the heteroaryl is a 9-10 membered heteroaryl, including, but not limited to, pyrazolo[l,5-a]pyridinyl.
[0042] The term “heteroaryl group fused to cycloalkyl” as used herein, unless otherwise specified, refers to a monovalent heteroaryl, as defined herein, where two adjacent carbon ring atoms of the heteroaryl are fused to a carbocycle where the carbocycle is a monocyclic ring of 4 to 7 carbon ring atoms and is not aromatic.
[0043] The term “heteroarylalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with one heteroaryl group as defined herein. In certain embodiments, the heteroarylalkyl is heteroarylCi-salkyl.
[0044] The term “heteroaryloxy” as used herein, and unless otherwise specified, refers to the group -OR'" where R'" is heteroaryl as defined herein.
[0045] The term “heterocycle,” as used herein, when fused to a phenyl or heteroaryl group in Ring B, when fused to a heteroaryl in R15cor in R17aor in R17cor in R19, when fused to aheteroaryl group in R17a, when fused to the indolewhen R5and R6come together, or when fused to Ring C when R3cand R15alcome together, and unless otherwise specified, refers to a partially unsaturated (but not aromatic) monocyclic or bicyclic group wherein the heterocycle contains at least one ring heteroatom independently selected from O, S(0)o-2, and N, and the remaining ring atoms are carbon atoms. In some or any embodiments, the bicyclic heterocycle is a bridged or non-bridged, a spirocyclic or not spirocyclic, and / or a fused or not fused bicyclic group. In some or any embodiments, the heterocycle comprises one or two heteroatom(s) that are nitrogen. In some or any embodiments, the heterocycle has from three to eight, four to seven, or five to six ring atoms. In certain embodiments, heteroaryl group fused to heterocycle is 4, 5,6,7-tetrahydropyrazolo[l,5-a]pyrazinyl, 6,7-dihydro-5H-pyrazolo[5,l-b][l,3]oxazinyl, 6,7-dihydro-4H-pyrazolo[5,l-c][l,4]oxazinyl, 4,5,6,7-tetrahydropyrazolo[l,5-a]pyrimidinyl, or 2,3-dihydropyrazolo[5,l-b]oxazolyl.
[0046] The term “heterocycloalkyl,” as used herein, and unless otherwise specified, refers to a monovalent monocyclic or multicyclic ring system that is saturated or partially unsaturated (but not aromatic) wherein one or more of the ring atoms is a heteroatom independently161107441203\1\AMERICASselected from O, S(0)o-2, Si, and N, and the remaining ring atoms are carbon atoms. In some or any embodiments, the heterocycloalkyl comprises one or two heteroatom(s) that are oxygen. In some or any embodiments, the heterocycloalkyl comprises one or two heteroatom(s) that are nitrogen. In some or any embodiments, the heterocycloalkyl comprises one heteroatom that is nitrogen. In some or any embodiments, the heterocycloalkyl has from 3 to 10, 3 to 7, 3 to 8, 4 to 8, or 5 to 6 ring atoms. In some or any embodiments, the heterocycloalkyl is a monocyclic or bicyclic ring system. In some or any embodiments, the heterocycloalkyl is a bridged or non-bridged, a spirocyclic or not spirocyclic, and / or a fused or not fused multicyclic group. In some or any embodiments, the heterocycloalkyl is saturated. In some or any embodiments, the heterocycloalkyl has 5 or 6 ring members. A heterocycloalkyl may be attached to the rest of the molecule via a nitrogen or a carbon atom. In some or any embodiments, the heterocycloalkyl, formed when R16aand R16bare taken together with the N to which they are attached, is a 3-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2. In some or any embodiments, the heterocycloalkyl is 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and S(0)o-2. In some or any embodiments, the heterocycloalkyl, formed when R17cand R17clare taken together with the N to which they are attached, is a 4-12 membered heterocycloalkyl.
[0047] The terms “heterocycloalkyloxy” and “heterocycloalkoxy,” as used herein, and unless otherwise specified, refers to an -OR group where R is heterocycloalkyl as defined here. In certain embodiments, the heterocycloalkyloxy is O-pyrrolidinyl or O-piperidinyl.
[0048] The term “heterocycloalkyloxyCi-salkyl” as used herein, unless otherwise specified, refers to a Ci-salkyl, as defined herein, substituted with heterocycloalkyloxy, as defined herein. In certain embodiments, the heterocycloalkyloxyCi-salkyl is heterocycloalkyloxyCi-2alkyl, including, but not limited to -Ckfc-O-piperidinyl.
[0049] The term “heterocycloalkylalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with one heterocycloalkyl group as defined herein. In some or any embodiments, the heterocycloalkylalkyl is heterocycloalkylCi-salkyl.
[0050] The term “heterocycloalkylalkyloxy” as used herein, unless otherwise specified, refers to an -O-alkyl group where the alkyl is as defined herein and is substituted with a heterocycloalkyl group as defined herein. In certain embodiments, the heterocycloalkylalkyloxy is heterocycloalkylCi-salkyloxy. In certain embodiments, the heterocycloalkylalkyloxy is heterocycloalkylCialkyloxy, including but not limited to -O- 171107441203\1\AMERICASCH2-pyrrolidinyl, -O-CH2-hexahydro-lH-pyrrolizinyl, and -O-CH2-3-azabicyclo[3.1.0]hexanyl.
[0051] The term “heterocycloalkylene” as used herein, unless otherwise specified, refers to a divalent heterocycloalkyl group as defined herein.
[0052] The term “heteroCi-salkylene” as used herein, unless otherwise specified, refers to an alkylene group as defined herein, in which one or more carbon atoms are replaced by O or N. The O or N atom can be at an attachment point where the heteroCi-salkylene is attached to the remainder of the molecule, or it can be at an interior position. In certain embodiments, the heteroCi-salkylene is -OCi-salkylene-, -Ci-3alkyleneO-, -Ci-3alkylene-OCi-3alkylene-, -NHCi-salkylene-, or -Ci-3alkyleneNH-. In certain embodiments, the heteroCi-salkylene is -NH-CH2-. In one embodiment, the Ci-3alkylene of heteroCi-salkylene is branched.
[0053] The term “hydroxyalkyl” as used herein, unless otherwise specified, refers to an alkyl group as defined herein substituted with one or more hydroxy groups (in some embodiments, 1 or 2 hydroxy). In some or any embodiments, the hydroxyalkyl is hydroxyCi-4alkyl or hydroxyCi-salkyl, including, but not limited to -C(CH3)2OH, -CH2CH2OH, -CH2C(CH3)2OH, -CH2CH(OH)CH2OH, -CH2CH(OH)CH3, and -CH2CH(OH)CH2OH.
[0054] The term “hydroxyalkyloxy” as used herein, unless otherwise specified, refers to an -O-alkyl group where alkyl is as defined herein and is substituted with one or more hydroxy groups (in some embodiments, 1 or 2 hydroxy). In some or any embodiments, the hydroxyalkyl is hydroxyCi-ealkyloxy or hydroxyCi-4alkyloxy. In some embodiments, hydroxyalkyloxy is 2-hydroxyethyloxy. In some embodiments, hydroxyalkyloxy is -OCH2C(CH3)2OH.
[0055] The term “hydroxyalkynyl” as used herein, unless otherwise specified, refers to an alkynyl group as defined herein substituted with one or more hydroxy groups (in some embodiments, 1 or 2 hydroxy).
[0056] The term “methanesulfonylamino” as used herein and unless otherwise specified, refers to -NHSO2CH3.
[0057] The term “oxo” as used herein and unless otherwise specified, refers to a keto group (C=O) when oxo is on a carbon. An oxo group that is a substituent of a nonaromatic carbon results in a conversion of a -CH2- to -C=O. An oxo group that is a substituent of an aromatic carbon results in a conversion of -CH- to -C=O. When a substituent is oxo, then two hydrogens on the atom are replaced. When an oxo group substitutes aromatic moieties, the corresponding partially unsaturated ring replaces the aromatic ring. For example, a pyridyl group substituted by an oxo group is a pyridonyl. The person of ordinary skill in the art will 181107441203\1\AMERICASappreciate that in some embodiments such a group, e.g. hydroxypyridinyl, can exist intautomeric form, e.g. pyridonyl. In one embodiment,exists asBoth tautomeric forms are included unless stated otherwise or clearly dictated by context.
[0058] The term “Ph” as used herein and unless otherwise specified, refers to phenyl.
[0059] As used herein, illustrations showing substituents bonded to a cyclic group (e.g., aryl, heteroaryl, cycloalkyl, heterocycloalkyl, heterocycloalkylene fused to a benzo or heteroaryl group, a heteroaryl group fused to 5-6 membered heterocycle, or a benzo group fused to heterocycle group) through a bond between ring atoms are meant to indicate, unless specified otherwise, that the cyclic group may be substituted with that substituent at any ring position in the cyclic group or on any ring in the fused ring group, according to techniques set forth herein or which are known in the field to which the instant disclosure pertains. Forexample, the groupwhich the positions of substituent R3bare not described as directly attached to any vertex of the bond line structure, i.e., a specific ring carbon atom,includeshuman or non-human animal in need of treatment of a disease or condition associated with the aggregation of pathogenic protein aggregates. Typically the host is a human. A “patient” or “host” or “subject” also refers to for example, mammals, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
[0060] A “pharmaceutically acceptable salt” includes a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, nontoxic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salt can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting a free base form of the compound with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-191107441203\1\AMERICASaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practicable.
[0061] Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC — (CH2)„ — COOH where n is 0-4, and the like. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences. 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
[0062] A “therapeutically effective amount” of a compound or pharmaceutical composition thereof is an amount that is effective, when administered to a host or subject, to provide a therapeutic benefit, such as an amelioration of symptoms of the selected condition or disease.
[0063] The term “substantially free of’ or “substantially in the absence of’ stereoisomers with respect to a composition refers to a composition that includes at least 85 or 90% by weight, in certain embodiments 95%, 98%, 99% or 100% by weight, of a designated stereoisomer of a compound in the composition. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of stereoisomers.
[0064] Similarly, the term “isolated” with respect to a composition refers to a composition that includes at least 85, 90%, 95%, 98%, 99% to 100% by weight, of a specified compound, the remainder comprising other chemical species or stereoisomers.
[0065] The term “isotopic composition,” as used herein, and unless otherwise specified, refers to the amount of each isotope present for a given atom, and “natural isotopic composition” refers to the naturally occurring isotopic composition or abundance for a given atom. Atoms containing their natural isotopic composition may also be referred to herein as “non-enriched” atoms. Unless otherwise designated, the atoms of the compounds recited herein are meant to represent any stable isotope of that atom. For example, unless otherwise stated, when a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its natural isotopic composition.201107441203\1\AMERICAS
[0066] The term “isotopic enrichment,” as used herein, and unless otherwise specified, refers to the percentage of incorporation of an amount of a specific isotope at a given atom in a molecule in the place of that atom's natural isotopic abundance. In certain embodiments, deuterium enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. The isotopic enrichment of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
[0067] The term “isotopically enriched,” as used herein, and unless otherwise specified, refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.
[0068] “Treating” or “treatment” of a disease, disorder, or condition, as used herein, includes (a) inhibiting the disease, disorder, or condition, i.e., arresting its development and (b) relieving the disease, disorder, or condition, e.g., relieving or reducing a symptom thereof, and / or causing regression of the disease, disorder, or condition. Alternatively, “treating” or “treatment” can refer to the prevention the disease, disorder, or condition, from occurring, i.e., causing the clinical symptoms of the disease, disorder, or condition not to develop in a host that may be exposed to or predisposed to the disease, disorder, or condition, but does not yet experience or display symptoms of the disease, disorder, or condition. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition, disease, or disorder may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art. “Treating” or “treatment” of any condition, disease, or disorder refers, in certain embodiments, to ameliorating a condition, disease, or disorder that exists in a subject. In another embodiment, “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In yet another embodiment, “treating” or “treatment” includes modulating the condition, disease, or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both. In yet another embodiment, “treating” or “treatment” includes delaying the onset of the condition, disease, or disorder.211107441203\1\AMERICAS
[0069] The term “disorders, diseases, and / or conditions associated with the STAT6 signaling pathway” are used herein to mean any disorder, disease, or condition in which STAT6 or a mutant thereof is known to play a role.Compounds
[0070] The aspects and embodiments described herein include the recited compounds as well as any pharmaceutically acceptable salt and / or stereoisomer thereof. For instance, aspects and embodiments described herein include a pharmaceutically acceptable salt thereof and / or a single stereoisomer of mixture of stereoisomers thereof.
[0071] In the first embodiment, the compound of Formula (I) is a compound of Formula (P-V):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof; whereinL is selected from -NR26-, -Ci-salkylene-, -Cs-ecycloalkylene-, -heterocycloalkylene-optionally substituted with 1 or 2 substituents independently selected from R25, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25;-Ci-3alkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -C3-6cycloalkylene-, -heterocycloalkylene- (optionally substituted with 1 or 2221107441203\1\AMERICASsubstituents independently selected from R25), -heteroCi-salkylene-, or bond,CR1, X5is N or CRla, and X6is N or CR2provided that only one of X4, X5, and X6is N; or X4is CR1, X5is CRla, and X6is CR2; wherein X7is N or CR6; and whereinthe attachment to the C ring;R26is H, Ci-3alkyl, hydroxyCi-2alkyl, Ci-2alkoxyCi-3alkyl, C3-4cycloalkyl, or heterocycloalkyl optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a phenyl group fused to a heterocycle or 5- to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18; or a phenyl group fused to a heteroaryl or 5- to 6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18;RingY1is CR3borN;Y2is CR3aorN;Y3is CR3b, CR3C, orN;Y4is CR3borN;wherein no more than 3 of Y1, Y2, Y3, or Y4are N;R15is -NR15alC(O)R15a2, -C(O)NR15bR15c, a 5- or 6-membered heterocycloalkyl, a 5-membered heteroaryl, or pyridonyl wherein the 5- or 6-membered heterocycloalkyl, 5-231107441203\1\AMERICASmembered heteroaryl, and pyridonyl are optionally substituted with 1, 2, 3, 4, 5, or 6 groups independently selected from R19;R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17c;R15alandR15bare independently H or Ci-ealkyl;or R15aland R3ccome together to form a 5- to 7-membered heterocycle;R15cis H; Ci-3alkyl optionally substituted with NR28aR28b; Ci-3alkylcarbonyl wherein the Ci-3alkyl is optionally substituted with NR28aR28b; hydroxy Ci-ealkyl; heterocycloalkyl; heterocycloalkylCi-salkyl; heterocycloalkyloxyCi-salkyl; -CH2-C(O)NR28aR28b; or -CH2-phenylene-NHC(O)NR28aR28b; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with Ci-4alkyl, Ci-3alkoxyCi-3alkyl, aryl, arylCi-salkyl, halo, heterocycloalkyl, or heterocycloalkylCi-salkyl;or R15band R15care taken together, with the N to which they are attached, to form a 3-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from hydroxy, Ci-3alkyl, halo, C2-3alkylcarbonyl, Ci-3alkoxy, hydroxyCi-3 alkyl, Ci-3alkoxyCi-3alkyl, cyano, Cs-ecycloalkyl, -S(O)2R9, -C(O)NR28aR28b, or -NHC(=O)CH3; or 2 substituents on the same carbon come together to form an oxo group;is a single bond or a double bond;R1is H, halo, Ci-salkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, aryl, heteroaryl, heterocycloalkyl, arylCi-salkyl, heteroarylCi-salkyl, aryloxy, heteroaryloxy, haloCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, deuterium, -OCi-3alkylOCi-3alkyl, -CN, or -SO2R9;Rlais H, halo, deuterium, or methyl;R2is H, F, Cl, deuterium, Ci-salkyl, haloCi-4alkyl, hydroxyCi-4alkyl, Ci-2alkoxyCi-salkyl, C2-4 alkenyl, Ci-4alkoxy, NR17bR17c, -OCi-3alkyl-C3-6cycloalkyl, or -OCi-3alkylOCi-2alkyl;R3aand R3bare independently selected from H; F; Cl; Ci-4alkyl; OH; -CN; hydroxyCi-4alkyl; Ci-4alkoxy wherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is optionally substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl; Ci-2alkoxyCi-5alkyl; -OCi-5alkylOCi-2alkyl; -OC2-5alkyl-NR17bR17c; aryl optionally substituted with heterocycloalkyl; heteroaryl; aryloxy; heterocycloalkyl; heteroaryl oxy; -O-Co-Csalkylene-heterocycloalkyl; and C2-ealkynyl optionally substituted with hydroxy, Ci-3alkyloxy, -(Co-3alkylene)NR17bR17c, Cs-ecycloalkyl optionally substituted with NR17bR17c, or heterocycloalkyl; wherein the heteroaryl and241107441203\1\AMERICASheterocycloalkyl, alone or part of another group, are optionally substituted with Ci-ealkyl or NR17bR17c;R3Cis hydrogen or R15aland R3ccome together to form a 5- to 7-membered heterocycle;R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; C3-6 alkynyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; -(Ci-Csalkylene)-C(O)NR17bR17c; -(C2-C5alkylene)-NR17b-C(O)R17c; aryl; arylCi-3alkyl; heteroaryl; heteroarylCi-salkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyl; or Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCo-2alkyl and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroarylCi-salkyl, are optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-3alkoxy, and Cs-ecycloalkyl and wherein the aryl of arylCi-salkyl is optionally substituted with heterocycloalkyl;R5ais Ci-ealkyl; haloCi-salkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; C3-ecycloalkyl; or, Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 halo which are independently selected;R6is H; F; Cl; Br; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; cyanoCi-salkyl; C2-ealkynyl optionally substituted with Cs-scycloalkyl or NR17bR17c; hydroxyCs-ealkynyl; Ci-2alkoxyCi-salkyl wherein the Ci-salkyl of Ci-2alkoxyCi-salkyl are independently optionally substituted with hydroxy or Cs-ecycloalkyl; Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl; C(O)NR16aR16b; Cs-scycloalkyl; Cs-scycloalkylCi-salkyl wherein the Ci-3alkyl of Cs-scycloalkylCi-salkyl is optionally substituted with hydroxy; deuterium; heterocycloalkyl; heterocycloalkylCi-salkyl; -(Co-3alkylene)-SC>2R9;-SO2NR17bR17c; cyano; -(Ci-C3alkylene)-NR17bR17c; P(O)(CH3)2; heteroaryl; and heteroarylCi-salkyl wherein the Cs-xcycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl, and cyano; and heteroaryl, alone or part of heteroarylCi-salkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected; or251107441203\1\AMERICASR5and R6together with the atoms to which they are attached form a heterocycle optionally substituted with 1 or 2 substituents independently selected from Ci-3alkyl, C3-4cycloalkyl and halo;R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH, Ci-ealkyl or Cs-ecycloalkyl;R13and R13aare independently H; halo; hydroxyCi-2alkyl; heterocycloalkyl optionally substituted with Ci-3alkyl; Cs-scycloalkyl; Ci-3alkoxyCi-3alkyl; -(Co-3alkylene)-NR17bR17c; aryl; heteroaryl; Cs-scycloalkylCi-salkyl; or alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl;R21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl; orR21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl; orR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form cycloalkyl or heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, Cs-scycloalkyl, or alkyl;provided that only one of a) R13and R13a; b) R21and R21a, and c) R13aand R21aform cycloalkyl or heterocycloalkyl;R16aand R16bare independently selected from H; Ci-ealkyl; phenyl; C3-7cycloalkyl; C5-7cycloalkenyl; a 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and S(0)o-2; and a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orR16aand R16bare taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2;R17is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; methanesulfonylamino; -SO2NR17bR17c; Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; Ci-ealkoxy; Ci-ealkoxy-Ci-ealkyl wherein the Ci-ealkyl of Ci-ealkoxy-Ci-ealkyl is independently optionally substituted with hydroxy; cyano-Ci-ealkyl; Ci-ealkylcarbonyl; dimethylamino-Ci-ealkylcarbonyl; -(Ci-6alkylene)NR17bR17c; N-acetylamino-Ci-ealkyl; Ci-ealkylcarbamoyl; N-methyl-Ci-6alkylcarbamoyl; -C(O)NR17aR17b; -C(O)R17c,-COOH; -NR17bC(O)R17c;-NR17bC(O)NR17cR17cl; -NR17bC(O)C(O)NR17cR17cl; aryl, heterocycloalkyl; and a 5-6- 261107441203\1\AMERICASmembered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;R17ais selected from H, Ci-ealkyl, OH, Ci-ealkoxy, halo-Ci-ealkoxy, Ci-3alkoxy-Ci-salkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, Cs-ecycloalkyloxy, Cs-ecycloalkylCi-salkyloxy, cyano-Ci-ealkyl, halo-Ci-ealkyl, hydroxy-Ci-ealkyl, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, NR17bR17c-Ci-6alkylcarbonyl, -(Ci-C3alkylene)-NR17bR17c, -OC2-4alkylene-NR17bR17c, Ci-2alkoxyCi-3alkyl, -C(O)NHOR24, heterocycloalkyl, -O-heterocycloalkyl, heterocycloalkylCi-salkyl, heterocycloalkylCi-salkoxy, aryl, a 5- or 6-membered heteroaryl group, heteroaryl group fused to heterocycle or cycloalkyl, or heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-3alkyl, the aryl, the heteroaryl, the heteroaryl of heteroarylCi-salkyl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;R17bis selected from hydrogen, Ci-ealkyl, Ci-ealkyloxy, haloCi-ealkyl, and Ci-6alkyloxyCi-3alkyl;R17Cis independently selected from hydrogen, Ci-ealkyl, Ci-ealkyloxy, hydroxy, haloCi-ealkyl, Ci-6alkyloxyCi-3alkyl, -(Ci-C3alkylene)-NR28aR28b, heterocycloalkyl, a 5- or 6-membered heteroaryl group, heteroaryl group fused to heterocycle or cycloalkyl, or heteroarylCi-salkyl wherein the heterocycloalkyl, heteroaryl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;R17C1is selected from hydrogen; Ci-ealkyl optionally substituted with 1, 2, or 3 groups independently selected from Cs-scycloalkyl, heterocycloalkyl, or methoxy wherein the C3-scycloalkyl is optionally substituted with 1 or 2 groups independently selected from -OH and Ci-3alkyl; Cs-scycloalkyl; haloCi-ealkyl; hydroxyCi-ealkyl; Ci-6alkyloxyCi-3alkyl; -CH2-phenylene-NHC(O)NR28aR28b; and heterocycloalkyl; or R17band R17care taken together, with the N to which they are attached, to form a 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or R17Cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R28;each R19is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi -ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy;271107441203\1\AMERICASCs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19groups on the same carbon come together to form an oxo group and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or one pair of R19groups on the same carbon come together to form an oxo group; a second pair of R19groups on the same carbon come together to form an oxo group; and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;281107441203\1\AMERICASor two R19groups on the same carbon come together to form a Cs-scycloalkyl and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5-to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19groups on the same carbon come together to form an oxo group; two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23; and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; C3- 291107441203\1\AMERICASecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;R18, R20, R22, and R23are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-3alkoxy; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxy, and hydroxyCi-ealkyl; C3-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy: haloCi-ealkyl; hydroxyCi-ealkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-Csalkylene)-NR17bR17c; -C(O)R27; -(Co-C3alkylene)-SC>2R9; heteroaryl; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl is optionally substituted with 1 or 2 substituents selected from -NR17bR17c, halo, and -OH; or two R20or R22groups on the same carbon come together form an oxo group;R24is H, Ci-salkyl, C3-6cycloalkylCi-3alkyl, heterocycloalkylCi-salkyl, hydroxyC2-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl;R25is independently selected from halo, Ci-3alkyl, -NR17bR17c, hydroxy, Ci-3alkoxy, and Ci-3alkoxy-Ci-2alkyl;or two R25groups on the same carbon come together to form C3-6cyclopropyl or heterocycloalkyl;R27is selected from Ci-3alkyl optionally substituted with hydroxy; Cs-ecycloalkyl; NR17bR17c; and Ci-3alkoxy;R28is independently selected from Ci-3alkyl, halo, haloCi-salkyl, halo-Ci-ealkoxy, cyano, cyanoCi-salkyl, hydroxyl, hydroxyCi-salkyl, -O-(hydroxyCi-3alkyl), -(Co-C3alkylene)NR28aR28b, Ci-3alkoxy, Ci-3alkoxy-Ci-3alkyl, heterocycloalkyl, heterocycloalkylCi-salkyl, and heterocycloalkyloxy; and301107441203\1\AMERICASR28aand R28bare independently H or Ci-ealkyl.
[0072] In a second embodiment, the compound of Formula (I) is of Formula (P-IV):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof; whereinL is selected from -NR26-, -Ci-salkylene-, -Cs-ecycloalkylene-, -heterocycloalkylene-optionally substituted with 1 or 2 substituents independently selected from R25, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25;-Ci-3alkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -Cs-ecycloalkylene-, -heterocycloalkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -heteroCi-salkylene-, or bond,CR1, X5is N or CRla, and X6is N or CR2provided that only one of X4, X5, and X6is N; or X4311107441203\1\AMERICASis CR1, X5is CRla, and X6is CR2; wherein X7is N or CR6; and wherein the attachment to the C ring;R26is H, Ci-3alkyl, hydroxyCi-2alkyl, Ci-2alkoxyCi-3alkyl, C3-4cycloalkyl, or heterocycloalkyl optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a phenyl group fused to a heterocycle or 5- to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18; or a phenyl group fused to a heteroaryl or 5- to 6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18;kyl, a 5-membered heteroaryl, or pyridonyl wherein the 5- or 6-membered heterocycloalkyl, 5-membered heteroaryl, and pyridonyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from R19;R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17c;R15al, R15band R15care independently H or Ci-ealkyl; or R15aland R3ccome together to form a 5- to 6-membered heterocycle;is a single bond or a double bond;R1is H, halo, Ci-salkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, aryl, heteroaryl, heterocycloalkyl, arylCi-salkyl, heteroarylCi-salkyl, aryloxy, heteroaryloxy, haloCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, deuterium, -OCi-3alkylOCi-3alkyl, -CN, or -SO2R9;Rlais H, halo, deuterium, or methyl;321107441203\1\AMERICASR2is H, F, Cl, deuterium, Ci-salkyl, haloCi-4alkyl, hydroxyCi-4alkyl, Ci-2alkoxyCi-salkyl, C2-4 alkenyl, Ci-4alkoxy, NR17bR17c, -OCi-salkyl-Cs-ecycloalkyl, or -OCi-salkylOCi-2alkyl;R3aand R3bare independently selected from H; F; Cl; Ci-4alkyl; OH; -CN; hydroxyCi-4alkyl; Ci-4alkoxy wherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is optionally substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl; Ci-2alkoxyCi-5alkyl; -OCi-5alkylOCi-2alkyl; -OC2-salkyl-NR17bR17c; aryl optionally substituted with heterocycloalkyl; heteroaryl; aryloxy; heterocycloalkyl; heteroaryl oxy; -O-Co-Csalkylene-heterocycloalkyl; and C2-ealkynyl optionally substituted with hydroxy, Ci-3alkyloxy, -(Co-3alkylene)NR17bR17c, Cs-ecycloalkyl optionally substituted with NR17bR17c, or heterocycloalkyl; wherein the heteroaryl and heterocycloalkyl, alone or part of another group, are optionally substituted with Ci-ealkyl or NR17bR17c;R3Cis hydrogen or R15aland R3ccome together to form a 5- to 6-membered heterocycle;R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; C3-6 alkynyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; -(Ci-Csalkylene)-C(O)NR17bR17c; -(C2-C5alkylene)-NR17b-C(O)R17c; aryl; arylCi-3alkyl; heteroaryl; heteroarylCi-salkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyl; or Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCo-2alkyl and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroaryl Ci -sal kyl, are optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-3alkoxy, and Cs-ecycloalkyl and wherein the aryl of arylCi-salkyl is optionally substituted with heterocycloalkyl;R5ais Ci-ealkyl; haloCi-salkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; C3-ecycloalkyl; or, Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 halo which are independently selected;R6is H; F; Cl; Br; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; cyanoCi-salkyl; C2-ealkynyl optionally substituted with Cs-scycloalkyl or NR17bR17c; hydroxyCs-ealkynyl; Ci-2alkoxyCi-salkyl wherein the Ci-salkyl of Ci-2alkoxyCi-salkyl are independently optionally substituted with hydroxy or Cs-ecycloalkyl; Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl; C(O)NR16aR16b; Cs-scycloalkyl; Cs-scycloalkylCi-salkyl 331107441203\1\AMERICASwherein the Ci-3alkyl of Cs-scycloalkylCi-salkyl is optionally substituted with hydroxy; deuterium; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C0-3alkylene)-SO2R9; -SO2NR17bR17c; cyano; -(Ci-C3alkylene)-NR17bR17c; P(O)(CH3)2; heteroaryl; and heteroarylCi-3alkyl wherein the Cs-scycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl, and cyano; and heteroaryl, alone or part of heteroarylCi-3alkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected; or R5and R6together with the atoms to which they are attached form a heterocycle optionally substituted with 1 or 2 substituents independently selected from Ci-3alkyl, C3-4cycloalkyl and halo;R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH, Ci-ealkyl or Cs-ecycloalkyl;R13and R13aare independently H; halo; hydroxyCi-2alkyl; heterocycloalkyl optionally substituted with Ci-3alkyl; Cs-scycloalkyl; Ci-3alkoxyCi-3alkyl; -(Co-3alkylene)-NR17bR17c; aryl; heteroaryl; Cs-scycloalkylCi-salkyl; or alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl;R21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl or R21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl; orR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form cycloalkyl or heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, Cs-scycloalkyl, or alkyl;provided that only one of a) R13and R13a; b) R21and R21a, and c) R13aand R21aform cycloalkyl or heterocycloalkyl;R16aand R16bare independently selected from H; Ci-ealkyl; phenyl; C3-7cycloalkyl; C5-7cycloalkenyl; a 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and S(0)o-2; and a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orR16aand R16bare taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2;341107441203\1\AMERICASR17is independently selected from H, deuterium; halo; cyano; hydroxyl; NR17bR17c; methanesulfonylamino; -SO2NR17bR17c; Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; Ci-ealkoxy; Ci-ealkoxy-Ci-ealkyl wherein the Ci-ealkyl of Ci-ealkoxy-Ci-ealkyl are independently optionally substituted with hydroxy; cyano-Ci-ealkyl; Ci-ealkylcarbonyl; dimethylamino-Ci-ealkylcarbonyl; -(Ci-6alkylene)NR17bR17c; N-acetylamino-Ci-ealkyl; Ci-ealkylcarbamoyl; N-methyl-Ci-6alkylcarbamoyl; -C(O)NR17aR17b; -COOH; -NR17bC(O)R17c;-NR17bC(O)NR17cR17cl; aryl, heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;R17ais selected from H, Ci-ealkyl, OH, Ci-ealkoxy, halo-Ci-ealkoxy, Ci-3alkoxy-Ci-salkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, Cs-ecycloalkyloxy, Cs-ecycloalkylCi-salkyloxy, cyano-Ci-ealkyl, halo-Ci-ealkyl, hydroxy-Ci-ealkyl, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, NR17bR17c-Ci-6alkylcarbonyl, -(Ci-C3alkylene)-NR17bR17c, -OC2-4alkylene- NR17bR17c, Ci-2alkoxyCi-3alkyl, -C(O)NHOR24, heterocycloalkyl, -O-heterocycloalkyl, heterocycloalkylCi-salkyl, heterocycloalkylCi-salkoxy, aryl, a 5- or 6-membered heteroaryl group, heteroaryl group fused to heterocycle or cycloalkyl, or heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-3alkyl, the aryl, the heteroaryl, the heteroaryl of heteroaryl Ci -sal kyl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;R17b, R17C, and R17clare independently selected from hydrogen, Ci-ealkyl, haloCi-ealkyl, and Ci-6alkyloxyCi-3alkyl;or R17band R17care taken together, with the N to which they are attached, to form a 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;each R19is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi -ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another351107441203\1\AMERICASgroup, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19groups on the same carbon come together to form an oxo group and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19groups on the same carbon come together to form a Cs-scycloalkyl and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5-to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23and the remaining of the R19groups are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl;361107441203\1\AMERICASheteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19groups on the same carbon come together to form an oxo group; two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23; and the remaining R19group is selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;R18, R20, R22, and R23are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-3alkoxy; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxy, and hydroxyCi-ealkyl; C3-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy: haloCi-ealkyl; hydroxyCi-ealkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-Csalkylene)-NR17bR17c; -C(O)R27; -(C0-C3alkylene)-SO2R9; heteroaryl; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl is optionally substituted with 1 or 2 substituents selected from -NR17bR17c, halo, and -OH; or two R22groups on the same carbon come together form an oxo group;R24is H, Ci-salkyl, C3-6cycloalkylCi-3alkyl, heterocycloalkylCi-salkyl, hydroxyC2-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl;371107441203\1\AMERICASR25is independently selected from halo, Ci-salkyl, -NR17bR17c, hydroxy, Ci-3alkoxy, and Ci-3alkoxy-Ci-2alkyl;or two R25groups on the same carbon come together to form C3-6cyclopropyl or heterocycloalkyl; andR27is selected from Ci-3alkyl optionally substituted with hydroxy; Cs-ecycloalkyl; NR17bR17c; and Ci-3alkoxy.
[0073] In a third embodiment, the compound of Formula (I) is of Formula (P-III):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof; whereinL is selected from -NR26-, -Ci-3alkylene-, -Cs-ecycloalkylene-, -heterocycloalkylene-, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25;-Ci-3alkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -Cs-ecycloalkylene-, -heterocycloalkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -heteroCi-salkylene-, or bond,381107441203\1\AMERICASCR1, X5is N or CRla, and X6is N or CR2provided that only one of X4, X5, and X6is N; or X4is CR1, X5is CRla, and X6is CR2; wherein X7is N or CR6; and whereinthe attachment to the C ring;R26is H, Ci-3alkyl, hydroxyCi-2alkyl, Ci-2alkoxyCi-3alkyl, C3-4cycloalkyl, or heterocycloalkyl optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a phenyl group fused to a heterocycle or 5- to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to -10-membered fused ring wherein the 8- to -10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18; or a phenyl group fused to a heteroaryl or 5- to 6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18;yl, a 5-membered heteroaryl, or pyridonyl wherein the 5- or 6-membered heterocycloalkyl, 5-membered heteroaryl, and pyridonyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from R19;R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17c;R15al, R15band R15care independently H or Ci-ealkyl; or R15aland R3ccome together to form a 5- to 6-membered heterocycle;391107441203\1\AMERICASis a single bond or a double bond;R1is H, halo, Ci-salkyl, Cs-ecycloalkyl, Cs-ecycloalkylCi-salkyl, aryl, heteroaryl, heterocycloalkyl, arylCi-salkyl, heteroarylCi-salkyl, aryloxy, heteroaryloxy, haloCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, deuterium, -OCi-3alkylOCi-3alkyl, -CN, or -SO2R9;Rlais H, halo, deuterium, or methyl;R2is H, F, Cl, deuterium, Ci-salkyl, haloCi-4alkyl, hydroxyCi-4alkyl, Ci-2alkoxyCi-salkyl, C2-4 alkenyl, Ci-4alkoxy, NR17bR17c, -OCi-salkyl-Cs-ecycloalkyl, or -OCi-salkylOCi-2alkyl;R3aand R3bare independently selected from H; F; Cl; Ci-4alkyl; OH; -CN, hydroxyCi-4alkyl; Ci-4alkoxywherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is optionally substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl; Ci-2alkoxyCi-5alkyl; -OCi-5alkylOCi-2alkyl; -OC2-5alkyl-NR17bR17c; aryl; heteroaryl; aryloxy; heterocycloalkyl; heteroaryl oxy; and -O-Co-Csalkylene-heterocycloalkyl; wherein the heteroaryl and heterocycloalkyl, alone or part of another group, are optionally substituted with Ci-ealkyl;R3Cis hydrogen or R15aland R3ccome together to form a 5- to 6-membered heterocycle;R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; C3-6 alkynyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; -(Ci-Csalkylene)-C(O)NR17bR17c; -(C2-C5alkylene)-NR17b-C(O)R17c; aryl; arylCi-3alkyl; heteroaryl; heteroarylCi-salkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyl; or Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCo-2alkyl and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroaryl Ci -sal kyl, are optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-3alkoxy, and Cs-ecycloalkyl and wherein the aryl of arylCi-salkyl is optionally substituted with heterocycloalkyl;R5ais Ci-ealkyl; haloCi-salkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; C3-ecycloalkyl; or, Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 halo which are independently selected;R6is H; F; Cl; Br; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; cyanoCi-salkyl; C2-ealkynyl optionally substituted with Cs-scycloalkyl or NR17bR17c; hydroxyCs-ealkynyl; Ci-401107441203\1\AMERICAS2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl are independently optionally substituted with hydroxy or Cs-ecycloalkyl; Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl; C(O)NR16aR16b; Cs-scycloalkyl; Cs-scycloalkylCi-salkyl wherein the Ci-3alkyl of Cs-scycloalkylCi-salkyl is optionally substituted with hydroxy; deuterium; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C0-3alkylene)-SO2R9;-SO2NR17bR17c; cyano; -(Ci-C3alkylene)-NR17bR17c; -P(O)(CH3)2; heteroaryl; and heteroarylCi-salkyl wherein the Cs-scycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl, and cyano; and heteroaryl, alone or part of heteroarylCi-salkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH, Ci-ealkyl or Cs-ecycloalkyl;R13and R13aare independently H; halo; hydroxyCi-2alkyl; heterocycloalkyl optionally substituted with Ci-3alkyl; Cs-scycloalkyl; Ci-3alkoxyCi-3alkyl; -(Co-3alkylene)-NR17bR17c; aryl; heteroaryl; Cs-scycloalkylCi-salkyl; or alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl;R21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl or R21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl; orR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form cycloalkyl or heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, Cs-scycloalkyl, or alkyl;R16aand R16bare independently selected from H; Ci-ealkyl; phenyl; C3-7cycloalkyl; C>.7cycloalkenyl; a 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and S(0)o-2; and a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orR16aand R16bare taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2;411107441203\1\AMERICASR17is independently selected from H; deuterium; halo; cyano; hydroxyl; NR17bR17c; methanesulfonylamino; -SO2NR17bR17c; Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; Ci-ealkoxy; Ci-ealkoxy-Ci-ealkyl wherein the Ci-ealkyl of Ci-ealkoxy-Ci-ealkyl are independently optionally substituted with hydroxy; cyano-Ci-ealkyl; Ci-ealkylcarbonyl; dimethylamino-Ci-ealkylcarbonyl; -(Ci-6alkylene)NR17bR17c; N-acetylamino-Ci-ealkyl; Ci-ealkylcarbamoyl; N-methyl-Ci-6alkylcarbamoyl; -C(O)NR17aR17b; -COOH; -NR17bC(O)R17c;-NR17bC(O)NR17cR17cl; aryl; heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;R17ais selected from H, Ci-ealkyl, OH, Ci-ealkoxy, halo-Ci-ealkoxy, Ci-3alkoxy-Ci-salkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, Cs-ecycloalkyloxy, Cs-ecycloalkylCi-salkyloxy, cyano-Ci-ealkyl, halo-Ci-ealkyl, hydroxy-Ci-ealkyl, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, NR17bR17c-Ci-6alkylcarbonyl, -(Ci-C3alkylene)-NR17bR17c, -OC2-4alkylene-NR17bR17c, Ci-2alkoxyCi-3alkyl, -C(O)NHOR24, heterocycloalkyl, -O-heterocycloalkyl, heterocycloalkylCi-salkyl, heterocycloalkylCi-salkoxy, aryl, a 5- or 6-membered heteroaryl group, a heteroaryl group fused to heterocycle or cycloalkyl, or heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-3alkyl, the aryl, the heteroaryl, the heteroaryl of heteroaryl Ci -sal kyl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;R17b, R17C, and R17clare independently selected from hydrogen and Ci-ealkyl;or R17band R17care taken together, with the N to which they are attached, to form a 4-7 membered heterocycloalkyl;each R19is independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on the same carbon come together to form an oxo group and the remaining of the R19groups are independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on the same carbon come together to form a Cs-scycloalkyl and the remaining of the R19groups are independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;421107441203\1\AMERICASor two R19groups on adjacent carbons come together to form a benzo group or a 5- to 6-membered heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from R23; andR18, R20, R22, and R23are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-3alkoxy; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxy, and hydroxyCi-ealkyl; C3-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy; haloCi-ealkyl; hydroxyCi-ealkyl wherein the Ci-ealkyl is optionally substituted with C3-ecycloalkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-C5alkylene)-NR17bR17c; -C(O)R27; -(C0-C3alkylene)-SO2R9; heteroaryl; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl is optionally substituted with 1 or 2 substituents selected from -NR17bR17c, halo, and -OH; or two R22groups on the same carbon come together form an oxo group;R24is H, Ci-salkyl, C3-6cycloalkylCi-3alkyl, heterocycloalkylCi-salkyl, hydroxyC?-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl; andR25is independently selected from halo, Ci-3alkyl, -NR17bR17c, hydroxy, Ci-3alkoxy, and Ci-3alkoxy-Ci-2alkyl;or two R25groups on the same carbon come together to form C3-6cyclopropyl or heterocycloalkyl; andR27is selected from Ci-3alkyl optionally substituted with hydroxy; Cs-ecycloalkyl; NR17bR17c; and Ci-3alkoxy.
[0074] In a fourth embodiment, the compound of Formula (I) is a compound of Formula (P-II):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof; whereinL is selected from -NR26-, -Ci-3alkylene-, -Cs-ecycloalkylene-, -heterocycloalkylene-, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25;431107441203\1\AMERICAS-Ci-3alkylene-, -Cs-ecycloalkylene-, -heterocycloalkylene-, -heteroCi-salkylene-, or bond,CR1, X5is N or CRla, and X6is N or CR2provided that only one of X4, X5, and X6is N; or X4is CR1, X5is CRla, and X6is CR2; wherein X7is N or CR6; and whereinthe attachment to the C ring;R26is H, Ci-3alkyl, hydroxyCi-2alkyl, Ci-2alkoxyCi-3alkyl, C3-4cycloalkyl, or heterocycloalkyl optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a phenyl group fused to a heterocycle or 5- to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to -10-membered fused ring wherein the 8- to -10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18; or a phenyl group fused to a heteroaryl or 5- to 6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring441107441203\1\AMERICASwherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18;yl, a 5-membered heteroaryl, or pyridonyl wherein the 5- or 6-membered heterocycloalkyl, 5- or 6-membered heterocycloalkyl fused to a benzo ring, 5-membered heteroaryl, and pyridonyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from R19;R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17c;R15al, R15band R15care independently H or Ci-ealkyl;is a single bond or a double bond;R1is H, halo, Ci-salkyl, Cs-ecycloalkyl, Cs-ecycloalkylCi-salkyl, aryl, heteroaryl, arylCi-salkyl, heteroarylCi-salkyl, aryloxy, heteroaryloxy, haloCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, deuterium, -OCi-3alkylOCi-3alkyl, or -SO2R9;Rlais H, halo, deuterium, or methyl;R2is H, F, Cl, deuterium, Ci-salkyl, haloCi-4alkyl, hydroxyCi-4alkyl, Ci-2alkoxyCi-salkyl, C2-4 alkenyl, Ci-4alkoxy, NR17bR17c, -OCi-3alkyl-C3-6cycloalkyl, or -OCi-3alkylOCi-2alkyl;R3aand R3bare independently selected from H; F; Cl; Ci-4alkyl; OH; hydroxyCi-4alkyl; Ci-4alkoxywherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is optionally substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl; Ci-2alkoxyCi-5alkyl; -OCi-5alkylOCi-2alkyl; -OC2-salkyl-NR17bR17c; aryl; heteroaryl; aryloxy; heterocycloalkyl; heteroaryl oxy; and -O-Co-Csalkylene-heterocycloalkyl; wherein the heteroaryl and heterocycloalkyl, alone or part of another group, are optionally substituted with Ci-ealkyl;R3Cis hydrogen or R15aland R3ccome together to form a 5- to 6-membered heterocycle;R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; C3-6 alkynyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; -(Ci-Csalkylene)-C(O)NR17bR17c; -(C2-C5alkylene)-NR17b-C(O)R17c; aryl; arylCi-3alkyl; heteroaryl; heteroarylCi-salkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyl; or Cs-7cycloalkenyl wherein the451107441203\1\AMERICASCs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCo-2alkyl and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroarylCi-salkyl, are optionally substituted with 1 or 2 groups independently selected from Ci-salkyl, haloCi-salkyl, halo, Ci-3alkoxy, and Cs-ecycloalkyl and wherein the aryl of arylC alkyl is optionally substituted with heterocycloalkyl;R5ais Ci-ealkyl; haloCi-salkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; C3-ecycloalkyl; or, Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 halo which are independently selected;R6is H; F; Cl; Br; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; cyanoCi-salkyl; C2-ealkynyl optionally substituted with Cs-scycloalkyl or NR17bR17c; hydroxyCs-ealkynyl; Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl are independently optionally substituted with hydroxy or Cs-ecycloalkyl; Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl; C(O)NR16aR16b; Cs-scycloalkyl; Cs-scycloalkylCi-salkyl wherein the Ci-3alkyl of Cs-scycloalkylCi-salkyl is optionally substituted with hydroxy; deuterium; heterocycloalkyl; heterocycloalkylCi-salkyl; -(Co-3alkylene)-SC>2R9;-SO2NR17bR17c; cyano; -(Ci-C3alkylene)-NR17bR17c; -P(O)(CH3)2; heteroaryl; and heteroarylCi-salkyl wherein the Cs-scycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl, and cyano; and heteroaryl, alone or part of heteroarylCi-salkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH, Ci-ealkyl or Cs-ecycloalkyl;R13and R13aare independently H; halo; hydroxyCi-2alkyl; heterocycloalkyl optionally substituted with Ci-3alkyl; Cs-scycloalkyl; Ci-3alkoxyCi-3alkyl; -(Co-3alkylene)-NR17bR17c; aryl; heteroaryl; Cs-scycloalkylCi-salkyl; or alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl;R21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl or R21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl; or461107441203\1\AMERICASR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form cycloalkyl or heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, Cs-scycloalkyl, or alkyl;R16aand R16bare independently selected from H; Ci-ealkyl; phenyl; C3-7cycloalkyl; Cs-7cycloalkenyl; a 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and S(0)o-2; and a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orR16aand R16bare taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2;R17is independently selected from H; deuterium; halo; cyano; hydroxyl; NR17bR17c; methanesulfonylamino; -SO2NR17bR17c; Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; Ci-ealkoxy; Ci-ealkoxy-Ci-ealkyl wherein the Ci-ealkyl of Ci-ealkoxy-Ci-ealkyl are independently optionally substituted with hydroxy; cyano-Ci-ealkyl; Ci-ealkylcarbonyl; dimethylamino-Ci-ealkylcarbonyl; -(Ci-6alkylene)NR17bR17c; N-acetylamino-Ci-ealkyl; Ci-ealkylcarbamoyl; N-methyl-Ci-ealkylcarbamoyl; imidazolyl; thiazolyl; triazolyl; tetrazolyl; -C(O)NR17aR17b;-COOH; -NR17bC(O)R17c; -NR17bC(O)NR17cR17cl; aryl; heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;R17ais selected from H, Ci-ealkyl, OH, Ci-ealkoxy, halo-Ci-ealkoxy, Ci-3alkoxy-Ci-3alkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, Cs-ecycloalkyloxy, Cs-ecycloalkylCi-salkyloxy, cyano-Ci-ealkyl, halo-Ci-ealkyl, hydroxy-Ci-ealkyl, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, NR17bR17c-Ci-6alkylcarbonyl, -(Ci-C3alkylene)-NR17bR17c, -OC2-4alkylene-NR17bR17c, Ci-2alkoxyCi-3alkyl, -C(O)NHOR24, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylCi-salkyl, heterocycloalkylCi-salkoxy, aryl, a 5- or 6-membered heteroaryl group, a heteroaryl group fused to heterocycle or cycloalkyl, or heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-3alkyl, the aryl, the heteroaryl, the heteroaryl of heteroaryl Ci -sal kyl, or the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;R17b, R17C, and R17clare independently selected from hydrogen and Ci-ealkyl;or R17band R17care taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl;471107441203\1\AMERICASeach R19is independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on the same carbon come together to form an oxo group and the remaining of the R19groups are independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on the same carbon come together to form a Cs-scycloalkyl and the remaining of the R19groups are independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on adjacent carbons come together to form a benzo group optionally substituted with 1, 2, or 3 substituents independently selected from R23; and R18, R20, R22, and R23are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-3alkoxy; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl and hydroxy; Cs-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy; haloCi -ealkyl; hydroxyCi-ealkyl wherein the Ci-ealkyl is optionally substituted with Cs-ecycloalkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-Csalkylene)-NR17bR17c; -C(O)R27; -(C0-C3alkylene)-SO2R9; heteroaryl; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl is optionally substituted with -NR17bR17c; or two R22groups on the same carbon come together form an oxo group;R24is H, Ci-salkyl, C3-6cycloalkylCi-3alkyl, heterocycloalkylCi-salkyl, hydroxyC?-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl; andR25is independently selected from halo, Ci-3alkyl, -NR17bR17c, hydroxy, Ci-3alkoxy, and Ci-3alkoxy-Ci-2alkyl;or two R25groups on the same carbon come together to form C3-6cyclopropyl or heterocycloalkyl; andR27is selected from Ci-3alkyl optionally substituted with hydroxy; Cs-ecycloalkyl; NR17bR17c; and Ci-3alkoxy.481107441203\1\AMERICAS
[0075] In certain embodiments of Formula (II), (III), and (IV), R17is not hydrogen.
[0076] In a fifth embodiment, the compound of Formula (I) is a compound of Formula (P-or a pharmaceutically acceptable salt and / or stereoisomer thereof; whereinwherein X4is N or CR1, X5is N or CRla, and X6is N or CR2provided that only one of X4, X5, and X6is N or X4is CR1, X5is CRla, and X6is CR2; wherein X7is N orCR6; and whereinis the attachment to the C ring;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a phenyl group fused to a heterocycle or 5- to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to -10-membered fused ring wherein the 8- to -10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18; or a phenyl group fused to a heteroaryl or 5- to 6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18;491107441203\1\AMERICASyl, a 5-membered heteroaryl, or pyridonyl wherein the 5- or 6-membered heterocycloalkyl, 5-membered heteroaryl, and pyridonyl are optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from R19;R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17c;R15al, R15band R15care independently H or Ci-ealkyl;is a single bond or a double bond;R1is H, halo, Ci-salkyl, Cs-ecycloalkyl, Cs-ecycloalkylCi-salkyl, aryl, heteroaryl, arylCi-salkyl, heteroarylCi-salkyl, aryloxy, heteroaryloxy, haloCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, deuterium, -OCi-3alkylOCi-3alkyl, or -SO2R9;Rlais H, halo, deuterium, or methyl;R2is H, F, Cl, deuterium, Ci-salkyl, haloCi-4alkyl, hydroxyCi-4alkyl, Ci-2alkoxyCi-salkyl, C2-4 alkenyl, Ci-4alkoxy, NR17bR17c, -OCi-3alkyl-C3-6cycloalkyl, or -OCi-3alkylOCi-2alkyl;R3aand R3bare independently selected from H, F, Cl, Ci-4alkyl, OH, hydroxyCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, -OCi-5alkylOCi-2alkyl, -OC2-salkyl-NR17bR17c, aryl, heteroaryl, aryloxy, and heteroaryloxy wherein the heteroaryl, alone or part of another group, is optionally substituted with Ci-ealkyl;R3Cis hydrogen or R15aland R3ccome together to form a 5- to 6-membered heterocycle;R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; C3-6 alkynyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl, -(C2-C5alkylene)-NR17bR17c, -(Ci-Csalkylene)-C(O)NR17bR17c, -(C2-C5alkylene)-NR17b-C(O)R17c, aryl, arylCi-3alkyl; heteroaryl; heteroarylCi-salkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyl; or Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCo-2alkyl and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroarylCi-salkyl, are optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-3alkoxy, and Cs-ecycloalkyl;501107441203\1\AMERICASR5ais Ci-ealkyl; haloCi-salkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; C3-ecycloalkyl; or, Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 halo which are independently selected;R6is H; F; Cl; Br; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; cyanoCi-salkyl; C2-ealkynyl optionally substituted with Cs-scycloalkyl or NR17bR17c; hydroxyCs-ealkynyl; Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl is optionally substituted with Cs-ecycloalkyl; C(O)NR16aR16b; Cs-scycloalkyl; Cs-scycloalkylCi-salkyl wherein the Ci-3alkyl of Cs-scycloalkylCi-salkyl is optionally substituted with hydroxy; deuterium; heterocycloalkyl; heterocycloalkylCi-salkyl; -(Co-3alkylene)-SC>2R9;-SO2NR17bR17c; cyano; -(Ci-C3alkylene)-NR17bR17c; -P(O)(CH3)2; heteroaryl; and heteroarylCi-salkyl wherein the Cs-scycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, and cyano; and heteroaryl, alone or part of heteroarylCi-salkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH, Ci-ealkyl or Cs-ecycloalkyl;R13and R13aare independently H or alkyl, or R13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl;R21and R21aare independently H or alkyl or R21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl;R16aand R16bare independently selected from H; Ci-ealkyl; phenyl; C3-7cycloalkyl; C5-7cycloalkenyl; a 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and S(0)o-2; and a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orR16aand R16bare taken together, with the N to which they are attached, to form a 4-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2;R17is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; methanesulfonylamino; -SO2NR17bR17c; Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; Ci-ealkoxy; Ci-ealkoxy-Ci-ealkyl cyano-Ci-ealkyl; Ci-ealkylcarbonyl; dimethylamino-Ci-ealkylcarbonyl; -(Ci-6alkylene)NR17bR17c; N-acetylamino-Ci-ealkyl; Ci-ealkylcarbamoyl; N-methyl-Ci-ealkylcarbamoyl; imidazolyl; thiazolyl; triazolyl; -C(O)NR17aR17b; -COOH, a 5-511107441203\1\AMERICAS6-membered heteroaryl group which is optionally substituted with 1, 2, or 3 substituents independently selected from R20;R17ais selected from H, Ci-ealkyl, Cs-ecycloalkyl, Cs-ecycloalkylCi-salkyl, cyano-Ci-ealkyl, halo-Ci-ealkyl, NR17bR17c-Ci-6alkylcarbonyl, -(Ci-C3alkylene)-NR17bR17c, Ci-2alkoxyCi-3alkyl, -C(O)NHOR24, heterocycloalkyl, heterocycloalkylCi-salkyl, aryl, a 5- or 6-membered heteroaryl group, or heteroaryl C alkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-salkyl, the aryl, the heteroaryl, or the heteroaryl of heteroarylCi-salkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;R17band R17care independently selected from hydrogen and Ci-ealkyl;or R17band R17care taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl;R19are independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on the same carbon come together to form an oxo group and the remaining of the R19groups are independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on the same carbon come together to form a Cs-scycloalkyl and the remaining of the R19groups are independently selected from hydrogen, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or two R19groups on adjacent carbons come together to form a benzo group optionally substituted with 1, 2, or 3 substituents independently selected from R23; and R18, R20, R22, and R23are independently selected from deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, Ci-3alkoxy, Cs-ecycloalkyl, haloCi-ealkyl, hydroxyCi-ealkyl, Ci-2alkoxyCi-3alkyl, and heterocycloalkyl; andR24is H, Ci-salkyl, C3-6cycloalkylCi-3alkyl, heterocycloalkylCi-salkyl, hydroxyC2-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl.
[0077] In one embodiment, the compound of Formula (I) is a compound wherein:L is selected from -NH-, -Ci-3alkylene-, -Cs-ecycloalkylene-, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- is optionally substituted with 1 or 2 substituents independently selected from R25;521107441203\1\AMERICASwherein when L is -Ci-3alkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -Cs-ecycloalkylene-, -heteroCi-salkylene-, or bond,wherein X4is CR1, X5is CRla, and X6is CR2;and wherein is the attachment to the C ring;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17;RingY2is CR3aorN;Y4is CR3borN;R15is -NR15alC(O)R15a2, -C(O)NR15bR15c, a 5- or 6-membered heterocycloalkyl, wherein the 5- or 6-membered heterocycloalkyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 groups independently selected from R19;R15aland R15bare independently H or Ci-ealkyl;R15Cis H or Ci-3alkyl;is a single bond or a double bond;R1is H, halo, Ci-salkyl, haloCi-4alkyl, or Ci-4alkoxy;Rlais H or halo;531107441203\1\AMERICASR2is H, F, Cl, Ci-salkyl, Ci-2alkoxyCi-5alkyl, C2-4 alkenyl, or Ci-4alkoxy;R3aand R3bare independently selected from H; F; Ci-4alkyl; -OCi-5alkylOCi-2alkyl; aryl optionally substituted with heterocycloalkyl; heterocycloalkyl; and C2-ealkynyl optionally substituted with hydroxy;R3Cis hydrogen; orR15aland R3ccome together to form a 5- to 7-membered heterocycle;R5is H; Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; arylCi-salkyl wherein the aryl is optionally substituted with heterocycloalkyl; heteroarylCi-salkyl; Cs-ecycloalkyl; wherein the Cs-ecycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, and cyanoCo-2alkyl, and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroarylCi-salkyl, are optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl and heterocycloalkyl;R5ais haloCi-salkyl;R6is H; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl are independently optionally substituted with 1 or 2 hydroxy groups or 1 Cs-ecycloalkyl group; heterocycloalkyloxyCi-salkyl; Cs-scycloalkyl; heterocycloalkyl; wherein the Cs-scycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, hydroxyCi-salkyl, Ci-3alkoxyCi-3alkyl, and Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; orR5and R6together with the atoms to which they are attached form a heterocycle; R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH;R13and R13aare independently alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl;R21and R21aare independently H or alkyl; orR21and R21acome together to form an oxo group; orR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form heterocycloalkyl; and R13and R21are independently H, halo, or alkyl;541107441203\1\AMERICASprovided that only one of a) R13and R13a; b) R21and R21a, and c) R13aand R21aform cycloalkyl or heterocycloalkyl;R17is independently selected from halo; cyano; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; -C(O)NR17aR17b; -C(O)R17C; -COOH; -NR17bC(O)R17c; -NR17bC(O)NR17cR17cl; aryl; heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;each R17ais selected from H; OH; Ci-ealkyl; halo-Ci-ealkyl; Ci-ealkoxy; halo-Ci-ealkoxy; Ci-3alkoxy-Ci-3alkyl; Cs-ecycloalkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyloxy; C3-ecycloalkylCi-salkyloxy; cyano-Ci-ealkyl; hydroxy-Ci-ealkyl; hydroxy-Ci-ealkyloxy; Ci-ealkoxy-Ci-ealkyloxy; -(Ci-C3alkylene)-NR17bR17c; heterocycloalkyloxy; a 5- to 10-membered heteroaryl group; heterocycloalkyl; heteroaryl group fused to heterocycle or cycloalkyl wherein the heteroaryl or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;each R17bis independently selected from hydrogen and Ci-ealkyl;each R17Cis independently selected from hydrogen, Ci-ealkyl, deuteroCi-ealkyl, C2-ealkenyl optionally substituted with 1 halo, Ci-ealkyloxy, hydroxy, and a 5- or 6-membered heteroaryl group, wherein the heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from R22;each R17C1is selected from hydrogen; Ci-ealkyl; or deuteroCi-ealkyl;or R17Cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R28;each R19is independently selected from cyano; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl; or each R19is as follows:(a) two R19groups on the same carbon come together to form an oxo group;551107441203\1\AMERICAS(d) two R19groups on the same carbon come together to form a Cs-scycloalkyl and a second pair of R19groups on the same carbon come together to form an oxo group; or (f) two R19groups on the same carbon come together to form an oxo group and two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;and the remaining of the R19groups in (a), (d), and (f) are independently selected from cyano; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-O-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl;R18, R20, R22, and R23are independently selected from halo; cyano; hydroxyl;NR17bR17c; Ci-ealkyl; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxy, and hydroxyCi-ealkyl; Cs-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy; haloCi-ealkyl; hydroxyCi-ealkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-Csalkylene)-NR17bR17c; -C(O)R27; -(C0-C3alkylene)-SO2R9; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl of heterocycloalkylalkyl is optionally substituted with 1 or 2 substituents selected from -NR17bR17c, halo, and -OH; ortwo R20or R22groups on the same carbon come together form an oxo group;R25is independently selected from halo, Ci-3alkyl, -NR17bR17c, hydroxy, and Ci-salkoxy;or two R25groups on the same carbon come together to form C3-6cyclopropyl;R27is selected from Cs-ecycloalkyl, Ci-3alkoxy, and Ci-3alkyl wherein the Ci-3alkyl is optionally substituted with hydroxy; andR28is independently selected from Ci-3alkyl and hydroxyl.
[0078] In one embodiment, the compound of Formula (I) is a compound wherein:561107441203\1\AMERICASL is selected from -NH-, -Ci-3alkylene-, -Cs-ecycloalkylene-, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- is optionally substituted with 1 or 2 substituents independently selected from R25;is the attachment to the C ring;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17;RingY2is CR3aorN;Y4is CR3borN;R15is -C(O)NR15bR15c, a 5- or 6-membered heterocycloalkyl, wherein the 5- or 6-membered heterocycloalkyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 groups independently selected from R19;R15bis H or Ci-ealkyl;R15Cis H or Ci-3alkyl;R1is H or halo;R2is H or F;R3aand R3bare independently selected from H; -OCi-5alkylOCi-2alkyl; aryl optionally substituted with heterocycloalkyl; and C2-ealkynyl optionally substituted with hydroxy;R9is Ci-3alkyl;R13and R13aare independently alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl;R21and R21aare independently H or alkyl; orR21and R21acome together to form an oxo group; or571107441203\1\AMERICASR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form heterocycloalkyl; and R13and R21are independently H, halo, or alkyl;provided that only one of a) R13and R13a; b) R21and R21a, and c) R13aand R21aform cycloalkyl or heterocycloalkyl;R17is independently selected from halo; cyano; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; -C(O)NR17aR17b; -C(O)R17C; -COOH; -NR17bC(O)R17c; -NR17bC(O)NR17cR17cl; aryl; heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;each R17ais selected from H; OH; Ci-ealkyl; halo-Ci-ealkyl; Ci-ealkoxy; halo-Ci-ealkoxy; Ci-3alkoxy-Ci-3alkyl; Cs-ecycloalkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyloxy; C3-ecycloalkylCi-salkyloxy; cyano-Ci-ealkyl; hydroxy-Ci-ealkyl; hydroxy-Ci-ealkyloxy; Ci-ealkoxy-Ci-ealkyloxy; -(Ci-C3alkylene)-NR17bR17c; heterocycloalkyloxy; heterocycloalkyl; a 5- to 10-membered heteroaryl group; heteroaryl group fused to heterocycle or cycloalkyl wherein the heteroaryl or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;each R17bis independently selected from hydrogen and Ci-ealkyl;each R17Cis independently selected from hydrogen, Ci-ealkyl, C2-ealkenyl optionally substituted with 1 halo, deuteroCi-ealkyl, Ci-ealkyloxy, hydroxy, and a 5- or 6-membered heteroaryl group, wherein the heteroaryl is optionally substituted with 1, 2, or 3 substituents independently selected from R22;each R17C1is selected from hydrogen; Ci-ealkyl; or deuteroCi-ealkyl;or R17Cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R28;each R19is independently selected from cyano; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group is optionally581107441203\1\AMERICASsubstituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl; or each R19is as follows:(a) two R19groups on the same carbon come together to form an oxo group;(d) two R19groups on the same carbon come together to form a Cs-scycloalkyl and a second pair of R19groups on the same carbon come together to form an oxo group; or (f) two R19groups on the same carbon come together to form an oxo group and two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;and the remaining of the R19groups in (a), (d), and (f) are independently selected from cyano; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-O-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl;R18, R20, R22, and R23are independently selected from halo; cyano; Ci-ealkyl; C3-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxy, and hydroxyCi-ealkyl; Cs-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy; haloCi-ealkyl; hydroxyCi-ealkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-Csalkylene)-NR17bR17c; -C(O)R27; -(C0-C3alkylene)-SO2R9; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl of heterocycloalkylalkyl is optionally substituted with 1 or 2 substituents selected from -NR17bR17c, halo, and -OH; ortwo R20or R22groups on the same carbon come together form an oxo group;R25is independently selected from halo, Ci-3alkyl, -NR17bR17c, hydroxy, and Ci-salkoxy;or two R25groups on the same carbon come together to form C3-6cyclopropyl;R27is selected from Cs-ecycloalkyl, Ci-3alkoxy, and Ci-3alkyl wherein the Ci-3alkyl is optionally substituted with hydroxy; and591107441203\1\AMERICASR28is independently selected from Ci-salkyl and hydroxyl.
[0079] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,is the attachment to the C ring. In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,601107441203\1\AMERICAS
[0080] In one embodiment of Formula (I), (P-V), or (P-IV), including any of theone embodiment of Formula (I), (P-V), or (P-IV), including any of the foregoing,. In one embodiment of Formula (I) or (P-I)-(P-V), including any of thewherein R1is H, halo, Ci-salkyl, or deuterium. In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,611107441203\1\AMERICASwherein R1is H or halo; and R2is H, F, Cl, Ci-salkyl, Ci-2alkoxyCi-5alkyl, or C2-4 alkenyl.
[0081] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,is the attachment to the C ring. In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,one embodiment of Formula (I) or (P-I)-(P-V),including any of the foregoing,one embodiment of Formula (I) or (P-I)-(P-V), including any of theone embodiment of Formula (I) or(P-I)-(P-V), including any of the foregoing,embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,621107441203\1\AMERICASone embodiment of Formula (I) or (P-I)-(P-V), including any of theone embodiment of Formula(I) or (P-II)-(P-V), including any of the foregoing,
[0082] In one embodiment of Formula (I) or (P-II)-(P-V), including any of the foregoing,4alkyl, or Ci-4alkoxy and R2is H, F, Cl, Ci-salkyl, Ci-2alkoxyCi-5alkyl, C2-4 alkenyl, or Ci- 4alkoxy.
[0083] In one embodiment of Formula (I) or (P-II)-(P-V), including any of the foregoing,is the attachment to the C ring. In631107441203\1\AMERICASone embodiment of Formula (I) or (P-II)-(P-V), including any of the foregoing,one embodiment of Formula (I) or (P-II)-(P-
[0084] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,641107441203\1\AMERICASembodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,one embodiment of Formula (I) or (P-I)-(P-V), including any of theforegoing,
[0085] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,wherein R1is H or halo; and R2is H, F, or Ci-4alkoxy.
[0086] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,is the attachment to the C ring.
[0087] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,is the attachment to the C ring.
[0088] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,is the attachment to the C ring.651107441203\1\AMERICAS
[0089] In one embodiment of Formula (I) or (P-I)-(P-V), including any of the foregoing,is the attachment to the C ring.
[0090] In one embodiment of Formula (I), (P-II)-(P-V), (I-b2), or (I-b4), including any of the foregoing, L is -NR26-.
[0091] In one embodiment of Formula (I), (P-II)-(P-V), (I-b2), or (I-b4), including any of the foregoing, L is -NH-. In one embodiment of Formula (I), (P-II)-(P-V), (I-b2), or (I-b4), including any of the foregoing, L is -N(CH3)-.
[0092] In one embodiment of Formula (I), (P-II)-(P-V), (I-b2), or (I-b4), including any ofthe foregoing, L is -NR26- and R26is selected from
[0093] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), including any of the foregoing, L is -Ci-3alkylene- optionally substituted with 1 or 2 substituents independently selected from R25. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), including any of the foregoing, L is unsubstituted -Ci-3alkylene-. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), (I-b2), or (I-b4), including any of the foregoing, L is unsubstituted -CH2- or unsubstituted -CH2CH2-. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), (I-b2), or (I-b4), including any of the foregoing, L is -CH2CH2- optionally substituted with 1 or 2 substituents independently selected from -NH2, F, methyl, hydroxy, -OCH3, and -OCH2OCH3. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), (I-b2), or (I-b4), including any of the foregoing, L is -CH2CH2- optionally substituted with 1 methyl or hydroxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), (I-b2), or (I-b4), including any of the foregoing, L is -CH(NH2)CH2-, -CF2, -CH(CH3)-, -CH(OH)-, -CH(OCH3)-, or -CH(CH2OCH3)-. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), (I-b2), or (I-b4), including any of the foregoing, L is -CH(CH3)- or -CH(OH)-.
[0094] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), (including any of the foregoing, L is -Ci-3alkylene- substituted with 2 R25groups wherein the R25groups on the same carbon come together to form C3-6cyclopropyl or heterocycloalkyl. In one661107441203\1\AMERICASembodiment of Formula (I), (I-al ), (P-II)-(P-V), (I-b2), or (I-b4), including any of theforegoing,
[0095] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), including any of the foregoing, L is -C3-6cycloalkylene-. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), including any of the foregoing, L is -cyclopropylene.
[0096] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), including any of the foregoing, L is heterocycloalkylene. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), (I-b2), or (I-b4), including any of the foregoing, L is a 4- to 8-membered heterocycloalkylene optionally substituted with 1 or 2 substituents independently selected from R25. In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), including any of the foregoing, L is azetidinyl.
[0097] In one embodiment of Formula (I), (P-II)-(P-V), or (I-b4), including any of the foregoing, L is -heteroC1-3alkylene-. In one embodiment of Formula (I), (P-II)-(P-V), or (I-b4), including any of the foregoing, L is -O-C1-3alkylene- or -C1-3alkylene-O-. In one embodiment of Formula (I), (P-II)-(P-V), or (I-b4), including any of the foregoing, L is -OCH2- or -CH2O-. In one embodiment of Formula (I), (P-II)-(P-V), or (I-b4), including any of the foregoing, L is -NHCi-3alkylene- or -Ci-3alkyleneNH-. In one embodiment of Formula (I), (P-II)-(P-V), or (I-b4), including any of the foregoing, L is -NHCH2- or -CH2NH-. In one embodiment of Formula (I), (P-II)-(P-V), or (I-b4), including any of the foregoing, L is -NHCH2-.
[0098] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b4), including any of the foregoing, L is bond.
[0099] In one embodiment of Formula (I), (P-II)-(P-V), or (I-b4), including any of the671107441203\1\AMERICASone embodiment of Formula (I) or (P-II)-(P-V), including any of the foregoing, L is -NHCH2- wherein the -CH2- of L is attached to the B ring andone embodiment of Formula (I) or (P-II)-(P-V), including any of the foregoing, L is -NHCH2- wherein theattached to the B ring,
[0102] In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a phenyl group substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), (I-bl), or (I-b2), including any of the foregoing, Ring B is a phenyl group substituted681107441203\1\AMERICASwith 1 R17group. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), (I-b 1), (I-b2), or (I-b4), including any of the foregoing, Ring B is a phenyl group substituted with 2 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), (I-bl), (I-b2), or (I-b4), including any of the foregoing, Ring B is a phenyl group substituted with 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a phenyl group substituted with 4 or 5 substituents independently selected from R17.
[0103] In one embodiment of Formula (I), (P-I)-(P-V), (I-b2), or (I-b4), including any of the foregoing, Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17and L is -NH-. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17and L is -Ci-3alkylene- or -C3-6cycloalkylene wherein the -Ci-3alkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25. In one embodiment of Formula (I), (P-I)-(P-V), (I-b2), or (I-b4), including any of the foregoing, Ring B is a phenyl group or heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from R17and L is -NHCH2- wherein the -CH2- is attached to the B ring.
[0104] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is deuterium. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is halo. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is Cl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is cyano. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-bl)-(I-b4), including any of the foregoing, R17is hydroxyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b l)-(I-b4), including any of the foregoing, R17is methanesulfonylamino. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-bl)-(I-b4), including any of the foregoing, R17is -SO2NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b l)-(I-b4), including any of the foregoing, R17is n-pentyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is halo-Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -CH2CH2CH2CH2F. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the691107441203\1\AMERICASforegoing, R17is hydroxy-Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -CH2CH2CH2CH2OH. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is Ci-ealkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -O-n-butyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is Ci-ealkoxy-Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -CH2OCH2CH2CH2CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is cyano-Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -CH2CH2CH2CH2CN. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is Ci-ealkylcarbonyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)-Ci-6alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)-n-butyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is dimethylamino-Ci-ealkylcarbonyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)-Ci-6alkylene-N(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)CH2CH2CH2N(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -(Ci-6alkylene)NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -CH2CH2NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is N-acetylamino-Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -CH2CH2CH2NHC(O)CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is Ci-ealkylcarbamoyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is N-methyl-Ci-ealkylcarbamoyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)N(CH3)Ci-6alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)N(CH3)CH2CH2CH2CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)NR17aR17b. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the701107441203\1\AMERICASforegoing, R17is -C(O)NHCi-6alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -C(O)N(CH3)Ci-6alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)NHCH2CH2CH2CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -C(O)N(CH3)CH2CH2CH2CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -COOH.
[0105] In one embodiment of Formula (P-IV), (P-III), (P-II), (I-b 1), (I-b2), (I-b3), or (Ib-4), including any of the foregoing, R17is H. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is Ci-ealkoxy-Ci-ealkyl wherein the Ci-ealkyl is independently optionally substituted with hydroxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -CH2CH(OH)CH2OCH3.
[0106] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NR17bC(O)R17c. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)Ci-6alkoxy. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)OCH3. In one embodiment of Formula (I), (P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)OCH2CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)Ci-6alkyl. In one embodiment of Formula (I), (P-IV)-(P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)Ci-6alkyloxyCi-3alkyl. In one embodiment of Formula (I), (P-IV)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)CH2CH3. In one embodiment of Formula (I), (I-al), or (I-bl)-(I-b4), including any of the foregoing, R17is -NHC(O)C2-ealkenyl wherein the C2-ealkenyl is optionally substituted with halo. In one embodiment of Formula (I), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)CH=CH2 or -NHC(O)CF=CH2. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)R17cwherein R17cis a 5- or 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R22. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)R17cwherein R17cis a 5- or 6-membered heteroaryl group optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl. In one embodiment of Formula (I), (P-V), (I-al), or (I- 711107441203\1\AMERICASal), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)R17cwherein R17cis heterocycloalkyl optionally substituted with 1 substituent selected from R22. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)R17Cwherein R17cis tetrahydrofuranyl.
[0107] In one embodiment of Formula (I), (I-al), or (I-b 1 )-(I-b4), including any of the721107441203\1\AMERICASo(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is H or
[0108] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NR17bC(O)NR17cR17cl. In one embodiment of Formula (II), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)N(Ci-6alkyl)2. In one embodiment of Formula (II), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)CH3 or -NHC(O)N(CH3)2. In one embodiment of Formula (I), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)N(deuteroCi-6alkyl)2. In one embodiment of Formula (I), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)N(CD3)2. In one embodiment of Formula (I), (P-V), (P-IV), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)NHCi-6haloalkyl. In one embodiment of Formula (I), (P-V), (P-IV), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)NHCH2CHF2 or -NHC(O)N(CH3)CH2CHF2. In one embodiment of Formula (I), (P-V), (P-IV), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)NHOH. In one embodiment of Formula (I), (P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)NH(Ci-6alkyloxy). In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1)-(I-b4), including any of the foregoing, R17is -NHC(O)NH(OCH3). In one embodiment of Formula (I), (P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)NHR17Cwherein R17cis a 5- or 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R22. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NHC(O)NHR17cwherein R17cis a 5- or 6-membered heteroaryl group optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl. In one embodiment of Formula (I), (P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NHC(O)NHR17cwherein R17cis
[0109] In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NR17bC(O)NR17cR17cland R17cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted731107441203\1\AMERICASwith 1, 2, 3, or 4 substituents independently selected from R28. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NR17bC(O)NR17cR17cland R17cand R17clare taken together, with the N to which they are attached, to form a 6 membered heterocycloalkyl optionally substituted with 1 or 2 substituents independently selected from R28. In one embodiment of Formula (I), (P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is -NR17bC(O)NR17cR17cland R17cand R17C1are taken together, with the N to which they are attached, to form a 4-10 membered heterocycloalkyl optionally substituted with 1 or 2 substituents independently selected fromObl)-(I-b4), including any of the foregoing, R17is741107441203\1\AMERICASembodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), including any of theOforegoing, R17isHI. In one embodiment of Formula (I), (P-V), (I-al), or (I-bl)-(I- Ob4), including any of the foregoing, R17is. In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is -NR17bC(O)C(O)NR17cR17cl.
[0110] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is aryl optionally substituted with 1, 2, or 3 substituents independently selected from R20. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-bl)-(I-b4), including any of the foregoing, R17is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from R20. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from halo and NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the751107441203\1\AMERICASforegoing, one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-bl)-(I-b4), including any of the foregoing, R17is 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is imidazolyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b 1)-(I-b4), including any of the foregoing, R17is thiazolyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b l)-(I-b4), including any of the foregoing, R17is triazolyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is tetrazolyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, R17is piperidinyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is. In one embodiment of Formula (I), (P-IV)-(P-I), (I-al), (I-b 1), (I-b2), or (I-b3), including any of the foregoing, R17is. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is heterocycloalkyl.
[0111] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is independently selected from deuterium, Cl, cyano, hydroxyl, NR17bR17c, methanesulfonylamino, -SO2NR17bR17c, n-pentyl, -CH2CH2CH2CH2F, CH2CH2CH2CH2OH, -O-n-butyl, -CH2OCH2CH2CH2CIB, -CH2CH2CH2CH2CN, -C(O)-n-butyl, -C(O)CH2CH2CH2N(CH3)2, -(Ci-6alkylene)NR17bR17c, -CH2CH2CH2NHC(O)CH3, -C(O)N(CH3)CH2CH2CH2CH3, imidazolyl, thiazolyl, -C(O)NHCH2CH2CH2CH3,
[0112] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is independently selected from deuterium, Cl, Br, cyano, -CH2CH(OH)CH2OCH3, hydroxyl, NR17bR17c, -C(O)NR17aR17b, -NHC(O)CH3, -NHC(O)N(CH3)2, methanesulfonylamino, -SO2NR17bR17c, n-pentyl, -CH2CH2CH2CH2F, -CH2CH2CH2CH2OH, -CH2C(CH3)2OH, -CH2CH(OH)CH2OH, -CH2C(OH)(CH3)2, -CH2C(NH2)(CH3)2, -O-n-butyl, -CH2OCH2CH2CH2CIR, -CH2CH2CH2CH2CN, -C(O)-n-761107441203\1\AMERICASbutyl, -C(O)CH2CH2CH2N(CH3)2, -(Ci-6alkylene)NR17bR17c, -CH2CH2CH2NHC(O)CH3, -C(O)N(CH3)CH2CH2CH2CH3, imidazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, thiophenyl, oxadiazolonyl, piperdinyl, -C(0)NH2, -C(O)NHCH3, -C(O)NHCH2CH2CH2CH3,one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, each R17is independently selected from halo; cyano; NR17bR17c; Ci-ealkyl; Ci-6alkoxy; -C(O)NR17aR17b; -COOH; -NR17bC(O)R17c; -NR17bC(O)NR17cR17cl; aryl; heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl, heterocycloalkyl, and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20.
[0113] In one embodiment of Formula (I), (P-V), (I-al), or (I-b 1 )-(I-b4), including any of the foregoing, each R17is independently selected from halo; cyano; NR17bR17c; Ci-ealkoxy; -C(O)NR17aR17b; -C(O)R17C; -NR17bC(O)R17c; -NR17bC(O)NR17cR17cl; aryl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20.
[0114] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, each R17is independently selected from halo; -C(O)NR17aR17b; -NR17bC(O)R17c; and -NR17bC(O)NR17cR17cl.
[0115] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is independently selected from halo, -C(O)NR17aR17b, and -COOH. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, R17is independently selected from halo, -C(O)NHR17a, and -COOH. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring B is a phenyl group substituted with 1, 2, or 3 substituents independently selected from R17wherein R17is halo, -C(O)NR17aR17b, and -COOH. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring B is a phenyl group substituted with 2 substituents independently selected from R17wherein R17is halo, -C(O)NR17aR17b, and -COOH. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring B is a phenyl group substituted with halo and -C(O)NR17aR17b. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring B is a phenyl group substituted with F and -C(O)NR17aR17b. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4),771107441203\1\AMERICASincluding any of the foregoing, Ring B is a phenyl group substituted with halo and -C(O)NH2.
[0116] In one embodiment of Formula (I), (P-I)-(P-V), or (I-b l)-(I-b4), including any ofthe foregoing, Ringone embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ringone embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of theforegoing, Ringone embodiment of Formula -al), or (I-b l)-(I-b4), including any of the foregoing, Ring B isin one embodiment of Formula (I), (P-I)-(P-V), or (I-b 1 )-(I-b4), including
[0117] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), includingany of the foregoing, Ring
[0118] In one embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), includingany of the foregoing, Ringone embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring B is781107441203\1\AMERICASone embodiment of Formula (I), (P-II)-(P-V), (I-al ), or (I-b l)-(I-b4),including any of the foregoing, Ring
[0119] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b2)-(I-b4), including any of the foregoing, Ring B is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b2)-(I-b4), including any of the foregoing, Ring B is a 5-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b2)-(I-b4), including any of the foregoing, Ring B is a 5-membered heteroaryl group comprising 1, 2, or 3 heteroatoms independently selected from N, O, and S and further optionally substituted with 1 R17group. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b2)-(I-b4), including any of the foregoing, Ring B is a 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b2)-(I-b4), including any of the foregoing, Ring B is a 6-membered heteroaryl group comprising 1, 2, or 3 heteroatoms independently selected from N, O, and S and further optionally substituted with 1 R17group.
[0120] In one embodiment of Formula (I), (P-II)-(P-V), (I-b2), (I-al), or (I-b4), including any of the foregoing, Ring B is a 6-membered heteroaryl group comprising 1, 2, or 3 heteroatoms independently selected from N, O, and S and further optionally substituted with 1 R17group and L is -Ci-3alkylene- or -Cs-ecycloalkylene wherein the -Ci-3alkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25. In one embodiment of Formula (I), (P-II)-(P-V), (I-b2), or (I-b4), including any of the foregoing, Ring B is a 6-membered heteroaryl group comprising 1, 2, or 3 heteroatoms independently selected from N, O, and S and further optionally substituted with 1 R17group and L is -heteroCi-salkylene-.
[0121] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b2)-(I-b4), includingany of the foregoing, Ring B is selected fromvan. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b2)-(I-b4), including any of the791107441203\1\AMERICASforegoing, Ring B is selected from. In one embodiment of Formula (I), (P-I)-(P-V), (I-al ), or (I-b2)-(I-b4), including any of the foregoing, Ring B isIn one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b2)-(I-b4), including any of the foregoing, Ringone embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b2)-(I-b4), including any of the foregoing, Ring B isincluding any of the foregoing, Ring B is selected from801107441203\1\AMERICASal), or (I-b2)-(I-b4), including any of the foregoing, Ring B is selected fromFormula (I), (P-IV)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring B is811107441203\1\AMERICASone embodiment of Formula (I), (P-II)-(P-V), (I-al ), or (I-b l)-(I-b4),including any of the foregoing, Ringone embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring B is
[0123] In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 5-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 5-membered heteroaryl group comprising 1, 2, or 3 heteroatoms independently selected from N, O, and S and further optionally substituted with 1 R17group. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 6-membered heteroaryl group comprising 1, 2, or 3 heteroatoms independently selected from N, O, and S and further optionally substituted with 1 R17group. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B isFormula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is selected fromIn one embodiment of Formula (I) or (P-I)-(P-V),821107441203\1\AMERICASincluding any of the foregoing, Ring B is selected from. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing,Ring B is selected fromembodiment of Formula (I), (P-II)-(P-V), or (I-al), including any of the foregoing, Ring B is. In one embodiment of Formula (I), (P-II)-(P-V), or (I-al),including any of the foregoing, Ring B isHI
[0124] In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a phenyl group fused to a heterocycle to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a phenyl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a 5- to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18. In one embodiment of Formula (I), (P-I)-(P-V), or (I-al), including any of the foregoing, Ring B is a 5- to 6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18.
[0125] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(Ib-4),, including any of the foregoing, R17is independently selected from halo, C(O)NR17aR17b, -COOH, Ci-ealkoxy, and Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(Ib-4),, including any of the foregoing, R17is independently selected from F, C(O)NHR17a, -COOH, -OCH3, and CH3.831107441203\1\AMERICAS
[0126] In embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(Ib-4)„ including any of the foregoing, R17is -C(O)NHR17aand R17ais selected from OH, Ci-ealkoxy, C3-ecycloalkylCi-salkyloxy, Ci-ealkoxy, C3-6cycloalkylCi-3alkyloxy, heterocycloalkylCi-salkoxy, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, and -OC2-4alkylene- NR17bR17c.
[0127] In embodiment of Formula (I), (P-II)-(P-V), (I-al), or (I-b l)-(Ib-4), including any of the foregoing, at least one R17is -C(O)NHR17awherein each R17ais selected from H; OH; Ci-ealkoxy; halo-Ci-ealkoxy; Ci-3alkoxy-Ci-3alkyl; Cs-ecycloalkyl; Cs-ecycloalkyloxy; C3-ecycloalkylCi-salkyloxy; cyano-Ci-ealkyl; hydroxy-Ci-ealkyl; hydroxy-Ci-ealkyloxy; Ci-ealkoxy-Ci-ealkyloxy; -(Ci-C3alkylene)-NR17bR17c; a 5- to 10-membered heteroaryl group; a heteroaryl group fused to heterocycle or cycloalkyl; or heteroarylCi-salkyl wherein the heterocycloalkyl of heterocycloalkylCi-salkyl, the heteroarylor any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22.
[0128] In one embodiment of Formula (I), (P-I)-(P-V), (I-al), (I-b3), or (I-b4), includingany of the foregoing, Ringone embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b3), including any of the foregoing, Ringone embodiment of Formula (I), (P-I)-(P-V), (I-al), (I-b3), or (I-b4),including any of the foregoing, Ringone embodiment of Formula (I),(P-I)-(P-V), (I-al), (I-b3), or (I-b4), including any of the foregoing, RingIn one embodiment of Formula (I) or (P-V), including any of the foregoing, Ring C is841107441203\1\AMERICAS
[0129] In one embodiment of Formula (I) or (P-V), including any of the foregoing, Ring,,,,including any of the foregoing, Ringselected fromone embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4), including any of the foregoing, Ring C is In one embodiment of Formula (I), (P-I)-(P-V), (I-al), or (I-b l)-(I-b4),including any of the foregoing, Ring851107441203\1\AMERICAS
[0130] In one embodiment of Formula (I), (P-I)-(P-V), (I-b3), or (I-b4), including any ofwherein X1is CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;R19aand R19bare independently selected from H, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or R19aand R19bcome together to form a Cs-scycloalkyl;or two R19agroups, on adjacent carbons, together with the carbons to which they are attached, form a substituted benzo group;R19Cis H, deuterium, Ci-ealkyl, Cs-ecycloalkyl, haloC2-ealkyl, and heterocycloalkyl; anda,' is a single bond or a double bond.
[0131] In one embodiment of Formula (I), (P-I)-(P-V), (I-b3), or (I-b4), including any ofwherein X1is CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;R19aand R19bare independently selected from H, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;861107441203\1\AMERICASor R19aand R19bcome together to form a Cs-scycloalkyl;or two R19agroups, on adjacent carbons, together with the carbons to which they are attached, form a benzo group optionally substituted with 1, 2, or 3 substituents independently selected from R23;R19Cis H, deuterium, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloC2-ealkyl, and heterocycloalkyl; anda,' is a single bond or a double bond.
[0132] In one embodiment of Formula (I), (P-V), (P-IV), (I-b3), or (I-b4), including anywherein X1is CR19aR19b, N(R19c), or O;Xlais CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;R19aand R19bare independently selected from hydrogen; deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and any ring of the heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19agroups, on adjacent carbons, together with the carbons to which they are attached, form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to871107441203\1\AMERICAS6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;R19Cis H; deuterium; Ci-ealkyl; deuteroCi-ealkyl; Cs-ecycloalkyl; haloC2-ealkyl; heterocycloalkyl; hydroxy-Ci-ealkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; and C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl; and a,' is a single bond or a double bond.
[0133] In one embodiment of Formula (I), (P-V), (P-IV), (I-b3), or (I-b4), including anywherein R19ais selected from hydroxyl; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy;-(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-3alkylOC3-5cycloalkyl;hydroxy-Ci-6alkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl; andR19Cis Ci-ealkyl; deuteroCi-ealkyl; or Cs-ecycloalkyl.881107441203\1\AMERICAS
[0134] In one embodiment of Formula (I), (P-V), (P-IV), (I-b3), or (I-b4), including anywherein R19ais selected from hydroxyl; cyano; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl; andR19Cis Ci-ealkyl; deuteroCi-ealkyl; or Cs-ecycloalkyl.
[0135] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-a):or a pharmaceutically acceptable salt and / or stereoisomer thereof.
[0136] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-al ):or a pharmaceutically acceptable salt and / or stereoisomer thereof; wherein L is -Ci-3alkylene-(optionally substituted with 1 or 2 substituents independently selected from R25), -C3-891107441203\1\AMERICASecycloalkylene-, -heterocycloalkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), or bond.
[0137] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-b):or a pharmaceutically acceptable salt and / or stereoisomer thereof.
[0138] In one embodiment, Formula (I) or (P-II)-(P-V) is Formula (I-b 1):or a pharmaceutically acceptable salt and / or stereoisomer thereof; wherein the B ring is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a pyridinyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I-b 1), Ring B is an unsubstituted phenyl group or unsubstituted pyridinyl group.
[0139] In one embodiment, Formula (I) or (P-II)-(P-V) is Formula (I-b2):or a pharmaceutically acceptable salt and / or stereoisomer thereof; wherein L is -NR26- or -Ci-2alkylene- optionally substituted with 1 or 2 substituents selected from R25and Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I-b2), including any of the foregoing, L is -NH-. In one embodiment of Formula (I-b2), including any of the foregoing, Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently901107441203\1\AMERICASselected from R17. In one embodiment of Formula (I-b2), Ringone embodiment of Formula (I-b2), including any of the foregoing, Ring B isone embodiment of Formula (I-b2), including any of the foregoing, R1is F and R2is F. In one embodiment of Formula (I-b2), including any of the foregoing, R1is F, R2is F, R3ais H, and R3ais H.
[0140] In one embodiment, Formula (I) or (P-II)-(P-V) is Formula (I-b3):or a pharmaceutically acceptable salt and / or stereoisomer thereof; wherein Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.
[0141] In one embodiment, Formula (I) or (P-II)-(P-V) is Formula (I-b4):or a pharmaceutically acceptable salt and / or stereoisomer thereof; wherein Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.
[0142] In one embodiment of Formula (I-b3) or (I-b4), including any of the foregoing, Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17. In one embodiment of Formula (I-b3) or (I-b4), including any of the foregoing, Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo; -C(O)NR17aR17b; -NR17bC(O)R17c; and911107441203\1\AMERICAS-NR17bC(O)NR17cR17cl. In one embodiment of Formula (I-b3) or (I-b4), Ring B isembodiment of Formula (I-b3) or (I-b4), Ringone embodiment of Formula (I-b3) or (I-b4), including any of the foregoing, R17cand R17clare both Ci-ealkyl. In one embodiment of Formula (I-b3) or (I-b4), including any of the foregoing, R17cand R17clare both methyl. In one embodiment of Formula (I-b3) or (I-b4), including any of the foregoing, R3ais H, R3bis H, Y4is N, and Y3is CH. In one embodiment of Formula (I-b3) or (I-b4), including any of the foregoing, R3ais H, R3bis H, Y4is CH, and Y3is CH.
[0143] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-c):or a pharmaceutically acceptable salt and / or stereoisomer thereof.921107441203\1\AMERICAS
[0144] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-d):or a pharmaceutically acceptable salt and / or stereoisomer thereof.
[0145] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-e):or a pharmaceutically acceptable salt and / or stereoisomer thereof.
[0146] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-f):or a pharmaceutically acceptable salt and / or stereoisomer thereof.
[0147] In one embodiment, Formula (I) or (P-I)-(P-V) is Formula (I-g):or a pharmaceutically acceptable salt and / or stereoisomer thereof.
[0148] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4),(I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-a), (I-al), (I-b), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is halo. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d),931107441203\1\AMERICAS(I-e), (I-f), or (I-g), R1is F or Cl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is Ci-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is methyl or ethyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is Cs-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is cyclopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is Cs-ecycloalkylCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is -CH2-cyclopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is aryl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is phenyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is heteroaryl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is heteroaryl wherein the heteroaryl is a 5- to 6-membered heteroaryl comprising 1, 2, or 3 N atoms. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al),embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is arylCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is -CFF-phenyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is heteroarylCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is heteroarylCi-salkyl wherein the heteroaryl is a 5-to 6-membered heteroaryl comprising 1, 2, or 3 N atoms. In one embodiment of Formula (I),, (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1isone embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is aryloxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1), (I-b2), (I-c), (I-b3), (I-d), (I-e), (I-f), or (I-g), R1is -O-phenyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (P-I), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is heteroaryl oxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1), (I-b2), (I-c), (I-b3), (I-d), (I-e), (I-f), or (I-g), R1is heteroaryloxy941107441203\1\AMERICASwherein the heteroaryl is a 5- to 6-membered heteroaryl comprising 1, 2, or 3 N atoms. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1isIn one embodiment Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is haloCi-4alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-b 1 )-(I-b4), (I-b), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is CF3, CHF2, or CH2CF3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is Ci-2alkoxyCi-5alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is -CH2OCH3 or -CH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is deuterium. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is -OCi-3alkylOCi- salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is -OCH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1), (I-b2), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is -SO2R9. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is -SO2CH3.
[0149] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g),R1is H, halo, or Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is halo. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is F. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is OCH3.
[0150] In one embodiment of Formula (I), (P-I)-(P-V) (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is H, halo, Ci-salkyl, haloCi-4alkyl, or Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V) (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is H, F, Cl, CH3, CH2CH3, or OCH3.951107441203\1\AMERICAS
[0151] In one embodiment of Formula (I), (P-I)-(P-V), Rlais H or halo. In one embodiment of Formula (I), (P-I)-(P-V), Rlais H. In one embodiment of Formula (I), (P-I)-(P-V), Rlais Cl.
[0152] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is F or Cl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is deuterium. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1), (I-b3), (I-b2), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is Ci-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is Me or Et. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is haloCi-4alkyl or hydroxyCi-4alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is Cn 2alkoxyCi-5alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is -CH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl), (I-b2), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is C2-4 alkenyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is -CH=CH2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is OCH3 or OCH2CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is NHCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is -OCi-3alkyl-C3-6cycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is -OCH2-cyclopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is -OCi.3alkylOCi.2alkyl.
[0153] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4),i-salkyl, or C2-4 alkenyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R2is H, F, Cl, -CH2CH2OCH3, OCH3, ethyl, or -CH=CH2.
[0154] In one embodiment of Formula (I), (P-I)-(P-V) (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), R1is H, halo, Ci-salkyl, haloCi-4alkyl, or Ci-4alkoxy and R2is H,961107441203\1\AMERICASF, Cl, Ci-2alkoxyCi-5alkyl, Ci-4alkoxy, Ci-salkyl, or C2-4 alkenyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (Lal), (I-b), (Lbl)-(Lb4), (I-c), (Ld), (I-e), (Lf), or (I-g), R1is H, halo, or Ci-4alkoxy and R2is H, F, Cl, Ci-salkyl, Ci-2alkoxyCi-5alkyl, C2-4 alkenyl, or Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (Ld), (Le), (Lf), or (Lg), R1is H and R2is H. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl), (Lb2), (Lc), (Lb3), (Ld), (Le), (Lf), or (Lg), R1is halo and R2is H. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (I-d), (Le), (Lf), or (Lg), R1is F and R2is H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is Cl and R2is H. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (I-f), or (Lg), R1is halo and R2is halo. In one embodiment of Formula (I), (P-I)-(P-V), (La), (I-al), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is F and R2is F. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (I-f), or (Lg), R1is F and R2is Cl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is Cl and R2is F. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is halo. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(L b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is F. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is Cl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (I-d), (Le), (Lf), or (Lg), R1is H and R2is Ci-2alkoxyCi-5alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is -CH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is C2-4 alkenyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is -CH=CH2. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is Ci-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), R1is H and R2is ethyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl), (Lb2), (Lc), (Ld), (Le), (Lf), or (Lg), R1is Ci-4alkoxy and R2is H. In one embodiment of971107441203\1\AMERICASFormula (I), (P-I)-(P-V), (I-a), (Lal), (I-b), (I-b 1 )-(I-b4), (I-c), (Ld), (I-e), (Lf), or (I-g), R1is OCH3and R2is H.
[0155] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (Lal), (Lb), (Lbl)-(I-b4), (I-c), (Ld), (Le), (Lf), or (I-g), Rlais Cl and R1and R2are both H.
[0156] In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is H. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is methyl, ethyl, or isopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is haloCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), or (Lg), R5is CH(CH3)CF3, CH2CH2F, CHF2, CH2CF3, or CH2CH2CF3. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is cyanoCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (Lc), or (Lg), R5is CH2CN. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is CH(CH3)CH2CN or C(CH3)2CN. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is hydroxyCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V),embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is C3-6 alkenyl or Cs-ealkynyl. In one embodiment Formula (I), (P-III), (P-I), (La), (Lc), or (Lg), R5is CH2CH=CH2 or. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is -(Co-C3alkylene)-SC>2R9. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is -SO2R9or -CH2SO2R9. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is -SO2CH3, -SO2CH2CH3, or -SO2-cyclopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is -(Co-C3alkylene)-C(0)R12. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is -C(O)R12. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is -CHCH3COOH. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lc), or (Lg), R5is heterocycloalkyl optionally substituted with 1 or 2 groups981107441203\1\AMERICASindependently selected from Ci-salkyl, haloCi-salkyl, halo, Ci-3alkoxy, and Cs-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is a 5- or 6-membered heterocycloalkyl comprising 1 atom selected from N, O, and S and further optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-salkoxy, and Cs-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-.,,,, g, heterocycloalkylCi-salkyl wherein the heterocycloalkyl is optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, and halo, Ci-3alkoxy, C3-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is heterocycloalkylCi-salkyl wherein the heterocycloalkyl is a 5- or 6-membered heterocycloalkyl comprising 1 atom selected from N, O, and S and further optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-salkoxy, and Cs-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-,,, c), or (I-g), R5is - (C2-Csalkylene)-NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is -CH2CH2N(CH3)2, -CH(CH3)CH2-N(CH3)2, or-CH2CH2N(CH2CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is -(Ci-C5alkylene)-C(O)NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is -CH(CH3)C(O)NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is -CH(CH3)CH2C(O)NH2, -CH(CH3)CH2CH2C(O)NH2,991107441203\1\AMERICASof Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is arylCi-3alkyl or aryl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is -CH2-Ph. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is heteroarylCi-3alkyl optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-3alkyl, halo, Ci-3alkoxy, and C3-6cycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is heteroarylCi-3alkyl wherein the heteroaryl is a 5- or 6-membered heteroaryl comprising 1 atom selected from N, O, and S and optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-3alkyl, halo, Ci-3alkoxy, and C3. ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is? OI or ' N in one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is heteroaryl optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-3alkyl, halo, Ci-3alkoxy, and C3-6cycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is a 5- or 6-membered heteroaryl comprising 1 atom selected from N, O, and S and optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-3alkyl, halo, Ci-3alkoxy, and C3-6cycloalkyl. In oneecycloalkyl or Cs-7cycloalkenyl wherein the C3-6cycloalkyl and Cs-ecycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCi-2alkyl. In one embodiment of Formula (I), (P-I)-1001107441203\1\AMERICAS(P-V), (I-a), (I-c), or (I-g), R5is Cs-ecycloalkyl optionally substituted with 1, 2, or 3 groups independently selected from halo and hydroxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is cyclopropyl, cyclobutyl,. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is C5- 7cycloalkenyl optionally substituted with 1 hydroxy group. In one embodiment of Formula
[0157] In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R5is OH. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R5is arylCi-salkyl wherein the aryl is optionally substituted with heterocycloalkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R5is
[0158] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is H, Ci- ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl; C2-4 alkenyl; -(Co-C3alkylene)-S02R9; heterocycloalkyl; heterocycloalkylCi-salkyl; or Cs-ecycloalkyl; wherein the Cs-ecycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo and cyanoCo-2alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-c), or (I-g), R5is H, methyl, isopropyl, CH2CH2F, CH2CF3, CH2CH2CF3, CHF2,cyclopropyl,
[0159] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-c), or (I-g), R5is H; OH; Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl; C2-4 alkenyl; -(Co-C3alkylene)-S02R9; -(C2-C5alkylene)-NR17bR17c, heterocycloalkyl; heterocycloalkylCi- 3alkyl; heteroarylCi-salkyl; Cs-ecycloalkyl wherein the Cs-ecycloalkyl is optionally substituted1011107441203\1\AMERICASwith 1, 2, or 3 groups independently selected from halo, OH, and cyanoCo-2alkyl; or arylCi-salkyl wherein the aryl is optionally substituted with heterocycloalkyl.
[0160] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-c), or (I-g), R5is H; Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl; C2-4 alkenyl; -(Co-C3alkylene)-S02R9; -(C2-Csalkylene)-NR17bR17c, heterocycloalkyl; heterocycloalkylCi-3alkyl; heteroarylCi-salkyl; Cs-ecycloalkyl wherein the Cs-ecycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, and cyanoCo-2alkyl; or arylCi-3alkyl wherein the aryl is optionally substituted with heterocycloalkyl.
[0161] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-c), or (I-g), R5is cyanoCi-salkyl; or arylCi-salkyl wherein the aryl is substituted with heterocycloalkyl.
[0162] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-c), or (I-g), R5is H, OH, methyl, ethyl, isopropyl, CHF2, CH2CH2F, CH2CF3, CH2CH2CF3, CHF2, CH(CH3)CF3,1021107441203\1\AMERICAS
[0164] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-c), or (I-g), R5is -SO2-cyclopropyl, -C(CH3)2CN, -C(CH3)2CH2CN, -CH(CH3)CH2CN,
[0165] In one embodiment of Formula (I), (P-I)-(P-V), (I-d) and (I-e), R5ais haloCi-salkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-d) and (I-e), R5ais CF3. In one embodiment of Formula (I), (P-I)-(P-V), (I-d) and (I-e), R5ais C3-6cycloalkyl optionally substituted with 1, 2, or 3 halo.
[0166] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is F, Cl, or Br. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is Ci-3alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is methyl, ethyl, or n-propyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is haloCi-3alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is CF3, CHF2, or CH2CF3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is hydroxyCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is CH2OH or CH2CH2OH. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is cyanoCi-3alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is -CH2CN. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is C2. ealkynyl optionally substituted with C3-scycloalkyl or NR17bR17c. In one embodiment of,,,,, s hydroxyC3-6alkynyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), R61031107441203\1\AMERICASone embodiment of Formula (I), (P- I)-(P-V), (I-a), (I-d), or (I-f), R6is Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCisalkyl is optionally substituted with Cs-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is CH2OCH3 or CH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is C(O)NR16aR16b. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is Cs-scycloalkyl optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-salkyl, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, and cyano. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is unsubstituted C3-8cycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6iscyclopropyl, cyclobutyl,. In one embodiment of Formula (I), (P-I)-(P-V),1041107441203\1\AMERICASembodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is cyclopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is Cs-scycloalkylCi-salkyl wherein the Ci-3alkyl of Cs-scycloalkylCi-salkyl is optionally substituted with hydroxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is -CFFcyclopropyl orinone embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is deuterium. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is heterocycloalkyl optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-salkyl, NR17bR17c, hydroxyCi-salkyl,-(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, and cyano. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is unsubstituted heterocycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is a 5- to 10-membered heterocycloalkyl comprising 1 atom selected from N, O, and S and optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, NR17bR17c, hydroxyCi-salkyl, -(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(O)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, and cyano. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is a 5- to 10-membered unsubstituted heterocycloalkyl comprising 1 atom selected from N, O, and S. In one embodiment of Formula (I), (P-I)-(P-V),,,,,, 3alkylene)-SC>2R9or -SO2NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-1051107441203\1\AMERICASd), or (I-f), R6is -SO2CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is cyano. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is -(Ci-C3alkylene)-NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is -CH2CH2-NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is -CH2CH2N(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is -P(O)(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-d), or (I-f), R6is heteroaryl or heteroarylCi-salkyl wherein the heteroaryl, alone or part of heteroarylCi-3alkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected. In one
[0167] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), including any of the foregoing, R6is Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), including any of the foregoing, R6is heterocycloalkyloxyCi-salkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), including any ofthe foregoing, R6is. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), including any of the foregoing, R6is Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl is optionally substituted with hydroxy or Cs-ecycloalkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), including any of the foregoing, R6is Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl are independently optionally substituted with 1 or 2 hydroxy groups. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), including any of the foregoing, R6is. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), including any of the foregoing, R6is Cs-scycloalkyl optionally substituted with halo, hydroxyCi-salkyl, or Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl.
[0168] In one embodiment of Formula (I), (P-II)-(P-V), (P-I), (I-a), (I-d), or (I-f), R6is H, Ci-3alkyl, haloCi-salkyl, Ci-2alkoxyCi-5alkyl, Cs-scycloalkyl, or heterocycloalkyl. In one1061107441203\1\AMERICAS, methyl, cyclopropyl,
[0169] In one embodiment of Formula (I), (P-II)-(P-V), (P-I), (I-a), (I-d), or (I-f), R6is H; Ci-3alkyl; haloCi-3alkyl; Ci-2alkoxyCi-5alkyl; Cs-scycloalkyl optionally substituted with halo, hydroxyCi-salkyl, Ci-3alkoxyCi-3alkyl, or Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; hydroxyCi-salkyl; heterocycloalkyl; Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl; or Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl is optionally substituted with hydroxy or Cs-ecycloalkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-d), or (I-f), R6is H, methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, -CHF2, -CH2OCH3, - CH2CH2OCH3, -CH2OH, -C(CH3)2CH2OH,
[0170] In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl; C2-4 alkenyl; -(Co-Csalkylene)-SO2R9; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; or C3-ecycloalkyl; wherein the Cs-ecycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo and cyanoCo-2alkyl and R6is hydrogen, Ci-3alkyl, Ci-2alkoxyCi-5alkyl, unsubstituted heterocycloalkyl, or unsubstituted Cs-scycloalkyl.
[0171] In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl; C2-4 alkenyl; -(Co-Csalkylene)-SO2R9; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-Csalkylene)-NR17bR17c; or C3-ecycloalkyl; wherein the Cs-ecycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo and cyanoCo-2alkyl and R6is hydrogen.
[0172] In one embodiment of Formula methyl,isopropyl, CH2CH2F, CH2CF3, CH2CH2CF1071107441203\1\AMERICASogen.
[0173] In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R6is Ci-3alkyl and R5is selected from H, Ci-ealkyl; Cs-ecycloalkyl; and haloCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R6is Ci-2alkoxyCi-5alkyl and R5is haloCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R6is heterocycloalkyl and R5is haloCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R6is Cs-scycloalkyl and R5is H, Ci-ealkyl, or haloCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R6is Cs-scycloalkyl and R5is H, methyl, or CHCF2. In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R6is cyclopropyl and R5is H, Ci-ealkyl, or haloCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), R6is unsubstituted cyclopropyl and R5is H, methyl, or CHCF2.
[0174] In one embodiment of Formula (I), (P-II)-(P-V), or (I-a), R5is haloCi-salkyl and R6is H; Ci-ealkyl; Ci-2alkoxyC2-5alkyl; hydroxyCi-salkyl; heterocycloalkyl; Cs-ecycloalkyl optionally substituted with halo, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl; Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; or heterocycloalkyloxyCi-salkyl.
[0175] In one embodiment of Formula (I), (P-II)-(P-V), or (I-a), R5is CHF2and R6is H; methyl; ethyl; isopropyl; -CH2OCH3; -CH2CH2OCH3; -CH2CH2OCH3; -CH2OH;
[0176] In one embodiment of Formula (I), (P-V), (P-IV), or (I-a), R5and R6together with the atoms to which they are attached form a heterocycle optionally substituted with 1 or 2 substituents independently selected from Ci-3alkyl, C3-4cycloalkyl and halo. In one embodiment of Formula (I), (P-V), (P-IV), or (I-a), R5and R6together with the atoms to1081107441203\1\AMERICASwhich they are attached form a heterocycle optionally substituted with 1 or 2 substituents independently selected from Ci-salkyl, C3-4cycloalkyl and halo and comprising an oxygenatom in addition to the nitrogen
[0177] In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), including any of the foregoing,R1is H or halo;R2is H, F, Cl, Ci-salkyl, Ci-2alkoxyCi-salkyl, or C2-4 alkenyl;R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-salkyl; C2-4 alkenyl; -(Co-C3alkylene)-S02R9; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-Csalkylene)-NR17bR17c; or Cs-ecycloalkyl; wherein the Cs-ecycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo and cyanoCo-2alkyl; and R6is H, Ci-salkyl, haloCi-salkyl, Ci-2alkoxyCi-5alkyl, unsubstituted Cs-scycloalkyl, or unsubstituted heterocycloalkyl.
[0178] In one embodiment of Formula (I), (P-II)-(P-V), or (I-a), including any of the foregoing,R1is H, halo, Ci-4alkoxy, Ci-salkyl;Rlais H or halo;R2is H, F, Cl, Ci-salkyl, Ci-2alkoxyCi-salkyl, or C2-4 alkenyl;R5is H, Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-salkyl; C2-4 alkenyl; -(Co-C3alkylene)-S02R9; heterocycloalkyl; heterocycloalkylCi-salkyl wherein the heterocycloalkyl of heterocycloalkylC alkyl is optionally substituted with Cisalkyl; heteroarylCi-salkyl; arylCi-salkyl optionally substituted with heterocycloalkyl; -(C2-Csalkylene)-NR17bR17c; or Cs-ecycloalkyl optionally substituted with 1, 2, or 3 groups independently selected from halo, cyanoCo-2alkyl, and hydroxy; andR6is H; Ci-salkyl; haloCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-salkyl; C3-scycloalkyl optionally substituted with halo, hydroxyCi- salkyl, Ci-salkoxyCi-salkyl, or Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl, Ci-2alkoxyCi-salkyl wherein the Ci-salkyl of Ci-2alkoxyCi-salkyl is substituted with hydroxy; or unsubstituted heterocycloalkyl.1091107441203\1\AMERICAS
[0179] In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), including any of the foregoing, R1is halo; R2is F or Cl; R5is haloCi-salkyl; and R6is unsubstituted C3-scycloalkyl.
[0180] In one embodiment of Formula (I), (P-I)-(P-V), or (I-a), including any of the1101107441203\1\AMERICAS129243.00015TTC002-PCTIll1107441203\1\AMERICASis the attachment to the C ring.
[0181] In one embodiment of Formula (
[0182] In one embodiment of Formula (I), (P-II)-(P-V), or (I-a), including any of theforegoing,1121107441203\1\AMERICAS129243.00015TTC002-PCT1131107441203\1\AMERICAS129243.00015TTC002-PCT1141107441203\1\AMERICAS129243.00015TTC002-PCT1151107441203\1\AMERICASattachment to the C ring.
[0183] In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of the foregoing, R13and R13aare both Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of the foregoing, R13and R13aare both Ci-3alkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of the foregoing, R13and R13aare both methyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of the foregoing, R13is hydrogen and R13ais Ci-3alkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form cycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form Cs-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form a 4- to 8-membered heterocycloalkyl. In one embodiment of Formula (I), (P-1161107441203\1\AMERICASthe attachment to the C ring. In one embodiment of Formula (I), (P-I)-(P-V), including any of
[0184] In one embodiment of Formula (I), (P-I)-(P-V), or (I-b), including any of theembodiment of Formula (I), (P-I)-(P-V), (I-b), or (I-b l)-(I-b4), including any of the1171107441203\1\AMERICASforegoing, one embodiment of Formula (I), (P-I)-(P-V), (I-b), (I-b 1), or (I-b2), including any of the foregoing,
[0185] In one embodiment of Formula (I), (P-I)-(P-V), (I-b), (I-b 1), or (I-b2), includingany of the foregoing,one embodiment of Formula (I), (P-II)-(P-V), (I-b), (I-b 1), or (I-b2), including any of the
[0186] In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13and R13aare independently H; halo; hydroxyCi-2alkyl; heterocycloalkyl optionally substituted with Ci-3alkyl; Cs-scycloalkyl; Ci-3alkoxyCi-3alkyl; -(Co-3alkylene)-NR17bR17c; aryl; heteroaryl; Cs-scycloalkylCi-salkyl; or alkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13and R13aare independently H or alkyl. In one embodiment of Formula (I), (P-IV), or (P-III), including any of the foregoing, R13and R13aare independently selected from fluoro, methyl, -CH2OH, -CH2OCH3, -CH2N(CH3)2,cyclopropyl, -CH₂-cyclopropyl,R21aare both hydrogen. In one embodiment of Formula (I), (P-V), (P-IV), or (P-III),1181107441203\1\AMERICASincluding any of the foregoing, R13and R13aare independently selected from fluoro, methyl, ethyl, -CH2OH, -CH2OCH3,-CH2N(CH3)2, cyclopropyl, -CH₂-cyclopropyl,,, phenyl, andQ' and R21and R21aare both hydrogen.
[0187] In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-salkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form Cs-ecycloalkyl or a 4- to 8-membered heterocycloalkyl wherein the Cs-ecycloalkyl and 4- to 8-membered heterocycloalkyl are optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form pyrrolidine wherein the nitrogen atom of the pyrrolidine is optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-salkoxyCi-salkyl and R21and R21aare both hydrogen. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form unsubstituted cyclopropyl and R21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13and R13a, together with the carbon to which they are attached, form unsubstituted cycloalkyl and R21and R21a, together with the carbon to which they are attached, also form unsubstituted cycloalkyl.
[0188] In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl.
[0189] In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13aand R21a, together with the carbons to which they are attached, form cycloalkyl or heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, C3-1191107441203\1\AMERICASscycloalkyl, or alkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13aand R21a, together with the carbons to which they are attached, form heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, C3-scycloalkyl, or alkyl. In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing, R13aand R21a, together with the carbons to which they are attached, form cycloalkyl and R13and R21are both alkyl.
[0190] In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing,
[0191] In one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing,one embodiment of Formula(I), (P-V), or (P-IV), including any of the foregoing,-cyclopropylene-. In one embodiment of Formula (I), (P-II)-(P-V),including any of the foregoing,2alkylene- optionally substituted with 1 or 2 substituents selected from -NH2, F, and methyl.1201107441203\1\AMERICASIn one embodiment of Formula (I), (P-II)-(P-V), including any of the foregoing,
[0192] In one embodiment of Formula (I), (P-I)-(P-V), or (I-c), including any of the foregoing, R1is H, Ci-salkyl, Ci-4alkoxy, or halo; R2is H, F, Cl, or Ci-4alkoxy; and R5is H, Ci-ealkyl; haloCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl; or Cs-ecycloalkyl.
[0193] In one embodiment of Formula (I), (P-I)-(P-V), or (I-c), including any of the foregoing, R1is H or halo; R2is H, F, Cl, or Ci-4alkoxy; and R5is H, Ci-ealkyl; haloCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyCi-5alkyl; or Cs-ecycloalkyl.
[0194] In one embodiment of Formula (I), (P-I)-(P-V), or (I-c), including any of the foregoing, R1is H or halo; R2is H, F, Cl, or Ci-4alkoxy; and R5is -CHF2.
[0195] In one embodiment of Formula (I), (P-I)-(P-V), or (I-c), including any of the1211107441203\1\AMERICAS
[0196] In one embodiment of Formula (I), (P-I)-(P-V), or (I-c), including any of theis the attachment to the C ring.
[0197] In one embodiment of Formula (I), (P-I)-(P-V), or (I-e), including any of the foregoing, R1is H and R2is H or Ci-2alkoxyCi-5alkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-e), including any of the foregoing, R1is H; R2is H or Ci-2alkoxyCi-5alkyl; and R5ais haloCi-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), or (I-e), including any of1221107441203\1\AMERICAS
[0198] In one embodiment of Formula (I), (P-I)-(P-V), or (I-e), including any of the
[0199] In one embodiment of Formula (I), (P-I)-(P-V), or (I-g), including any of theone embodiment of Formula (I), (P-I)-(P-V), or (I-g), including any of the foregoing,one embodiment of Formula (I), (P-I)-(P-V), or (I-g), including any of the foregoing, R5is hydroxyCi-salkyl.
[0200] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R17ais selected from H, Ci-ealkyl, OH, Ci-ealkoxy, halo-Ci-ealkoxy, Ci-3alkoxy-Ci-3alkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, Cs-ecycloalkyloxy, C3-6cycloalkylCi-3alkyloxy, cyano-Ci-ealkyl, halo-Ci-ealkyl, hydroxy-Ci-ealkyl, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, -(Ci-C3alkylene)-NR17bR17c, -OC2-4alkylene- NR17bR17c, Ci-2alkoxyCi-3alkyl, heterocycloalkyl, -O-heterocycloalkyl, heterocycloalkylCi-salkyl, heterocycloalkylCi-salkoxy, aryl, a 5- or 6-membered heteroaryl group, a heteroaryl group fused to heterocycle or cycloalkyl, or heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-3alkyl, the aryl, the heteroaryl, the heteroaryl of heteroaryl Ci -sal kyl, or any ring of the1231107441203\1\AMERICASheteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22.
[0201] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais methyl or n-propyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Cs-ecycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais cyclopropyl or cyclohexyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Cs-ecycloalkylCi-salkyl. Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -CFh-cyclopropyl or -CFFCFF-cyclopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais cyano-Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -CH2CH2CN. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais halo-Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais CH2CF3 or CH2CF3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais NR17bR17c-Ci-ealkylcarbonyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -C(O)Ci-6alkylene-NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -C(O)Ci-6alkylene-N(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -C(O)CH2CH2CH2N(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -(Ci-C3alkylene)-NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais1241107441203\1\AMERICAS-CH2CH2CH2-NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -CH2CH2N(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Ci-2alkoxyCi-3alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -CH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -C(O)NHOR24wherein H, Ci-salkyl, C3-ecycloalkylCi-salkyl, heterocycloalkylCi-salkyl, hydroxyC2-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-YHbl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17aisHIn one embodiment of Formula (I), (P-I)-(P- V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais heterocycloalkyl or heterocycloalkylCi-salkyl, wherein the heterocycloalkyl or the heterocycloalkyl of heterocycloalkylCi-salkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R22. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais heterocycloalkyl or heterocycloalkylCi-salkyl wherein the heterocycloalkyl or the heterocycloalkyl of heterocycloalkylCi-salkyl is a 5- or 6-membered heterocycloalkyl comprising 1, 2, or 3 heteroatoms independently selected from N, O, and S and further optionally substituted with 1, 2, or 3 substituents independently selected from R22. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d),(I-e), (I-f), or (I-g), including any of the foregoing, R17ais,Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g),1251107441203\1\AMERICASincluding any of the foregoing, R17ais a 5- or 6-membered heteroaryl group or heteroarylCi-salkyl wherein the heteroaryl or the heteroaryl of heteroarylCi-salkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais a 5- or 6-membered heteroaryl group or heteroarylCi-salkyl wherein the heteroaryl or the heteroaryl of heteroarylCi-salkyl comprise 1, 2, or 3 heteroatoms independently selected from N, O, and S and are optionally substituted with 1, 2, or 3 substituents independently selected from R22. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (Lc), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais heteroaryl optionally substituted with 1 or 2 R22groups and R22is independently selected from halo; Ci-ealkyl; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl and hydroxy; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; cyano; haloCi-ealkyl; hydroxyCi-ealkyl wherein the Ci-ealkyl is optionally substituted with Cs-ecycloalkyl; cyanoCi-ealkyl; -(Co-C3alkylene)-SC>2R9; -(Ci-C5alkylene)-NR17bR17c; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl optionally substituted with -NR17bR17c. In one embodiment of Formula (I), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais a 5- to 10- membered heteroaryl optionally substituted with 1 or 2 R22groups. In one embodiment of Formula (I), (P-III)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(Lb4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais
[0202] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4),embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(Lb4), (I-c), (I-d), (I-e), (I-1261107441203\1\AMERICASf), or (I-g), including any of the foregoing, R17ais
[0203] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais OH. In one1271107441203\1\AMERICASembodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Ci-ealkoxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -OCH3. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais halo-Ci-ealkoxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -OCH2CH2F. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Ci-3alkoxy-Ci-3alkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -CH2CH2OCH3. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Cs-ecycloalkyloxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -O-cyclopropyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Cs-ecycloalkylCi-salkyloxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -OCFfc-cyclopropyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais hydroxy-Ci-ealkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -CH2CH2OH. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais hydroxy-Ci-ealkyloxy. In one embodiment of Formula (I), (P-H)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -OCH2CH2OH or -OCH2C(CH3)2OH. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais Ci-ealkoxy-Ci-ealkyloxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais -OCH2CH2OCH3. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais halo-Ci-ealkyloxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais heterocycloalkyloxy. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I- 1281107441203\1\AMERICASb), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais
[0204] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R17ais a heteroaryl group fused to heterocycle or cycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from R22In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais a heteroaryl group fused to heterocycle or cycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-salkyl, hydroxyl, halo, haloCi-ealkyl, hydroxyCi-ealkyl, Cs-ecycloalkyl, Cs-ecycloalkylCi-ealkyl, Ci-2alkoxyCi-3alkyl, -(Co-C3alkylene)-S02R9, -C(O)R27, and unsubstituted heterocycloalkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais a heteroaryl group fused to heterocycle or cycloalkyl wherein the heterocycle or cycloalkyl is optionally substituted with hydroxyl or Ci-3alkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-1291107441203\1\AMERICAS
[0205] In one embodiment of Formula (I), (P-II)-(P-V), (P-I), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais H, Ci-ealkyl, halo-Ci-ealkyl, Cs-ecycloalkyl, Cs-ecycloalkylCi-salkyl, -(Ci-C3alkylene)-NR17bR17c, Ci-ealkoxy-Ci-ealkyl, heterocycloalkyl, heterocycloalkylCi-salkyl, aryl, heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-salkyl, the heteroaryl, or the heteroaryl of heteroarylCi-salkyl are optionally substituted with 1 R22group and R22is selected from Ci-ealkyl, Cs-ecycloalkyl, Ci-2alkoxyCi-3alkyl, haloCi-ealkyl, and hydroxyCi-ealkyl.1301107441203\1\AMERICAS
[0206] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais H, Ci-ealkyl, OH, Ci-ealkoxy, halo-Ci-ealkoxy, Ci-3alkoxy-Ci-3alkyl, halo-Ci-ealkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, Cs-ecycloalkyloxy, C3-6cycloalkylCi-3alkyloxy, hydroxy-Ci-ealkyl, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, cyano-Ci-ealkyl, halo-Ci-ealkyloxy, -(Ci-C3alkylene)-NR17bR17c, Ci-ealkoxy-Ci-ealkyl, heterocycloalkyl, -O-heterocycloalkyl, heterocycloalkylCi-salkyl, aryl, heteroaryl, heteroarylCi-salkyl, or heteroaryl group fused to heterocycle or cycloalkyl, wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-salkyl, the heteroaryl, the heteroaryl of heteroarylCi-salkyl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1 or 2 R22groups and R22is independently selected from halo; Ci-ealkyl; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl and hydroxy; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; cyano; haloCi-ealkyl; hydroxyCi-ealkyl wherein the Ci-ealkyl is optionally substituted with Cs-ecycloalkyl; cyanoCi-6alkyl; -(Co-C3alkylene)-S02R9; -(Ci-C5alkylene)-NR17bR17c; -C(O)R27; and heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl.
[0207] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R17ais H, OH, CH3, -OCH3, -OCH2CH3, -CH2CF3, -OCH2CH2F, cyclopropyl, -O-cyclopropyl, -CH2-cyclopropyl, -OCH2-cyclopropyl, -CH2CH2OH, -OCH2CH2OH, -OCH2C(CH3)2OH, -OCH2CH2OCH3, -1311107441203\1\AMERICAS1321107441203\1\AMERICAS129243.00015TTC002-PCT1331107441203\1\AMERICAS1341107441203\1\AMERICAS129243.00015TTC002-PCT1351107441203\1\AMERICAS
[0211] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R17ais H or Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-1361107441203\1\AMERICASf), or (I-g), including any of the foregoing, R17ais H or CH3. In one embodiment of Formula (I), (P-I)-(P-V), ( a), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17ais H. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17ais CH3.
[0212] In one embodiment of Formula (I), (P-II)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17ais Ci-ealkoxy, halo-Ci-ealkoxy, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, halo-Ci-ealkyloxy, or heterocycloalkyloxy.
[0213] In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17bis H. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17bis Ci-ealkyl. In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17bis haloCi-ealkyl. In one embodiment of Formula (I), (P-V), (P-IV), (La), (I-al), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17bis Ci-6alkyloxyCi-3alkyl.
[0214] In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17band R17care both H. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (I-e), (Lf), or (Lg), including any of the foregoing, R17bis H and R17cis Ci-ealkyl. In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R17band R17care taken together, with the N to which they are attached, to form a 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl.
[0215] In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R3ais selected from H, F, Cl, Ci-4alkyl, OH, hydroxyCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, -OCi-5alkylOCi-2alkyl, -OC2-5alkyl-NR17bR17c, aryl, heteroaryl, aryloxy, and heteroaryloxy wherein the heteroaryl, alone or part of another group, is optionally substituted with Ci-ealkyl; and R3bis H. In one embodiment of Formula (I), (P-I)-(P-V), (P-I), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (I-e), (Lf), or (Lg), including any of the foregoing, R3ais F or Cl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R3ais Ci-4alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the 1371107441203\1\AMERICASforegoing, R3ais methyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais OH. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais cyano. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais hydroxyCi-4alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais CH2OH. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1), (I-b2), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R3ais Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais Ci-2alkoxyCi-5alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais CH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais -OCi-5alkylOCi-2alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais OCH2CH2OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais -OC2-5alkyl-NR17bR17c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais OCH2CH2N(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais aryl, heteroaryl, aryloxy, or heteroaryloxy wherein the heteroaryl, alone or part of another group, is optionally substituted with Ci-ealkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I¬f), or (I-g), including any of the foregoing, R3ais. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al ), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais1381107441203\1\AMERICAS,. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais Ci-4alkoxy wherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I- b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais(I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais heterocycloalkyl optionally substituted with Ci-ealkyl. In one embodiment of Formula (I), (P-II)-(P-V), ( ny ofthe foregoing,one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais. In one embodiment of Formula (I), (P-II)-(P-V), I-a), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais -O-Co-Csalkylene-heterocycloalkyl. In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-1391107441203\1\AMERICASf), or (I-g), including any of the foregoing, R3ais
[0216] In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais C2-ealkynyl optionally substituted with hydroxy, Ci-3alkyloxy, -(Co-3alkylene)NR17bR17c, Cs-ecycloalkyl optionally substituted with NR17bR17c, and heterocycloalkyl optionally substituted with NR17bR17c. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais C2-ealkynyl optionally substituted with hydroxy. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais C2-ealkynyl optionally substituted with NH2. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais
[0217] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais selected from H, F, and Ci-4alkoxy. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R3ais selected from H, F, or OCH3.
[0218] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3bis H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3bis F.
[0219] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3aand R3bare independently selected from H, F, Cl, Ci-4alkoxy, and Ci-2alkoxyCi-5alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3aand R3bare independently selected from H, F, and -OCH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais selected from H, F, and -OCH3 and R3bis H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d),1401107441203\1\AMERICAS(I-e), (I-f), or (I-g), including any of the foregoing, R3ais H and R3bis H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (Lal), (I-b), (Lbl)-(Lb4), (Lc), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais F and R3bis H. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (Lc), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R3ais -OCH3 and R3bis H.
[0220] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R3aand R3bare independently selected from H, Cl, F, -OCH3, -CH2CH2OCH3, -OH, -CH2OH, -OCH2CH2OCH3,
[0221] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is -NR15alC(O)R15a2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is -NHC(O)R15a2, -NR15alC(O)H, -N(Ci-6alkylene)C(O)R15a2, -NR15alC(O)Ci-6alkyl, -NHC(O)H, or -NHC(O)Ci-6alkyl.
[0222] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is -C(O)NR15bR15c. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(Lb4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is -C(O)NHR15c, -C(O)NH2, -C(O)NH(Ci-ealkyl), or -C(O)N(Ci-6alkyl)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(Lb4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is -C(O)N(CH3)2.
[0223] In one embodiment of Formula (I), (P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (I-d), (I-e), (I-f), or (Lg), including any of the foregoing, R15is a 5- or 6-membered1411107441203\1\AMERICASheterocycloalkyl optionally substituted with 1, 2, 3, 4, 5, or 6 groups independently selected from R19. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is a 5- or 6-membered heterocycloalkyl optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from R19. In one embodiment of Formula (I), (P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is a 5- or 6-membered heterocycloalkyl comprising 1, 2, or 3 nitrogen atoms and further optionally with 1, 2, 3, 4, 5, or 6 groups independently selected from R19. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is a 5- or 6-membered heterocycloalkyl comprising 1, 2, or 3 nitrogen atoms and further optionally with 1, 2, 3, 4, or 5 groups independently selected from R19. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is a 5- or 6-membered heterocycloalkyl comprising 1 nitrogen atom and 1 oxygen atom and further optionally with 1, 2, 3, 4, or 5 groups independently selected from R19.
[0224] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R15is a 5- or 6-membered heteroaryl optionally substituted with 1, 2, 3, or 4 groups independently selected from R19. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is a 5- or 6-membered heteroaryl comprising 1, 2, or 3 nitrogen atoms and further optionally with 1, 2, 3, or 4 groups independently selected from R19.
[0225] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is pyridonyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R19.
[0226] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15iswherein X1is CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;1421107441203\1\AMERICASR19aand R19bare independently selected from H, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or R19aand R19bcome together to form a Cs-scycloalkyl;or two R19agroups, on adjacent carbons, together to the carbons to which they are attached, form a benzo group optionally substituted with R23;R19Cis H, deuterium, Ci-ealkyl, Cs-ecycloalkyl, haloC2-ealkyl, and heterocycloalkyl; andis a single bond or a double bond.
[0227] In one embodiment of Formula (I), (P-II)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15iswherein X1is CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;R19aand R19bare independently selected from H, deuterium, halo, cyano, hydroxyl, NR17bR17c, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloCi-ealkyl, and heterocycloalkyl;or R19aand R19bcome together to form a Cs-scycloalkyl;or two R19agroups, on adjacent carbons, together to the carbons to which they are attached, form a benzo group optionally substituted with R23;R19Cis H, deuterium, Ci-ealkyl, deuteroCi-ealkyl, Cs-ecycloalkyl, haloC2-ealkyl, and heterocycloalkyl; andis a single bond or a double bond.
[0228] In one embodiment of Formula (I), (P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15iswherein X1is CR19aR19b, N(R19c), or O;1431107441203\1\AMERICASXlais CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;R19aand R19bare independently selected from hydrogen; deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19agroups, on adjacent carbons, together with the carbons to which they are attached, form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;or two R19agroups on the same carbon come together to form an oxo group;R19Cis H; deuterium; Ci-ealkyl; deuteroCi-ealkyl; Cs-ecycloalkyl; haloCi-ealkyl; heterocycloalkyl; hydroxy-Ci-ealkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; and C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl; and is a single bond or a double bond.
[0229] In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15iswherein X1is CR19aR19b, N(R19c), or O;1441107441203\1\AMERICASXlais CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;R19aand R19bare independently selected from hydrogen; deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19agroups, on adjacent carbons, together with the carbons to which they are attached, form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;R19Cis H; deuterium; Ci-ealkyl; deuteroCi-ealkyl; Cs-ecycloalkyl; haloC2-ealkyl; heterocycloalkyl; hydroxy-Ci-ealkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; and C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl; and is a single bond or a double bond.
[0230] In one embodiment of Formula (I), (P-V), (P-IV), (I-b3), or (I-b4), including any of the foregoing, R15iswherein R19ais selected from hydroxyl; cyano; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; C3-6cycloalkylCi-3alkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-1451107441203\1\AMERICAS2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl; andR19Cis Ci-ealkyl; deuteroCi-ealkyl; or Cs-ecycloalkyl.
[0231] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1), (I-b3), (I-b2), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is CR19aR19b. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is C(CH3)2. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is CR19aR19band R19aand R19bcome together to form a Cs-scycloalkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is CR19aR19band R19aand R19bcome together to form cyclopropyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is CR19aR19band R19aand R19bcome together to form cyclobutyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(R19c). In one embodiment of Formula (I), (P-II)-(P-V), (P-I), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(Ci-6alkyl). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(CH3). In one embodiment of Formula (I), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(hydroxy-Ci-6alkyl). In one embodiment of Formula (I), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(CH2CH2OH). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(CD3). In one embodiment of Formula (I), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(haloCi-6alkyl). In one embodiment of Formula (I), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is N(CHF2). In one embodiment of Formula (I), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X1is O.1461107441203\1\AMERICAS
[0232] In one embodiment of Formula (I), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Xlais N(R19c). In one embodiment of Formula (I), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Xlais N(Ci-6alkyl). In one embodiment of Formula (I), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Xlais N(CH3).
[0233] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is N. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is CR19a. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is C(Ci-6alkyl). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is CHs). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is N(R19C). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is N(Ci-6alkyl). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is N(CH3).
[0234] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is N. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CR19a. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CH. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is -C(Ci-6alkyl). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is -C(CH3). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is C(NR17bR17c). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is -C(NH(CH3)) or C(N(CH3)2). (I-b l)-(I-b4),(I-b l)-(I-b4), In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is -C(deuteroCi-6alkoxy). In one embodiment of Formula 1471107441203\1\AMERICAS(I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is - OCDs). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (Lal), (Lb), (I-bl), (Lb2), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(C3-6cycloalkyl). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(cyclopropyl). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(C3-ecycloalkyloxy). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(Ocyclopropyl). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(C3-6cycloalkylCi-3alkyloxy). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (I-e), (Lf), or (Lg), including any of the foregoing, X3is -C(OCH2-cyclopropyl). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(halo-Ci-6alkoxy). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(OCHF2) or-C(OCH2CHF2). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(OCF3) or -C(O(CH2)3F. In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(L b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(OCi-3alkylOCi-2alkyl). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (I-c), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is - OCFhCFhOCFL). In one embodiment of Formula (I), (P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (I-f), or (Lg), including any of the foregoing, X3is -C(OCi-3alkylOC3-5cycloalkyl). In one embodiment of Formula (I), (P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is-C(OCH2CH2Ocyclopropyl). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C((Co-3alkylene)-0-(hydroxyCi-6alkyl)). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is-C(CH2OCH2C(CH3)2OH) or -C(OCH2C(CH3)2OH). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of 1481107441203\1\AMERICASthe foregoing, X3is -C(Ci-3alkoxy-Ci-3alkyl). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is-C(O(Ci-C3alkylene)-NR17bR17c). In one embodiment of Formula (I), (P-V), (P-IV), (La), (I-al), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(OCH2CH2N(CH3)2). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(O(Ci-C3alkylene)-SC>2R9). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(O(CH2CH2)-SO2CH3). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (I-b), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(CH2OCH3). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (I-bl), (I-b2), (Lc), (Lb3), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is CR19aand R19ais C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl. In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le),(Lf), or (Lg), including any of the foregoing, X3is CR19aand R19ais,,,,, Lb), (I-bl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is -C(CN). In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (I-e), (Lf), or (Lg), including any of the foregoing, X3is CR19aand R19ais heterocycloalkyl. In one embodiment of Formula (I), (P-V), (P-IV), (e), (Lf), or (Lg), including any of the foregoing,1491107441203\1\AMERICASone embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CR19aand R19ais heterocycloalkyloxyCi-salkyl. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), cluding any of the foregoing, X3is CR1In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is -C(Ci-6alkoxy). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is -C(0CH3) or - OCFhCHs). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is -C(OCi-3alkylOCi-2alkyl). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1), (I-b2), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is - OCFhCFhOCFb). In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CR19aand R19ais heterocycloalkyloxy. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing,embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CR19aand R19ais heterocycloalkylalkyloxy. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CR19a1501107441203\1\AMERICAS.,,, ), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CR19aand R19ais heteroaryl optionally substituted with Ci-ealkyl. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g),including any of the foregoing, X3is CR19aand R19ais. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is CR19aand R19ais heteroaryl group fused to heterocycle wherein the heterocycle is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), ( e), (I-f), or (I-g), including any of theforegoing, X3one embodiment of Formula (I), (P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X3is C(R19a)2 and the R19agroups of X3come together to form an oxo group.
[0235] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, X2is N and X3is CR19a. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is N and X3is C(Ci-6alkyl). In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, X2is N and X3is C(CH3)). In one embodiment of Formula (I),1511107441203\1\AMERICAS(P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X2is N and X3is CR19awherein R19ais selected from cyano; Ci-ealkyl; Ci-ealkoxy; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; hydroxy-Ci-ealkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; and C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl.
[0236] In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is N and X2is CR19a. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (I-f), or (Lg), including any of the foregoing, X3is N and X2is C(Ci-6alkyl). In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X3is N and X2is C(CH3).
[0237] In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X2and X3are CR19aand the two R19agroups come together to the carbons to which they are attached to form a benzo group optionally substituted with 1, 2, or 3 substituents independently selected from R23. In one embodiment of Formula (I), (P-III)-(P-V), (La), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (I-e), (Lf), or (Lg), including any of the foregoing, X2and X3are CR19aand the two R19agroups come together to the carbons to which they are attached to form a 5- to 6-membered heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from R23. In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X2and X3are CR19aand the two R19agroups come together to the carbons to which they are attached to form a 5- to 6-membered heterocycloalkyl optionally substituted with 1, 2, or 3 substituents independently selected from R23.
[0238] In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, X2and X3are both C(R19a)2. In one embodiment of Formula (I), (P-I)-(P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (I-e), (Lf), or (Lg), including any of the foregoing, X2is CH2 and X3is CH(CH3).
[0239] In one embodiment of Formula (I), (P-V), (P-IV), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (Lf), or (Lg), including any of the foregoing, R15is selected from1521107441203\1\AMERICAS,,,,, (I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is selected fromal), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl. In 1531107441203\1\AMERICASone embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al ), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is selected from,,,, >, R19ais selected from hydrogen; cyano; Ci-ealkyl; Ci-ealkoxy; halo-Ci-ealkoxy; -(Co-3alkylene)-O-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl.
[0241] In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4),(I-c), (I-d), (I-e), (I-f),or(I-g)> including any of the foregoing,wherein R19ais selected from hydrogen, cyano, methyl, -OCHF2, -OCF3, O(CH2)3F - CH3,1541107441203\1\AMERICASone embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing,wherein R19ais selected from hydrogen, cyano, methyl, -OCHF2, -CH2OCH2C(CH3)2OH, -CH2OCH3, -one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-1551107441203\1\AMERICASe), (I-f), or (I-g), including any of the foregoing, wherein R19ais selected from-CH2OCH2C(CH3)2OH, -CH2OCH3, -OCH2CH2OCH3, -O-cyclopropyl, -OCH3, and -OCH2CH3. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing,
[0242] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4),O-N-N(I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15isN^ \ Inoneembodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I¬f), or (I-g), including any of the foregoing,
[0243] In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1), (I-b2), (I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing, R15is selected fromone embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R23is Ci-6 alkyl, hydroxyCi-ealkyl, or unsubstituted C3. ecycloalkyl. In one embodiment of Formula (I), (P-V), (P-IV), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R15is selected from1561107441203\1\AMERICAS,,,,,,are independently selected from H, F, Cl, Ci-4alkoxy, and Ci-2alkoxyCi-5alkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Ring C or1571107441203\1\AMERICASIn one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Ring
[0245] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Ring1581107441203\1\AMERICASone embodiment of Formula (I), (P-I)-(P-V), (I-a), (Lal), (I-b), (Lbl)-(Lb4), (I-c), (Ld), (I-e), (I-f), or (I-g),including any of the foregoing, Ringembodiment of Formula (I), (P-IV), (P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le),(I-f), or (I-g), including any of the foregoing, RingIV), (I-a), (Lal), (Lb), (Lbl)-(Lb4), (Lc), (Ld), (Le), (Lf), or (I-g), including any of thewherein R19ais selected from hydrogen; cyano; Ci-ealkyl; Ci-ealkoxy; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl. In one embodiment of Formula (I), (P-V), (La), (Lal), (Lb), (Lbl)-(I-b4), (Lc), (Ld), (Le), (I-f), or (I-g), including any of the foregoing,1591107441203\1\AMERICASwherein R19ais selected from hydroxyl; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-3alkylOC3-5cycloalkyl;hydroxy-Ci-6alkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl.
[0247] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4),(I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Ringwherein R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17cand R3ccomes together with R15alto form a 5- to 6-membered heterocycle.
[0248] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4),,,,,, 1)- (I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, Ring C or1601107441203\1\AMERICASH, one R17is -C(O)NR17aR17b, and R17ais CH3. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the 1611107441203\1\AMERICASforegoing,In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d),O(I-e), (I-f), or (I-g), including any of the foregoing, R15isN^\, R1JSF R2JSp p3a jsH, R3bis H, and one R17is -C(O)NH2.
[0250] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4),(I-c), (I-d), (I-e), (I-f),or(I-g), including any of the foregoing,halo, R2is F, R3ais H, R3bis H, L is -NH-, and Ring B is a phenyl group substituted with 2 R17groups independently selected from halo and -C(O)NR17aR17b.
[0251] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R18is independently selected from deuterium, F, cyano, hydroxy, NR17bR17c, n-propyl, cyclopropyl, -CH2CF3,
[0252] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R20is independently selected from deuterium, F, cyano, hydroxy, NR17bR17c, n-propyl, cyclopropyl, -CH2CF3, -
[0253] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R22is independently selected from deuterium, F, cyano, hydroxy, NR17bR17c, n-propyl, cyclopropyl, -CH2CF3,
[0254] In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b 1 )-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R23is independently selected from deuterium, F, cyano, hydroxy, NR17bR17c, n-propyl, cyclopropyl, -CH2CF3,1621107441203\1\AMERICAS-CH2CH2OH, -CH2CH2OCH3, and. In one embodiment of Formula (I), (P-I)-(P- V), (I-a), (I-al), (I-b), (I-bl)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R23is independently selected from Ci-ealkyl and heterocycloalkyl optionally substituted with Ci-salkyl. In one embodiment of Formula (I), (P-I)-(P-V), (I-a), (I-al), (I-b), (I-b l)-(I-b4), (I-c), (I-d), (I-e), (I-f), or (I-g), including any of the foregoing, R23isindependently selected from methyl,
[0255] Non-limiting embodiments of the present disclosure include:
[0256] Embodiment 1: A compound of Formula (I) or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof.
[0257] Embodiment la: The compound of Embodiment 1, wherein the compound is of Formula (P-V) wherein the R groups are as defined in the first embodiment above.
[0258] Embodiment 2: The compound of Embodiment 1 or la, wherein the compound of Formula (I) is a compound of Formula (P-IV) wherein the R groups are as defined in the second embodiment above.
[0259] Embodiment 3: The compound of any one of Embodiments 1-2, wherein the compound of Formula (I) is a compound of Formula (P-III) wherein the R groups are as defined in the third embodiment above.
[0260] Embodiment 4: The compound of any one of Embodiments 1-3, wherein the compound of Formula (I) is a compound of Formula (P-II) wherein the R groups are as defined in the fourth embodiment above.
[0261] Embodiment 5: The compound of any one of Embodiments 1-4, wherein the compound of Formula (I) is a compound of Formula (P-I) wherein the R groups are as defined in the fifth embodiment above.1631107441203\1\AMERICAS
[0262] Embodiment 6: The compound of any one of Embodiments 1-5, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0263] Embodiment 7: The compound of any one of Embodiments 1-6, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0264] Embodiment 8: The compound of any one of Embodiments 1-7, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0265] Embodiment 9: The compound of any one of Embodiments 1-5, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,ring.
[0266] Embodiment 10: The compound of any one of Embodiments 1-5 and 9, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,1641107441203\1\AMERICAS
[0267] Embodiment 10a: The compound of any one of Embodiments 1-5 and 9-10, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0268] Embodiment 11: The compound of any one of Embodiments 1-4, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0269] Embodiment 12: The compound of any one of Embodiments 1-4 and 11, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0270] Embodiment 13: The compound of any one of Embodiments 1-5, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,whereinwherein is the attachment to the C ring.
[0271] Embodiment 14: The compound of any one of Embodiments 1-5 and 13, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,1651107441203\1\AMERICAS
[0272] Embodiment 15: The compound of any one of Embodiments 1-5 and 13-14, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0273] Embodiment 16: The compound of any one of Embodiments 1-5, or apharmaceutically acceptable salt and / or stereoisomer thereof, wherein
[0274] Embodiment 17: The compound of any one of Embodiments 1-5, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0275] Embodiment 18: The compound of any one of Embodiments 1-5, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein1661107441203\1\AMERICAS
[0276] Embodiment 19: The compound of any one of Embodiments 1-5, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein
[0277] Embodiment 20: The compound of any one of Embodiments 1-19, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -NH-.
[0278] Embodiment 21: The compound of any one of Embodiments 1-4, 9-12, and 18, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -Cs-ecycloalkylene-.
[0279] Embodiment 22: The compound of any one of Embodiments 1-4, 9-12, and 18, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -Ci-3alkylene- optionally substituted with 1 or 2 substituents independently selected from R25.
[0280] Embodiment 23: The compound of any one of Embodiments 1-4, 9-12, and 18, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -Cs-ecycloalkylene-.
[0281] Embodiment 23 a: The compound of any one of Embodiments 1-4, 9-12, 18, and 23, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is cyclopropylene.
[0282] Embodiment 24: The compound of any one of Embodiments 1-4, 9-12, and 18, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -heteroCi-salkylene-.
[0283] Embodiment 25: The compound of any one of Embodiments 1-4, 9-12, 18, and 24, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -NHCH2- wherein the -CH2- is attached to the B ring.
[0284] Embodiment 25a: The compound of any one of Embodiments 1-19, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -NH-, -NHCH2-, -OCH2-, -CH2CH2-, -CH2-, -CF2, -CH(NH2)CH2-, -CH(NH2)-,-04(043)-, -04(014)-, -04(0043)-, cyclopropylene,1671107441203\1\AMERICAS
[0285] Embodiment 26: The compound of any one of Embodiments l-25a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17.
[0286] Embodiment 27: The compound of any one of Embodiments 1-26, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.
[0287] Embodiment 28: The compound of any one of Embodiments 1-27, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R17is independently selected from halo, -C(O)NR17aR17b, and -COOH.
[0288] Embodiment 28a: The compound of any one of claims 1-27, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group substituted with 1 or 2 R17groups independently selected from halo, -C(O)NR17aR17b, -NR17bC(O)R17c, and -NR17bC(O)NR17cR17cl.
[0289] Embodiment 29: The compound of any one of Embodiments l-28a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group substituted with halo and -C(O)NR17aR17b.
[0290] Embodiment 30: The compound of any one of Embodiments 1-29, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0291] Embodiment 30a: The compound of any one of Embodiments l-28a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0292] Embodiment 31: The compound of any one of Embodiments 1-30, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring1681107441203\1\AMERICAS
[0293] Embodiment 31a: The compound of any one of Embodiments l-28a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0294] Embodiment 31b: The compound of any one of Embodiments l-28a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0295] Embodiment 31c: The compound of any one of Embodiments l-28a and 3 lb, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0296] Embodiment 32: The compound of any one of Embodiments l-25a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a 5- to 6-membered heteroaryl group, optionally substituted with 1, 2, or 3 substituents independently selected from R17.
[0297] Embodiment 33: The compound of any one of Embodiments l-25a and 32, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a 5- to 6-membered heteroaryl group optionally substituted with 1 R17group.
[0298] Embodiment 34: The compound of any one of Embodiments l-25a and 32-33, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring1691107441203\1\AMERICAS
[0299] Embodiment 35: The compound of any one of Embodiments l-25a and 32-34, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0300] Embodiment 36: The compound of any one of Embodiments l-25a and 32-35, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0301] Embodiment 36a: The compound of any one of Embodiments l-25a and 32-35, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0302] Embodiment 37: The compound of any one of Embodiments l-25a and 32-35, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring1701107441203\1\AMERICAS
[0303] Embodiment 37a: The compound of any one of Embodiments 1-4, 6-25a, and 32- 35, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0304] Embodiment 37b: The compound of any one of Embodiments 1-2, 6-25a and 32- 35, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0305] Embodiment 37c: The compound of any one of Embodiments 1-2, 6-25a, 32-35, and 37b, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer 1711107441203\1\AMERICAS
[0306] Embodiment 38: The compound of any one of Embodiments l-25a and 32-37, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0307] Embodiment 39: The compound of any one of Embodiments l-25a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.
[0308] Embodiment 40: The compound of any one of Embodiments l-25a and 39, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1 R17group.
[0309] Embodiment 41: The compound of any one of Embodiments l-25a and 39-40, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0310] Embodiment 42: The compound of any one of Embodiments l-25a and 39-41, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0311] Embodiment 43: The compound of any one of Embodiments 1-4, 6-27, 32-36a, and 39-41, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R17is independently selected from halo; -C(O)NR17aR17b;-NR17bC(O)R17c; and -NR17bC(O)NR17cR17cl.1721107441203\1\AMERICAS
[0312] Embodiment 44: The compound of any one of Embodiments 1—27, 28a, 32-36a, 39-41, and 43, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is independently selected from halo and -C(O)NR17aR17b.
[0313] Embodiment 45: The compound of any one of Embodiments 1-4, 6-27, 28a, 32-36a, 39-41, and 43, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -C(O)NR17aR17band R17ais selected from OH, Ci-ealkoxy, halo-Ci-ealkoxy, Cs-ecycloalkyloxy, Cs-ecycloalkylCi-salkyloxy, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, and heterocycloalkoxy.
[0314] Embodiment 45a: The compound of any one of Embodiments 1-4, 6-27, 28a, 32-36a, 39-41, and 43, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -C(O)NR17aR17band R17ais selected from OH, Ci-ealkoxy, halo-Ci-ealkoxy, Cs-ecycloalkyloxy, Cs-ecycloalkylCi-salkyloxy, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, -OC2-4alkylene-NR17bR17c, and heterocycloalkoxy.
[0315] Embodiment 45b: The compound of any one of Embodiments 1-4, 6-27, 28a, 32-36a, 39-41, and 43, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -C(O)NR17aR17band R17ais selected from H; OH; Ci-ealkoxy; halo-Ci-ealkoxy; Ci-3alkoxy-Ci-3alkyl; Cs-ecycloalkyl; Cs-ecycloalkyloxy; C3-ecycloalkylCi-salkyloxy; cyano-Ci-ealkyl; hydroxy-Ci-ealkyl; hydroxy-Ci-ealkyloxy; Ci-ealkoxy-Ci-ealkyloxy; -(Ci-C3alkylene)-NR17bR17c; a 5- to 10-membered heteroaryl group; a heteroaryl group fused to heterocycle or cycloalkyl; or heteroaryl Ci-ialkyl wherein the heterocycloalkyl of heterocycloalkylCi-salkyl, the heteroaryl or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22.
[0316] Embodiment 46: The compound of any one of Embodiments 1-4, 6-27, 28a, 32-36a, 39-41, and 43, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -NR17bC(O)NR17cR17cl.
[0317] Embodiment 47: The compound of any one of Embodiments 1-la, 6-27, 28a, 32-36a, 39-41, and 43, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -NHC(O)NR17cR17clwherein R17cland R17care both Ci-ealkyl or R17cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R28.1731107441203\1\AMERICAS
[0318] Embodiment 47a: The compound of any one of Embodiments 1-la, 6-27, 28a, 32-36a, 39-41, and 43, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -NHC(O)R17cand R17cis selected from Ci-ealkyl, Ci-ealkyloxy, and Ci-6alkyloxyCi-3alkyl.
[0319] Embodiment 48: The compound of any one of Embodiments 1 and 6-47a, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,
[0320] Embodiment 49: The compound of any one of Embodiments 1-48, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,wherein Ring
[0321] Embodiment 50: The compound of any o...
Claims
CLAIMS1. A compound of Formula (I):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof; whereinL is selected from -NR26-, -Ci-salkylene-, -Cs-ecycloalkylene-, -heterocycloalkylene-, -heteroCi-salkylene-, or bond wherein the -Ci-3alkylene- or -heterocycloalkylene- group is optionally substituted with 1 or 2 substituents independently selected from R25;-Ci-3alkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -Cs-ecycloalkylene-, -heterocycloalkylene- (optionally substituted with 1 or 2 substituents independently selected from R25), -heteroCi-salkylene-, or bond,CR1, X5is N or CRla, and X6is N or CR2provided that only one of X4, X5, and X6is N; or X4is CR1, X5is CRla, and X6is CR2; wherein X7is N or CR6; and whereinthe attachment to the C ring;5271107441203\1\AMERICASR26is H, Ci-3alkyl, hydroxyCi-2alkyl, Ci-2alkoxyCi-3alkyl, C3-4cycloalkyl, or heterocycloalkyl optionally substituted with 1 or 2 Ci-3alkyl which are independently selected;Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17; a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17; a phenyl group fused to a heterocycle or a 5 - to 6-membered heteroaryl group fused to a heterocycle to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18; or a phenyl group fused to a heteroaryl or 5- to 6-membered heteroaryl group fused to a heteroaryl to afford a 8- to 10-membered fused ring wherein the 8- to 10-membered fused ring is optionally substituted with 1, 2, or 3 substituents independently selected from R18;RingY1is CR3borN;Y2is CR3aorN;Y3is CR3b, CR3C, orN;Y4is CR3borN;wherein no more than 3 of Y1, Y2, Y3, or Y4are N;R15is -NR15alC(O)R15a2, -C(O)NR15bR15c, a 5- or 6-membered heterocycloalkyl, a 5-membered heteroaryl, or pyridonyl wherein the 5- or 6-membered heterocycloalkyl, 5-membered heteroaryl, and pyridonyl are optionally substituted with 1, 2, 3, 4, 5, or 6 groups independently selected from R19;R15a2is H, Ci-ealkyl, heteroarylalkyl, or NR17bR17c;R15bis H or Ci-ealkyl;R15cis H; Ci-3alkyl optionally substituted with NR28aR28b; Ci-3alkylcarbonyl wherein the Ci-3alkyl is optionally substituted with NR28aR28b; hydroxy Ci-ealkyl; heterocycloalkyl; heterocycloalkylCi-salkyl; heterocycloalkyloxyCi-salkyl; -CH2-C(O)NR28aR28b; -CH2-phenylene-NHC(O)NR28aR28b; or heteroaryl fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heteroaryl fused to5281107441203\1\AMERICASheterocycle is optionally substituted with Ci-4alkyl, Ci-3alkoxyCi-3alkyl, aryl, arylCi-salkyl, halo, heterocycloalkyl, or heterocycloalkylCi-salkyl;or R15band R15care taken together, with the N to which they are attached, to form a 3-10 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from hydroxy, Ci-3alkyl, halo, C2-3alkylcarbonyl, Ci-3alkoxy, hydroxyCi-3 alkyl, Ci-3alkoxyCi-3alkyl, cyano, Cs-ecycloalkyl, -S(O)2R9, -C(O)NR28aR28b, or -NHC(=O)CH3; or 2 substituents on the same carbon come together to form an oxo group;is a single bond or a double bond;R1is H, halo, Ci-salkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, aryl, heteroaryl, heterocycloalkyl, arylCi-salkyl, heteroarylCi-salkyl, aryloxy, heteroaryloxy, haloCi-4alkyl, Ci-4alkoxy, Ci-2alkoxyCi-5alkyl, deuterium, -OCi-3alkylOCi-3alkyl, -CN, or -SO2R9;Rlais H, halo, deuterium, or methyl;R2is H, F, Cl, deuterium, Ci-salkyl, haloCi-4alkyl, hydroxyCi-4alkyl, Ci-2alkoxyCi-salkyl, C2-4 alkenyl, Ci-4alkoxy, NR17bR17c, -OCi-3alkyl-C3-6cycloalkyl, or -OCi-3alkylOCi-2alkyl;R3aand R3bare independently selected from H; F; Cl; Ci-4alkyl; OH; -CN; hydroxyCi-4alkyl; Ci-4alkoxy wherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is optionally substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl; Ci-2alkoxyCi-5alkyl; -OCi-5alkylOCi-2alkyl; -OC2-5alkyl-NR17bR17c; aryl optionally substituted with heterocycloalkyl; heteroaryl; aryloxy; heterocycloalkyl; heteroaryl oxy; -O-Co-Csalkylene-heterocycloalkyl; and C2-ealkynyl optionally substituted with hydroxy, Ci-3alkyloxy, -(Co-3alkylene)NR17bR17c, heterocycloalkyl, or Cs-ecycloalkyl wherein the Cs-ecycloalkyl is optionally substituted with NR17bR17c; wherein the heteroaryl and heterocycloalkyl, alone or part of another group, are optionally substituted with Ci-ealkyl or NR17bR17c;R15alis H or Ci-ealkyl and R3cis hydrogen or R15aland R3ccome together to form a 5-to 7-membered heterocycle;R5is H; Ci-ealkyl; haloCi-salkyl; cyanoCi-salkyl; hydroxyCi-salkyl; Ci-2alkoxyC2-salkyl; C3-6 alkenyl; C3-6 alkynyl; -(Co-C3alkylene)-S02R9; -(Co-C3alkylene)-C(0)R12; heterocycloalkyl; heterocycloalkylCi-salkyl; -(C2-C5alkylene)-NR17bR17c; -(Ci-Csalkylene)-C(O)NR17bR17c; -(C2-C5alkylene)-NR17b-C(O)R17c; aryl; arylCi-salkyl wherein the aryl of arylCi-salkyl is optionally substituted with heterocycloalkyl; heteroaryl; heteroarylCi-salkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyl; or Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and5291107441203\1\AMERICASC5-7cycloalkenyl are optionally substituted with 1, 2, or 3 groups independently selected from halo, OH, cyanoCo-2alkyl, hydroxyCo-2alkyl, and Ci-2alkoxyCo-2alkyl and wherein the heterocycloalkyl, alone or part of heterocycloalkylCi-salkyl, and heteroaryl, alone or part of heteroarylCi-salkyl, are optionally substituted with 1 or 2 groups independently selected from Ci-3alkyl, haloCi-salkyl, halo, Ci-3alkoxy, heterocycloalkyl, and Cs-ecycloalkyl;R5ais Ci-ealkyl; haloCi-salkyl; aryl; heteroaryl; arylalkyl; heteroarylalkyl; C3-ecycloalkyl; or, Cs-7cycloalkenyl wherein the Cs-ecycloalkyl and Cs-7cycloalkenyl are optionally substituted with 1, 2, or 3 halo which are independently selected;R6is H; F; Cl; Br; Ci-3alkyl; haloCi-salkyl; hydroxyCi-salkyl; cyanoCi-salkyl; C2-ealkynyl optionally substituted with Cs-scycloalkyl or NR17bR17c; hydroxyCs-ealkynyl; Ci-2alkoxyCi-5alkyl wherein the Ci-salkyl of Ci-2alkoxyCi-5alkyl are independently optionally substituted with 1 or 2 hydroxy groups or 1 Cs-ecycloalkyl group; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl; heterocycloalkyloxyCi-salkyl;C(O)NR16aR16b; Cs-scycloalkyl; Cs-scycloalkylCi-salkyl wherein the Ci-3alkyl of C3-scycloalkylCi-salkyl is optionally substituted with hydroxy; deuterium; heterocycloalkyl; heterocycloalkylCi-salkyl; -(Co-3alkylene)-SC>2R9; -SO2NR17bR17c; cyano; -(Ci-Csalkylene)-NR17bR17c; p(Q)(CH3)2; heteroaryl; and heteroarylCi-salkyl; wherein the Cs-scycloalkyl and heterocycloalkyl are optionally substituted with 1, 2, 3, or 4 groups independently selected from deuterium, halo, OH, Ci-3alkyl, hydroxyCi-salkyl,-(Co-3alkylene)-NR17bR17c, -(Co-3alkylene)-NR17b-C(0)R17c, Ci-3alkoxy, Ci-3alkoxyCi-3alkyl, Ci-2alkoxyCi-5alkyloxy-Ci-2alkyl, and cyano; and the heteroaryl, alone or part of heteroarylCi-salkyl, is optionally substituted with 1 or 2 Ci-3alkyl which are independently selected; orR5and R6together with the atoms to which they are attached form a heterocycle optionally substituted with 1 or 2 substituents independently selected from Ci-3alkyl, C3-4cycloalkyl, and halo;R9is Ci-3alkyl or Cs-ecycloalkyl;R12is OH, Ci-ealkyl or Cs-ecycloalkyl;R13and R13aare independently H; halo; hydroxyCi-2alkyl; heterocycloalkyl optionally substituted with Ci-3alkyl; Cs-scycloalkyl; Ci-3alkoxyCi-3alkyl; -(Co-3alkylene)-NR17bR17c; aryl; heteroaryl; C3-8cycloalkylCi-3alkyl; or alkyl; orR13and R13a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl wherein the cycloalkyl and heterocycloalkyl are optionally substituted with Ci-3alkyl, Cs-scycloalkyl, hydroxy, halo, NR17bR17c, hydroxyCi-salkyl, or Ci-3alkoxyCi-3alkyl;5301107441203\1\AMERICASR21and R21aare independently H, hydroxyCi-2alkyl, Cs-scycloalkyl, heteroaryl, or alkyl; orR21and R21a, together with the carbon to which they are attached, form cycloalkyl or heterocycloalkyl; orR21and R21acome together to form an oxo group; orR13aand R21a, when R13aand R21aare on adjacent carbons, together with the carbons to which they are attached, form cycloalkyl or heterocycloalkyl; and R13and R21are independently H, halo, Ci-3alkoxy, heteroaryl, Cs-scycloalkyl, or alkyl;provided that only one of a) R13and R13a; b) R21and R21a, and c) R13aand R21aform cycloalkyl or heterocycloalkyl;R16aand R16bare independently selected from H; Ci-ealkyl; phenyl; C3-7cycloalkyl; Cs-7cycloalkenyl; a 4-7 membered heterocycloalkyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and S(0)o-2; and a 5-6 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; orR16aand R16bare taken together, with the N to which they are attached, to form a 3-7 membered heterocycloalkyl having 0-3 heteroatoms, in addition to the N to which they are attached, independently selected from nitrogen, oxygen, and S(0)o-2;each R17is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; methanesulfonylamino; -SO2NR17bR17c; Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; Ci-ealkoxy; Ci-ealkoxy-Ci-ealkyl wherein the Ci-ealkyl of Ci-ealkoxy-Ci-ealkyl are independently optionally substituted with hydroxy; cyano-Ci-ealkyl; Ci-ealkylcarbonyl; dimethylamino-Ci-ealkylcarbonyl; -(Ci-6alkylene)NR17bR17c; N-acetylamino-Ci-ealkyl; Ci-ealkylcarbamoyl; N-methyl-Ci-6alkylcarbamoyl; -C(O)NR17aR17b; -C(O)R17c; COOH;-NR17bC(O)R17c; -NR17bC(O)NR17cR17cl; -NR17bC(O)C(O)NR17cR17cl; aryl; heterocycloalkyl; and a 5-6-membered heteroaryl group wherein the aryl and 5-6-membered heteroaryl group are optionally substituted with 1, 2, or 3 substituents independently selected from R20;each R17ais independently selected from H; Ci-ealkyl; OH; Ci-ealkoxy; halo-Ci-ealkoxy; Ci-3alkoxy-Ci-3alkyl; Cs-ecycloalkyl; C3-6cycloalkylCi-3alkyl; Cs-ecycloalkyloxy; C3-ecycloalkylCi-salkyloxy; cyano-Ci-ealkyl; halo-Ci-ealkyl; hydroxy-Ci-ealkyl; hydroxy-Ci-ealkyloxy; Ci-ealkoxy-Ci-ealkyloxy; NR17bR17c-Ci-6alkylcarbonyl; -(C1-C3alkylene)-NR17bR17c; -OC2-4alkylene-NR17bR17c; Ci-2alkoxyCi-3alkyl; -C(O)NHOR24; heterocycloalkyl; heterocycloalkyloxy, heterocycloalkylCi-salkyl; heterocycloalkylCi-salkoxy; aryl; a 5- to 10-membered heteroaryl group; a heteroaryl group fused to heterocycle or cycloalkyl; or heteroarylCi-salkyl wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi- 5311107441203\1\AMERICASsalkyl, the aryl, the heteroaryl, the heteroaryl of heteroarylCi-salkyl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;each R17bis independently selected from hydrogen, Ci-ealkyl, Ci-ealkyloxy, haloCi-ealkyl, and Ci-6alkyloxyCi-3alkyl;each R17Cis independently selected from hydrogen; deuteroCi-ealkyl; Ci-ealkyl; C2-ealkenyl optionally substituted with 1 or 2 halo; Ci-ealkyloxy; hydroxy; haloCi-ealkyl; Ci-6alkyloxyCi-3alkyl; -(Ci-C3alkylene)-NR28aR28b; heterocycloalkyl; a 5- or 6-membered heteroaryl group; heteroaryl group fused to heterocycle or cycloalkyl; and heteroaryl C alkyl wherein the heterocycloalkyl, alone or part of another group, heteroaryl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R22;each R17C1is independently selected from hydrogen; Ci-ealkyl optionally substituted with 1, 2, or 3 groups independently selected from Cs-scycloalkyl, heterocycloalkyl, or methoxy wherein the Cs-scycloalkyl is further optionally substituted with 1 or 2 groups independently selected from -OH and Ci-3alkyl; deuteroCi-ealkyl; Cs-scycloalkyl; haloCi-ealkyl; hydroxyCi-ealkyl; Ci-6alkyloxyCi-3alkyl; -CH2-phenylene-NHC(O)NR28aR28b; and heterocycloalkyl;or R17band R17care taken together, with the N to which they are attached, to form a 4-7 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or R17Cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R28;each R19is independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi -ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxyCi-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heteroaryl group fused to5321107441203\1\AMERICASheterocycle are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl; or each R19is as follows:(a) two R19groups on the same carbon come together to form an oxo group;(b) one pair of R19groups on the same carbon come together to form an oxo group and a second pair of R19groups on the same carbon come together to form an oxo group;(c) two R19groups on the same carbon come together to form a Cs-scycloalkyl;(d) two R19groups on the same carbon come together to form a Cs-scycloalkyl and a second pair of R19groups on the same carbon come together to form an oxo group;(e) two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5-to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23; or(f) two R19groups on the same carbon come together to form an oxo group and two R19groups on adjacent carbons come together to form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;and the remaining of the R19groups in (a)-(f) are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(C1-C3alkylene)-SO2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heteroaryl group fused to heterocycle are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl; R18, R20, R22, and R23are independently selected from deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-3alkoxy; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxy, and hydroxyCi-ealkyl; C3-ecycloalkylCi-ealkyl wherein the Cs-ecycloalkyl is optionally substituted with hydroxy; haloCi-ealkyl; hydroxyCi-ealkyl; cyanoCi-ealkyl; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; -(Ci-C5alkylene)-NR17bR17c; -C(O)R27; -(Co- 5331107441203\1\AMERICASC3alkylene)-SC>2R9; heteroaryl; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-salkyl; and heterocycloalkylalkyl wherein the heterocycloalkyl of heterocycloalkylalkyl is optionally substituted with 1 or 2 substituents selected from -NR17bR17c, halo, and -OH; or two R20or R22groups on the same carbon come together form an oxo group;R24is H, Ci-salkyl, C3-6cycloalkylCi-3alkyl, heterocycloalkylCi-salkyl, hydroxyC?-4alkyl, C2-4alkoxyCi-2alkyl, or NR17bR17c-C2-4alkyl;R25is independently selected from halo, Ci-3alkyl, -NR17bR17c, hydroxy, Ci-3alkoxy, and Ci-3alkoxy-Ci-2alkyl;or two R25groups on the same carbon come together to form C3-6cyclopropyl or heterocycloalkyl;R27is selected from Ci-3alkyl optionally substituted with hydroxy; Cs-ecycloalkyl; NR17bR17c; and Ci-3alkoxy;R28is independently selected from Ci-3alkyl, halo, haloCi-salkyl, halo-Ci-ealkoxy, cyano, cyanoCi-salkyl, hydroxyl, hydroxyCi-salkyl, -O-(hydroxyCi-3alkyl), -(Co-C3alkylene)NR28aR28b, Ci-3alkoxy, Ci-3alkoxy-Ci-3alkyl, heterocycloalkyl, heterocycloalkylCi-salkyl, and heterocycloalkyloxy; andR28aand R28bare independently H or Ci-ealkylwherein whenselected fromCsalkylene)-NR17bR17c; C3-6cycloalkylCi-3alkyl; or Cs-ecycloalkyl.5341107441203\1\AMERICAS2. The compound of claim 1, or a pharmaceutically acceptable salt and / or stereoisomerthereof and / or tautomer thereof, whereinwhereinis the attachment to the C ring.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, whereinis4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein5. The compound of claim 1, or a pharmaceutically acceptable salt and / or stereoisomerthereof and / or tautomer thereof, wherein5351107441203\1\AMERICAS6. The compound of claim 1 or 5, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -NH-.
8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -Cs-ecycloalkylene-.
9. The compound of any one of claims 1-6 and 8, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is cyclopropylene.
10. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -Ci-3alkylene- optionally substituted with 1 or 2 substituents independently selected from R25.
11. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -heteroCi-salkylene-.
12. The compound of any one of claims 1-6 and 11, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -NHCH2- wherein the -CH2- is attached to the B ring.
13. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein L is -NH-, -NHCH2-, -OCH2-, -CH2CH2-, -CH2-, -CF2, -CH(NH2)CH2-, --CH(OH)-, -CH(OCH3)-, cyclopropylene,14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R17.
15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.5361107441203\1\AMERICAS16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R17is independently selected from halo, -C(O)NR17aR17b, and -COOH.
17. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group substituted with 1 or 2 R17groups independently selected from halo, -C(O)NR17aR17b, -NR17bC(O)R17c, and -NR17bC(O)NR17cR17cl.
18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a phenyl group substituted with halo and -C(O)NR17aR17b.
19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein Ring20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein Ring21. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt and / or5371107441203\1\AMERICAS22. The compound of any one of claims 1-15 and 17, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is23. The compound of any one of claims 1-15, 17, and 22, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is24. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a 5- to6-membered heteroaryl group, optionally substituted with 1, 2, or 3 substituents independently selected from R17.
25. The compound of any one of claims 1-13 and 24, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a 5- to 6- membered heteroaryl group optionally substituted with 1 R17group.
26. The compound of any one of claims 1-13 and 24-25, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is27. The compound of any one of claims 1-13 and 24-26, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is5381107441203\1\AMERICAS28. The compound of any one of claims 1-13 and 24-26, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is29. The compound of any one of claims 1-13, 24-26, and 28, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is30. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.
31. The compound of any one of claims 1-13 and 30, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring B is a heteroarylCi-salkyl group wherein the heteroaryl is a 5- to 6-membered heteroaryl group optionally substituted with 1 R17group.5391107441203\1\AMERICAS32. The compound of any one of claims 1-15, 24-26, and 30-31, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R17is independently selected from halo; -C(O)NR17aR17b; -NR17bC(O)R17c; and - NR17bC(O)NR17cR17cl.
33. The compound of any one of claims 1-1724-26, and 30-31, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is independently selected from halo and -C(O)NR17aR17b.
34. The compound of any one of claims 1-17, 24-26, 30-31, and 33 or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -C(O)NR17aR17band R17ais selected from OH, Ci-ealkoxy, halo-Ci-ealkoxy, Cs-ecycloalkyloxy, Cs-ecycloalkylCi-salkyloxy, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci- ealkyloxy, -OC2-4alkylene- NR17bR17c, and heterocycloalkoxy.
35. The compound of any one of claims 1-15, 17, 24-26, and 30-32, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -NR17bC(O)NR17cR17cl.
36. The compound of any one of claims 1-15, 17, 24-26, 30-32, and 35, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein at least one R17is -NHC(O)NR17cR17clwherein R17cland R17care both Ci- ealkyl or R17cand R17clare taken together, with the N to which they are attached, to form a 4-12 membered heterocycloalkyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R28.
37. The compound of any one of claims 1-15, 17, 24-26, 30-32, and 35, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R17is -NHC(O)R17cand R17cis selected from Ci-ealkyl, Ci-ealkyloxy, and Ci- ealkyloxyCi-salkyl.
38. The compound of any one of claims 1-37, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein Ring5401107441203\1\AMERICAS39. The compound of any one of claims 1-38, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein Ring40. The compound of any one of claims 1-39, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein Ring41. The compound of any one of claims 1-40, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein Ring42. The compound of any one of claims 1-39, or a pharmaceutically acceptable salt and / orstereoisomer thereof and / or tautomer thereof, wherein Ring C is5411107441203\1\AMERICAS43. The compound of claim 1, of Formula (I-b):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof.
44. The compound of claim 1, of Formula (I-b 1):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof;wherein the B ring is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a pyridinyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17, optionally wherein Ring B is an unsubstituted phenyl group or unsubstituted pyridinyl group.
45. The compound of claim 1, of Formula (I-b2):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof;wherein the L is -NR26- or -Ci-2alkylene- optionally substituted with 1 or 2 substituents selected from R25and Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.5421107441203\1\AMERICAS46. The compound of claim 44 or 45, wherein Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.
47. The compound of any one of claims 44-46, wherein Ringand L is -NH-.
48. The compound of any one of claims 44-47, wherein R1is F, R2is F, R3ais H, and R3ais H.
49. The compound of claim 1, of Formula (I-b3):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof;wherein Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.
50. The compound of claim 1, of Formula (I-b4):or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof;wherein Ring B is a phenyl group optionally substituted with 1, 2, or 3 substituents independently selected from R17or a 5- to 6-membered heteroaryl group optionally substituted with 1, 2, or 3 substituents independently selected from R17.5431107441203\1\AMERICAS51. The compound of claim 49 or 50, wherein Ring52. The compound of any one of claims 49-51, wherein Ring53. The compound of any one of claims 49-52, wherein R3ais H, R3bis H, Y4is N, and Y3is CH.
54. The compound of any one of claims 49-52, wherein R3ais H, R3bis H, Y4is CH, and Y3is CH.
55. The compound of any one of claims 1-54, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R1is independently selected from H, halo, and Ci-4alkoxy.
56. The compound of any one of claims 1-55, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R1is H.
57. The compound of any one of claims 1-55, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R1is halo.
58. The compound of any one of claims 1-55 and 57, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R1is F.
59. The compound of any one of claims 1-55, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R1is Ci-4alkoxy.5441107441203\1\AMERICAS60. The compound of any one of claims 1-55 and 59, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R1is OCH3.
61. The compound of any one of claims 1-60, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R2is H, F, Cl, Ci-2alkoxyCi- salkyl, Ci-4alkoxy, Ci-salkyl, or C2-4 alkenyl.
62. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R2is H, F, Cl, -CH2CH2OCH3, OCH3, ethyl, or -CH=CH2.
63. The compound of any one of claims 1-62, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R2is H.
64. The compound of any one of claims 1-55 or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R1is H and R2is H.
65. The compound of any one of claims 1-55, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R1is F and R2is H.
66. The compound of any one of claims 1-55, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R1is H and R2is F.
67. The compound of any one of claims 1-55, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein each R1is F and R2is F.
68. The compound of any one of claims 1-3 and 5-67, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R13and R13aare both methyl.
69. The compound of any one of claims 1-3 and 5-67, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R13and R13a, together with the carbon to which they are attached, form cycloalkyl.
70. The compound of any one of claims 1-3 and 5-67, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R13and R13a, together with the carbon to which they are attached, form cyclopropyl.
71. The compound of any one of claims 1—19, 24-26, 28, 30-33, and 38-70, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R17ais H, Ci-ealkyl, OH, Ci-ealkoxy, halo-Ci-ealkoxy, Ci-3alkoxy-Ci-3alkyl, halo-Ci-ealkyl, Cs-ecycloalkyl, C3-6cycloalkylCi-3alkyl, Cs-ecycloalkyloxy, C3- ecycloalkylCi-salkyloxy, hydroxy-Ci-ealkyl, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci- ealkyloxy, cyano-Ci-ealkyl, -(Ci-C3alkylene)-NR17bR17c, Ci-ealkoxy-Ci-ealkyl, heterocycloalkyl, heterocycloalkoxy, heterocycloalkylCi-salkyl, aryl, heteroaryl,5451107441203\1\AMERICASheteroarylCi-salkyl, or heteroaryl group fused to heterocycle or cycloalkyl, wherein the heterocycloalkyl, the heterocycloalkyl of heterocycloalkylCi-salkyl, the heteroaryl, the heteroaryl of heteroarylCi-salkyl, or any ring of the heteroaryl group fused to heterocycle or cycloalkyl are optionally substituted with 1 or 2 R22groups and R22is independently selected from halo; Ci-ealkyl; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl and hydroxy; Ci-2alkoxyCi-3alkyl wherein the alkyl is optionally substituted with hydroxy; cyano; haloCi-ealkyl; hydroxyCi-ealkyl wherein the Ci-ealkyl is optionally substituted with Cs-ecycloalkyl; cyanoCi-ealkyl; -(Co-C3alkylene)-S02R9; -(Ci-Csalkylene)- NRi7bRi7c. -C(O)R27; heterocycloalkyl optionally substituted with -NR17bR17cor Cisalkyl; and heterocycloalkylalkyl optionally substituted with -NR17bR17c.
72. The compound of any one of claims 1-19, 24-26, 28, 30-33, and 38-71, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R17ais H, OH, Ci-ealkyl, Ci-ealkoxy, Cs-ecycloalkylCi-salkyloxy, halo-Ci- ealkoxy, hydroxy-Ci-ealkyloxy, Ci-ealkoxy-Ci-ealkyloxy, heterocycloalkylCi-salkoxy, heterocycloalkoxy, or -OC2-4alkylene-NR17bR17c.
73. The compound of any one of claims 1-19, 24-26, 28, 30-34, and 38-72, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof,74. The compound of any one of claims 1-19, 24-26, 28, 30-33, and 38-71, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R17ais heteroaryl optionally substituted with 1 or 2 R22groups and R22is independently selected from halo; Ci-ealkyl; Cs-ecycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl and hydroxy; Ci-2alkoxyCi- 3alkyl wherein the alkyl is optionally substituted with hydroxy; cyano; haloCi-ealkyl; hydroxyCi-ealkyl wherein the Ci-ealkyl is optionally substituted with Cs-ecycloalkyl; cyanoCi-6alkyl; -(Co-C3alkylene)-S02R9; -(Ci-C5alkylene)-NR17bR17c; heterocycloalkyl optionally substituted with -NR17bR17cor Ci-3alkyl; and heterocycloalkylalkyl optionally substituted with -NR17bR17c.5461107441203\1\AMERICAS75. The compound of any one of claims 1-19, 24-26, 28, 30-33, and 38-71, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R17ais a heteroaryl group fused to heterocycle or cycloalkyl optionally substituted with 1 or 2 substituents independently selected from Ci-ealkyl, hydroxyl, halo, haloCi-ealkyl, hydroxyCi-ealkyl, Cs-ecycloalkyl, Cs-ecycloalkylCi-ealkyl, Ci- 2alkoxyCi-3alkyl, -(Co-C3alkylene)-S02R9, -C(O)R27, and unsubstituted heterocycloalkyl.
76. The compound of any one of claims 1-19, 24-26, 28, 30-33, and 38-72, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R17ais H or Ci-ealkyl.
77. The compound of any one of claims 1-76, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R3ais selected from H; F; Cl; Ci-4alkyl; OH; -CN; hydroxyCi-4alkyl; Ci-4alkoxy wherein the Ci-4alkyl of Ci-4alkoxy is optionally substituted with aryl wherein the aryl is optionally substituted with heterocycloalkyl and the heterocycloalkyl is optionally substituted with Ci-ealkyl; Ci- 2alkoxyCi-5alkyl; -OCi-5alkylOCi-2alkyl; -OC2-salkyl-NR17bR17c; aryl optionally substituted with heterocycloalkyl; heteroaryl; aryloxy; heterocycloalkyl; heteroaryl oxy; -O-Co-Csalkylene-heterocycloalkyl; and C2-ealkynyl optionally substituted with hydroxy, Ci-3alkyloxy, -(Co-3alkylene)NR17bR17c, Cs-ecycloalkyl further optionally substituted with NR17bR17c, and heterocycloalkyl; wherein the heteroaryl and heterocycloalkyl, alone or part of another group, are optionally substituted with Ci-ealkyl or NR17bR17c; and R3bis H.
78. The compound of any one of claims 1-77, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R3ais H, F, or Ci-4alkoxy.
79. The compound of any one of claims 1-77, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R3ais H and R3bis H.
80. The compound of any one of claims 1-79, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is -C(O)NR15bR15c.
81. The compound of any one of claims 1-80, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is -C(O)NH2 or -C(O)N(CH3)2.
82. The compound of any one of claims 1-79, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is a 5- or 6-membered5471107441203\1\AMERICASheterocycloalkyl comprising 1, 2, or 3 nitrogen atoms and optionally with 1, 2, 3, 4, 5, or 6 groups independently selected from R19.
83. The compound of any one of claims 1-79 and 83, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15iswherein X1is CR19aR19b, N(R19c), or O;Xlais CR19aR19bor N(R19c);X2and X3are independently selected from CR19a, C(R19a)2, N, and N(R19c) wherein at least one is CR19aor C(R19a)2;R19aand R19bare independently selected from hydrogen; deuterium; halo; cyano; hydroxyl; NR17bR17c; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkyl; deuteroCi-ealkoxy; C3-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; and heteroaryl group fused to heterocycle; wherein the heterocycloalkyl, alone or part of another group, and the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl;or two R19agroups, on adjacent carbons, together with the carbons to which they are attached, form a benzo group, a 5- to 6-membered heteroaryl, or a 5- to 6-membered heterocycloalkyl, wherein the benzo group, 5- to 6-membered heteroaryl, and 5- to 6-membered heterocycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from R23;or two R19agroups on the same carbon come together to form an oxo group;R19Cis H; deuterium; Ci-ealkyl; deuteroCi-ealkyl; Cs-ecycloalkyl; haloCi-ealkyl; heterocycloalkyl; hydroxy-Ci-ealkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; and C2-ealkynyl optionally substituted with hydroxy or5481107441203\1\AMERICASheterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo and Ci-ealkyl; and is a single bond or a double bond.
84. The compound of any one of claims 1-79 and 82-83, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15iswherein R19ais selected from hydroxyl; cyano; Ci-ealkyl; Ci-ealkoxy; deuteroCi-ealkoxy; Cs-ecycloalkyl; Cs-ecycloalkyloxy; Cs-ecycloalkylCi-salkyloxy; haloCi-ealkyl; halo-Ci-ealkoxy; -(Co-3alkylene)-0-(hydroxyCi-ealkyl); Ci-3alkoxy-Ci-3alkyl; -OCi-3alkylOCi-2alkyl; -OCi-salkylOCs-scycloalkyl; hydroxy-Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; -O(Ci-C3alkylene)-NR17bR17c; -O(Ci-C3alkylene)-SC>2R9; C2-ealkynyl optionally substituted with hydroxy; wherein the heterocycloalkyl, alone or part of another group, and any ring of the heterocycle fused to a heteroaryl group are optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl; andR19Cis Ci-ealkyl; deuteroCi-ealkyl; or Cs-ecycloalkyl.
85. The compound of any one of claims 1-79 and 82-83, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is selected from86. The compound of any one of claims 1-79 and 82-83, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is selected from5491107441203\1\AMERICAS87. The compound of any one of claims 1-79 and 82-84, or a pharmaceutically acceptablesalt and / or stereoisomer thereof and / or tautomer thereof, whereinand R19ais selected from hydrogen; cyano; Ci-ealkyl; Ci-ealkoxy; halo-Ci-ealkoxy; - (Co-3alkylene)-0-(hydroxyCi-6alkyl); Ci-3alkoxy-Ci-3alkyl; heteroaryl optionally substituted with Ci-ealkyl; heterocycloalkyloxyCi-salkyl; heterocycloalkyloxy; heterocycloalkylalkyloxy; C2-ealkynyl optionally substituted with hydroxy or heterocycloalkyl; wherein the heterocycloalkyl, alone or part of another group, is optionally substituted with 1, 2, 3, or 4 substituents independently selected from halo, hydroxy, and Ci-ealkyl.
88. The compound of any one of claims 1-79 and 82-84, or a pharmaceutically acceptablesalt and / or stereoisomer thereof and / or tautomer thereof, whereinand R19ais selected from hydrogen, cyano, methyl, -OCHF2, -OCF3, O(CH2)3F -CH2OCH2C(CH3)2OH, -CH2OCH3, -OCH2CH2OCH3, -O-cyclopropyl, -OCH3, -5501107441203\1\AMERICAS89. The compound of any one of claims 1-79 and 82-83, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is selected from90. The compound of any one of claims 1-79, 82-83, and 89, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is5511107441203\1\AMERICAS91. The compound of any one of claims 1-79 and 82-88, or a pharmaceutically acceptablesalt and / or stereoisomer thereof and / or tautomer thereof, wherein R15is92. The compound of any one of claims 1-79 and 82-85, or a pharmaceutically acceptablesalt and / or stereoisomer thereof and / or tautomer thereof, wherein93. The compound of any one of claims 1-79 and 82, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring C isare independently selected from H, F, Cl, Ci-4alkoxy, and Ci-2alkoxyCi-5alkyl.
94. The compound of any one of claims 1-79 and 82, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring C is5521107441203\1\AMERICAS95. The compound of any one of claims 1-79 and 82, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring C is96. The compound of any one of claims 1-79 and 82, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring C is97. The compound of any one of claims 1-79 and 82, or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof, wherein Ring C is5531107441203\1\AMERICAS98. The compound of claim 1, wherein the compound is a compound of Table A or Table A-l or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof.
99. A pharmaceutical composition comprising a compound of any one of claims 1-98 or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof and a pharmaceutically acceptable excipient, diluent, or carrier.
100. A method for treating a disease, disorder, or condition associated with the STAT6 signaling pathway comprising administering a compound of any one of claims 1-98 or a pharmaceutically acceptable salt and / or stereoisomer thereof and / or tautomer thereof; or a pharmaceutical composition of claim 99 to a host in need thereof.
101. The method of claim 100, wherein the disease, disorder, or condition is an inflammatory disease, disorder, or condition.
102. The method of claim 100, wherein the disease, disorder, or condition is an allergic inflammatory disease, disorder, or condition.
103. The method of claim 100, wherein the disease, disorder, or condition is selected from asthma, airway hyperresponsiveness (AHR), allergic rhinitis, allergic asthma, emphysema, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, psoriasis, contact dermatitis, and atopic dermatitis.
104. The method of claim 100, wherein the disease, disorder, or condition is a cellular proliferative disorder.
105. The method of claim 104, wherein the cellular proliferative disorder is cancer.
106. The method of claim 105, wherein the cancer is selected from colon cancer, prostate cancer, breast cancer, gastrointestinal cancer, Hodgkin’s lymphoma, nonHodgkin’s lymphoma, and pancreatic cancer.5541107441203\1\AMERICAS
